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ABSTRACT 
The key objective of this study was to examine whether leucocyte depletion 
generated or removed platelet-derived microvesicles in platelet concentrates for 
transfusion. Three in-process leucocyte removal filters for pooled buffy coat derived 
platelet concentrates, i. e. negative charged polyester, positively charged polyester, and 
non-charged polyurethane, were compared. The effects of three major leucocyte 
depletion technologies currently in use in the UK, i. e. Cobe LRS and Haemonetics 
MCS+ LD apheresis, and filtration of pooled buffy coat derive platelets, on platelet 
microvesiculation were also examined. Furthermore, the effects of various leucocyte 
filters and leucocyte depletion technologies on platelet activation and the activation of 
coagulation/complement systems were investigated. The procoagulant and anticoagulant 
properties of microvesicles isolated from platelet concentrates were explored. 
Leucocyte filtration of pooled bully coat derived platelet concentrates by all three 
filters did not have a net effect on the level of microvesicles. All three leucocyte 
depletion technologies gave similar values of microvesicles on day 1, but on day 5 
MCS+ LD apheresis showed the lowest value, whilst Cobe LRS apheresis and buffy coat 
methods were equivalent. 
Among the three filters, the negatively charged filter activated the coagulation 
system as measured by kallikrein-like and thrombin-like activities, but removed some 
activated complement C3a, whereas the positively charged filter generated C3a. Among 
the three leucocyte depletion technologies, platelets prepared by Cobe LRS showed the 
lowest degree of activation of the coagulation system. However, both Cobe LRS and 
MCS apheresis showed higher levels of C3a than filtered buffy coat 
derived platelets. 
The microvesicles isolated from day 1 platelet concentrates could act as a 
V 
catalytic surface for both the coagulant and anticoagulant reactions as measured by the 
formation of prothrombinase complex and the inactivation of FVa by activated protein C. 
The microvesicles isolated from day 5 platelets showed an increased procoagulant 
activity, whereas the anticoagulant activity substantially diminished. 
vi 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 PHYSIOLOGY OF HAEMOSTASIS 
Normal haemostasis embodies three interrelated compartments: vasculature, 
platelets and coagulation. The physiology of each compartment is briefly discussed 
below. Detailed description of all the changes at the molecular level are beyond the 
scope of this introduction. 
1.1.1 Vasculature 
The wall of a blood vessel is comprised of three layers: intima, media and 
adventitia. The intima consists of a monolayer of endothelial cells and an internal elastic 
membrane. The media consists of smooth muscle cells. The thickness of the media varies 
depending on the type, i. e. arterial or venous, and size of the blood vessel. The adventitia 
is composed of an external elastic membrane and supportive connective tissue. 
Three important properties are responsible for the pathophysiological role of 
vasculature: permeability, fragility and vasoconstriction. Increased vascular permeability 
results in blood leaving the blood vessel and manifests as petechiae, purpura or 
ecchymoses in severe cases. Increased fragility can lead to the rupture of the blood vessel 
also resulting in petechiae, purpura, ecchymoses or deep-tissue haemorrhage. 
Vasoconstriction is controlled by local factors e. g. temperature; pH; pCO2; sympathetic 
nervous system; and humoral factors e. g. epinephrine, norepinephrine, adenosine 
diphosphate (ADP), kinins, thromboxanes, fibrin(ogen)-degradation products (FDP). 
When injury to blood vessels occurs, a reflex vasoconstriction produces marked 
reduction or shunting of blood flow. The injury to vascular endothelium also results in 
the exposure of subendothelial collagen and basement membrane, platelets are 
immediately recruited to fill the endothelial gap and form a primary haemostatic plug. 
Concurrently, cells from the media layer differentiate and migrate through the internal 
elastic membrane and eventually differentiate into new endothelial cells to complete a 
reparative process. (Bick 1993, Jaffe 1995) 
Subendothelial collagen and basement membrane as well as the exposed tissue 
factor can activate platelets and coagulation system as described below. 
1.1.2 Platelets 
i. Morphology and biochemistry 
The platelets in peripheral blood are heterogeneous in size, density and 
morphology depending on the anticoagulant, temperature and method by which they are 
examined. The resting platelet is disc-shaped. Using a rheo-optical method, in which 
platelets are measured while rotating freely in suspension, the dimensions of resting 
platelets are 3.6 + 0.7 µm in diameter and 0.9 + 0.2 µm in thickness, with a mean platelet 
volume range from 4 to 8 fL. 
The platelet membrane consists of a bilayer of phospholipids. The distribution of 
phospholipids in the resting platelet is asymmetrical as shown by a simplified diagram in 
Figure 1.1. The outer leaflet consists mainly of phosphatidyl choline and sphingomyelin 
whereas the inner leaflet contains most of the negatively charged phospholipids, in 
particular phosphatidyl serine and phosphatidyl ethanolamine (Perret 1979). The 
mechanisms for the maintenance of an asymmetric distribution of phospholipids in 
platelet membranes are thought to be the selective affinity 
of 
cytoskeletal proteins for 
aminophospholipids (phosphatidyl serine and phosphatidyl ethanolamine) and/or the 
existence of an aminophospholipid-specific translocase activity which is ATP dependent 
and modulated by Ca 2+ (Schrott 1991). The latter actively transports aminophospholipids 
from the outer to the inner membrane. During platelet activation the aminophospholipids, 
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particularly phosphatidyl serine, become exposed on the outer leaflet of the platelet 
membrane and act as a procogulant catalytic surface as described later in this 
introduction. 
Figure 1.1 Asymmetric distribution of bilayer phospholipids of a resting 
platelet. 
EXTRACELLULAR SPACE (PLASMA) 
PC SM PC SM 
Q 
PI PE PS PC 
~/ VPS 
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(CYTOPLASM) 
PC phosphatidyl choline, SM sPhin8om elin, Pl hos hatid I inositol, PE hos hatid YPPYPPY 
ethanolamine, PS phosphatidyl serine 
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The lipid bilayer, in particular the inner leaflet, also serves as a reservoir for two 
important substrates, phosphatidyl ethanolamine and phosphatidyl inositol. Phosphatidyl 
ethanolamine is the substrate for arachidonic acid Used in prostaglandin synthesis (Schick 
1981), and phosphatidyl inositol is a substrate for inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol, the important intracellular second messengers (Siess 1986). 
Extending from the platelet surface is an extramembranous glycocalyx layer, 
which is composed of absorbed plasma proteins, 'membrane glycoproteins, 
mucopolysaccharides and sialic acids. The surface of platelet has a number of 
indentations which are the opening of the open canalicular system (surface-connecting 
tubular system). This tubular system is lined with the same membrane as the external 
surface of platelet membrane. During the release reaction, platelet granules fuse with 
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either the plasma membrane or the open canalicular system, and the substances in platelet 
organelles are then extruded to the exterior. 
Encircling the periphery of the platelet are microtubules, microfilaments, and 
actomyosin (thrombosthenin) which act as a cyotskeleton for the platelet plasma 
membrane maintaining resting platelets in their characteristic discoid shape (White 
1993). The dense tubular system is also seen at the periphery of platelets. The dense 
tubular system contains primarily adenine nucleotides and calcium. It can sequester and 
release ionised calcium when platelets are activated. It may also be a major site of 
prostaglandin synthesis. 
A schematic representative of a resting platelet as seen by electron microscopy is 
shown in Figure 1.2. 
The cytoplasm of the platelet contains several organelles: dense bodies, a- 
granules, mitocondria, lysosomes and glycogen granules. The major contents of dense 
bodies, a-granules and lysosomes are shown in Table 1.1. 
f 
4 
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Figure 1.2 A schematic representation of a resting platelet as seen by electron 
microscopy. 
Left-equatorial plane, right-cross-section (From Isenberg WM, Baintain DF. In: 
Hoffman R, Benz EJ, Shattill SJ, Furri B, Cohen HJ, Sulberstein LE, eds. Hematology: Basic 
principles and practice, p1516-1524. ) 
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Table 1.1 Major contents of dense bodies, alpha granules and lysosome. 
Organelles Contents 
Dense bodies Nonmetabolic adenine nucleotides, serotonin, catecholamines, 
secretable Cat' 
Alpha granules Platelet specific proteins: 
PF4, ßTG, PDGF, thrombospondin 
Nonspecific (plasma) proteins: 
Fibrinogen, fibronectin, albumin, factor V, plasminogen, HMWK, vWF, 
a2-antiplasmin, aI -antitrypsin, a2-macroglobulin 
Lysosomes Acid hydrolases 
PF4 - platelet factor 4,3TG -ß thromboglobulin, PDGF - platelet 
derived growth factor, 
HMWK - high molecular weight kininogen, vWF - von Willebrand 
Factor 
5 
ii. Platelet proteins 
Platelets contain several proteins, some of which are common to plasma, but 
some are unique to platelets and present in only trace amounts in plasma. Some platelet 
proteins which have major roles in haemostasis are described below. 
a. Platelet factors 
So far platelet factors 1 to 7 have been identified. The most important are platelet 
factor 3 (PF3) and platelet factor 4 (PF4). PF3 (platelet thromboplastin) is required in at 
least two steps in blood coagulation: the activation of factor X by factor IXa and factor 
VIIIa, and the formation of prothrombinase by the interaction between factor Xa and 
factor Va (Rosing 1988, Schrott 1991). As PF3 is made available on platelet membranes 
when platelets are activated, it has been suggested that it is associated with the exposed 
aminophospholipids. 
PF4 (antiheparin factor) binds to heparin with high affinity and neutralises 
heparin's anticoagulant activity. 
b. 6-thromboglobulin 
ßTG also binds to heparin but with lower affinity than PF4, thus ßTG neutralises 
heparin less well. 
c. Thrombospondin 
Thrombospondin is an adhesive glycoprotein present almost exclusively inside 
platelets. It binds to several receptors on platelet membrane including GPIIb/IIIa, 
proteoglycan, GPIV (CD36) and fibrinogen. Thrombospondin appears to stabilise formed 
platelet aggregates and may also modulate fibrinolysis. 
d. Platelet actomyosin (thrombosthenin) 
This protein functions in most aspects similarly to smooth muscle. An increase in 
cytoplasmic Ca 2+ leads to the activation of myosin and the conversion of monomeric 
actin to filamentous actin. Polymerisation of filamentous actin and myosin provides the 
6 
mechanical force for various phenomena involved in platelet activation i. e. shape change 
and release reaction. 
e. Platelet glycoproteins 
Platelet glycoproteins are important structural components of the platelet 
membrane that interact with the vasculature, other platelets and plasma proteins. The 
major glycoproteins on platelet surface membrane, lysosomal, alpha, and dense granule 
membranes are summarised in Table 1.2 and described below. 
GPIa/IIa (CD49b/CD29) 
Platelet adhesion to collagen mediated by GPIa/IIa requires magnesium and is 
inhibited by calcium. The interaction is not dependent on vWF. 
GPIb/GPIX (CD42) 
GPIb is composed of GEIba (CD42b) bound to GPIbß (CD42c) with a disulphide 
bond. GPIb extends much further out from the platelet surface than does GPIIb/IIIa, 
which may account for its major role in platelet adhesion. This long extension may also 
make it susceptible to conformational changes induced by shear forces. The extracellular 
region of GPIba can be cleaved by several proteases including platelet calpains, yielding 
a soluble fragment called glycocalicin that circulates in normal plasma at I to 3 gg/ml. 
The cytoplasmic domain of GPIba connects to actin-binding protein, so alterations in the 
platelet cytoskeleton can affect GPIb functional activity. 
GPIb appears on the surface of platelets in a one-to-one complex with GPIX. The 
function of GPIX is unknown but it is probably required for efficient surface expression 
of GPIb. 
GPIb mediates platelet interaction with vWF via the region which does not 
contain Arg-Gly-Asp (RGD) and unlike GPIIb/Illa does not require platelet activation. 
Plasma vWF will not bind to GPIb unless the antibiotic ristocetin or the snake venom 
7 
botrocetin is added. However, when vWF is immobilised on a surface, it may undergo a 
conformation change, allowing direct interaction between GPIb and vWF, even in the 
absence of ristocetin or botrocetin. 
GPIc/IIa (CD49e/CD29) 
GPIc/IIa mediates the adhesion of resting platelets to fibronectin. The biological 
role of these glycoproteins is not clear. It may involve in the binding of megakaryocytes 
to bone marrow matrix. 
GPIIb/IIIa (CD41 /CD61) 
There are 40,000 to 80,000 GPIIb/IHa molecules on the surface of a resting 
platelet. Another 20,000 to 40,000 molecules are present inside platelets, primarily in 
a-granule membranes and the membranes lining the open canalicular system. These can 
join the plasma membrane upon platelet activation and release reaction. 
On resting platelets, GPIIb/IIIa has a low affinity binding for soluble fibrinogen. 
When platelets are activated with various agonists, changes in GPIIb/IIIa occur, leading 
to strong binding to fibrinogen. Binding "Of fibrinogen to platelet GPIIb/IIIa leads to 
platelet aggregation via cross-linking of GPIIb/IIIa on two different platelets by 
fibrinogen. In addition to fibrinogen, upon platelet activation, GPIIb/IIIa can bind to 
several other adhesive proteins containing RGD sequences. These include vWF, 
fibronectin and thrombospondin. 
GPIV (CD36) 
GPIV has been proposed as a platelet receptor for thrombospondin and collagen 
but its functional significance remains unclear as no clinical 
symptoms have observed in 
individuals who lack GPIV. 
GPV 
GPV appears to form a non-covalent complex with GPIb/IX. However, since the 
number of GPV molecules is approximately 50 percent of the number of GPlb/IX 
8 
molecules, it has been suggested that the complex consists of two GPIb molecules, two 
GPIX molecules, and one GPV molecule. GPV possibly involves in the expression of 
GPIb/IX. 
GPVI 
The binding of GPVI to collagen occurs as a "two-site, two-step" interaction. The 
binding of GPIa/IIa to collagen allows the binding of GPVI. The interaction between GP 
VI and collagen induces platelet activation via the phospholipase C pathway leading to 
the generation of second messengers in platelets (Pasquet 1999, Watson 1999). 
P-selectin (GMP140, PADGEM, CD62P) 
There are 2,500 molecules of P-selectin on the surface of a resting platelet and 
20,000 molecules in the membrane of a granules which fuses with the plasma membrane 
when platelets are activated. The expression of P-selectin on the platelet membrane has, 
therefore, been used as an indicator of platelet activation (McEver 1990). P-selectin 
mediates the adherence of neutrophils and monocytes to platelets and endothelial cells 
via the sialyl-3-fucosyl-N-acetyl-lactosammne (SLex, CD155) (Larsen 1989, Handa 
1991). In intact blood vessels, the interaction between neutrophils and P-selectin on 
endothelial cells leads to leucocytes rolling on the endothelium, the first step in leucocyte 
transmigration (Mayadas 1993). The role of P-setectin in platelets has not been fully 
defined but is thought to be important in the imflammatory response. 
CD63 (LAMP-3) 
This protein is present in both lysosomal and dense granule membranes. When 
platelets are activated, it fuses with platelet surface membrane; making it a useful marker 
for platelet activation (Nieuwenhuis 1987, Abrams 1991). 
9 
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iii. Platelet energy generation 
Platelet energy is derived from the metabolism of glucose, which is taken up from 
the plasma, and to a lesser extent from the metabolism of fatty acids. The energy is 
utilised for the maintenance of platelet structural integrity and the response of platelet to 
stimuli. The metabolism of carbohydrate in platelets is similar to that of other cells. 
About 80% of the glucose taken up by platelets is metabolised anaerobically (glycolysis), 
whereas one-fifth is carried through aerobically (oxidative phosphorylation). However, 
during glycolysis one mole of glucose gives a net yield of two moles of ATP, whereas 
during oxidative phosphorylation 38 moles of ATP are produced. There are different 
opinions about which is most important in the production of ATP for maintenance of 
platelet function, as each of the pathways alone can produce sufficient ATP in platelets 
under normal nutritional conditions (Holmsen 1985). 
iv. Platelet function 
Only the platelet functions important in haemostasis are described. Other 
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functions including phagocytosis are not in the scope of this introduction. 
a. Platelet shape change 
Upon activation, platelets transformed from normal discoid shape to spiny 
spheres with several long, thin protrusions (filopodia, pseudopods). This process involves 
contraction of the cytoplasmic microfilaments, centralisation of organelles, actin 
polymerisation and bundling in the filopodia. Platelet shape change may facilitate platelet 
adhesion by the reduction of electrostatic repulsion, thus the end of the filopodia can 
approach and make contact with a surface or a cell. 
b. Platelet adhesion 
Platelet adhesion is defined as the process of platelets adhering to nonplatelet 
surfaces such as an artificial surface or subendothelial collagen/basement membrane. 
Subendothelial collagen in injured blood vessels is the major site of platelet adhesion. 
This process requires vWF, which forms a ligand between GPIb and GPIIb/IIIa on 
platelet membrane and subendothelial collagen. 
c. Platelet release reaction 
During platelet shape change, platelet organelles gather in the centre of the cell. 
The membranes of the organelles then fuse with the membranes of the canalicular 
system, resulting in extrusion of the organelle contents into the canalicular system and to 
the extracellular environment. The release of ADP from platelet dense bodies is believed 
to be the key factor in the initiation of physiologic platelet aggregation. It induces the 
conformational change of GPIIb/IIIa, the major fibrinogen-binding site on the platelet 
membrane. 
d. Platelet aggregation 
Platelet aggregation is defined as the attachment of activated platelets to one 
another. The attachment of two platelets to one molecule of fibrinogen via GPIIb/IIIa is 
the initial step in platelet aggregation, which leads to the formation of a primary 
haemostatic plug. Once fibrin is formed, it reinforces the primary haemostatic plug which 
becomes a consolidated or secondary haemostatic plug. 
e. Signal transduction pathway and modulation of platelet function 
Collagen and thrombin are primary activators at the site of vascular injury. The 
binding of platelet agonists to receptors on platelet surfaces generates signals. These 
signals are then transduced across the plasma membrane to appropriate effector enzymes, 
such as adenyl cyclease, phospholipase C, phospholipase A2, via guanine nucleotide 
binding (G) proteins. Once the effector enzymes are activated, the second messengers, 
including ' inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DG) are generated. IP3 
releases Ca 2+ from the dense tubular system, raising the cytosolic Caz+ concentration. In 
turn, this promotes the activity of enzymes which do not function at the low Caz+ 
12 
concentration present in resting platelets. DG activates protein kinase C, triggering 
granule secretion and fibrinogen receptor exposure on GPIIb/IIIa. The rise in cytoplasmic 
Ca 2+ also facilitates the release of arachidonic acid (AA) from membrane phospholipids 
by the action of phospholipase A2. This process may occur at both the plasma membrane 
and the membrane of dense tubular system. AA is then metabolised to thromboxane A2 
(TxA2) which is a potent stimulus for platelet activation. TxA2 can diffuse across the 
membrane and interacts with receptors on the platelet surface, resulting in further platelet 
activation. While the generation of second messengers promotes platelet aggregation, 
adenyl cyclase activates the formation of cyclic AMP (cAMP) which inhibits platelet 
activation. (Figure 1.3) 
Figure 13 Signal transdpction during platelet activation. 
(From Brass LF, Hoxie JA, Manning DR. Thrombosis and Haemostasis 1993; 70: 217- 
223. ) 
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f Platelet coagulant/anticoagulant activities 
The negatively charged phospholipids in particular phosphatidylserine on the 
membrane of activated platelets act as a catalytic surface for at least two membrane- 
associated enzyme-substrate complexes, i. e. the formation of tenase (FVIIIa, FIXa, FX, 
Cat+), and prothrombinase complexes (FXa, FVa, prothrombin, Cat+) (Rosing 1988, 
Mann 1988, Schrott 1991, Zwaal 1996). It also enhances the activation of FX by tissue 
factor-FVIIa (Morrrissey 1997). The presence of a catalytic membrane is essential for at 
least three reasons. Firstly, as the coagulation proteins circulate in plasma in relatively 
low concentrations in their zymogen (inactive) forms, a recruitment process is required to 
capture and concentrate the relevant subcomponents for optimal enzyme-substrate 
interactions. Secondly, the localised binding of the coagulation factors ensures that the 
amplification process does not propagate beyond the site of injury, resulting in 
pathological occlusion of vessels by thrombus. Finally, the membrane binding protects 
the activated coagulation proteins from inhibition by physiologic inhibitors due to stearic 
hindrance. It is believed that the exposed phosphatidyl serine is the overall rate limiting 
step in the coagulation cascade in vivo. 
Although less emphasis has been placed on the anticoagulant property of the 
same catalytic membrane, it should be noted that this membrane can also support the 
formation of the protein Case complex, one of the key components in the inhibition of 
coagulation pathway as described below. 
1.1.3 Blood coagulation 
Blood coagulation is an extremely complex process, involving several inter- 
related reactions. Numerous models have been proposed to explain this process 
consisting of: a successive step of activation of coagulation factors leading to the 
generation of thrombin and fibrin formation; inhibition where various physiologic 
inhibitors play the important role in limiting the clot formation to the site of injury and 
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neutralising active procoagulant factors that may enter the systemic circulation; and 
fibrinolysis where fibrin clot is digested after its haemostatic function has been fulfilled. 
The most recent concepts are discussed below. 
i. Activation of coagulation factors 
It is widely believed that tissue factor (TF, thromboplastin, CD142) is the most 
important physiological and pathological initiator of blood coagulation in vivo as shown 
in Figure 1.4. TF is an integral membrane protein found on the surface of a variety of cell 
types normally located outside the vasculature and exposed as a consequence of vascular 
damage from mechanical injury or inflammatory process. 
In normal circulation, approximately 1 to 2% of FVII molecules are present in the 
form of FVIIa. Free FVIIa does not express enzymatic activity. However, when FVIIa 
binds to TF, it can convert FX tp FXa. FXa can generate a small amount of thrombin but 
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once produced, thrombin together with the initially formed FXa activates FV to FVa and 
FVIII to FVIIIa. FXa-TF-FVIIa complex can also activate FIX to FIXa. FIXa-FVIIIa 
(intrinsic tenase) converts FX to FXa, 
' 
and FXa-FVa (prothrombinase) converts 
prothrombin to thrombin. The production of FXa by FIXa-FMIIa is 50-fold more efficient 
than FVIla-TF. In addition, tissue factor pathway inhibitor (TFPI) binds to FXa-TF-FVIIa 
to limit the production of FIXa and FXa by this pathway. Once this inhibitory reaction 
occurs, FXa can only be produced by the FIXa-FVIIIa complex. The importance of these 
two molecules is demonstrated by the pathology associated with their abnormalities in 
vivo (Davie 1995, Mann 1999, Morrissey 1997, Nemerson 1996) 
The initiation of blood coagulation through the activation of FXII, plasma 
prekallikrein (PK) and high molecular weight kininogen (HMWK) (contact system) is an 
important pathway in the presence of artificial surfaces (Colman 1999, Mann 1999, 
Schmaier 1997,1999). However, the initiation of coagulation through this system is 
believed to be less important in vivo than TF as the deficiency of factors involved in the 
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contact system is not associated with bleeding disorders. The deficiency of FXI is 
associated with bleeding, but the pathology is mild. 
In the presence of artificial negatively charged surfaces such as glass, kaolin, 
insoluble metal complexes of elagic acid, dextran sulphate, sulfatides, or phospholipids, 
the binding of FXII leads to the autoactivation of FXII to FXIIa (Silverberg 1980) as 
shown in Figure 1.5. In addition, PK and FXI, which circulate in plasma as a complex to 
HMWK, also bind to these surfaces. FXIIa activates PK to kallikrein, then kallikrein 
reciprocally activates more FXII in a reaction that is at least 1,000-fold faster than 
autoactivation. The rate of initiation and amplification of this system is accelerated by 
HMWK. Kallikrein as well as FXIIa releases bradykinin (BK) from HMWK. FXIIa and 
kallikrein activate FXI to FXIa which activates FIX to FIXa. In the presence of activated 
platelets, FXI can also be activated by thrombin. Together with FVIIIa, FIXa forms an 
intrinsic tenase leading to thrombin formation. FXIIa can also activate FVII. 
In the absence of negatively charged artificial surfaces, it has been proposed that 
the assembly of the contact factors Qn membranes of cells in the intravascular 
compartment such as platelets, endothelial cells, neutrophils, etc., triggers the activation 
of this system. More recently, it has been proposeed that binding of PK complexed to 
HMWK on endothelial cells can generate kallikrein and BK by endothelial cell cysteine 
protease, independent of FXII activation (Motta 1998, Rojkjaer 1998, Schmaier 1997, 
1998,1999). 
The role of the contact system in antithrombosis and profibrinolysis is believed to 
be more important than in haemostasis. Kallikrein and FXIIä cleave plasminogen directly 
although the reaction is slower than tissue-plasminogen activator or urokinase 
plasminogen activator. Kininogens inhibit platelet activation by a-thrombin. Bradykinin 
is a potent stimulator of prostacyclin synthesis in the endothelial cell. Prostacyclin 
stimulates adenylate cyclase leading to increased intracellular cAMP, which inhibits 
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platelet function. Bradykinin also stimulates nitric oxide formation, which then 
stimulates guanylate cyclase leading to the elevation of cGMP and inhibition of platelet 
function. Furthermore bradykinin stimulates tissue plasminogen activator secretion, 
enhancing fibrinolysis (Schmaier 1997,1998,1999). 
Apart from the coagulation system, FXIIa, kininogens and kallikrein also 
contribute to the activation of the first complement component (Cl), and granulocytes. 
Furthermore, FXII downregulates monocyte Fc receptors, and releases IL-1 and IL-6 
from monocytes and macrophages. 
The formation of fibrin begins when thrombin cleaves fibrinopeptides A and B 
from fibrinogen, leaving fibrin monomer which aggregates to form soluble fibrin. 
Thrombin also activates FXIII to FXIIIa which converts soluble fibrin to insoluble fibrin 
by cross-linking . 
v 
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Figure t. 4 The activation of coagulation cascade by tissue factor pathway. 
(From Davie EW, Fujikawa K, Kisiel W. Biochemistry 1991; 30: 10364-10370. ) 
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Figure 1.5 The activation of the contact system on artificial surfaces. 
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ii. Inhibition of coagulation' 
v 
Similarly to other biological processes, the blood coagulation system is regulated 
by a number of inhibitory mechanisms designed to restrict clotting to a given site. Apart 
from TFPI which is formed when TF pathway is activated, there are several other 
inhibitors, referred to as serpins, containing broad spectrum serine protease inhibitors. 
The main inhibitors with their neutralising capacity are summarised in Table 1.3. The 
most three important inhibitors, antithrombin III (ATIII), protein C and protein S, are 
also described below. 
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Table 1.3. Plasma serine protease inhibitors and their neutralising capacity. 
Inhibitors 
ATIII HCII Cl inh a, AT a2M a2AP PCI TFPI 
Target enzymes 
FIIa ++ - ++ + +- 
FVlla -- - -- - -+ 
FIXa +- - -- - -- 
FXa ++ - ++ + ++ 
FXIa +- + +- + +- 
FXIIa +- + -- + -- 
Kallikrein +- + -+ - +- 
APC -- + +- + +- 
tPA --, - -- - +- 
Plasmin +- + -+ + -- 
APC-Activated protein C, tPA-Tissue plasminogen inhibitor, ATIII-Antithrombin III, HCII- 
Heparin cofactor II, Cl inh-C I inhibitor, a1A"I'-(XI-antitrypsin, a2M-a2-macroglobulin, a2AP-a2- 
antiplasmin, PCI-Protein C inhibitor, TFPI-Tissue factor pathway inhibitor 
Antithrombin III binds irreversibly with the serine proteases, thrombin, FIXa, 
FXa, FXIa, FXIIa and kallikrein, and forms complexes which are then removed from the 
circulation. The inhibitory effect of ATIII is markedly enhanced in the presence of 
heparin. 
Two interrelated pathways of the inhibitory mechanism of protein C have been 
described, both of which require a catalytic surface. Thrombin binds to thrombomodulin 
on endothelium and converts protein C to activated protein C (APC). Activated protein C 
then inactivates FVa leading to the termination of prothrombinase activity. APC can also 
inactivate FVIIIa but from a physiological perspective this is thought to be irrelevant due 
20 
to the instability of FVIIIa. Another mechanism of anticoagulant activity of protein C is 
through the formation of membrane-associated enzyme-substrate complex (protein Case) 
consisting of thrombin, thrombomodulin, protein S, and protein C. The activity of APC 
is, in turn, regulated by two major serine protease inhibitors, protein C inhibitor and al- 
antitrypsin, and also by Cl inhibitor and a2-antiplasmin. 
ii. Fibrinolysis 
The fibrinolytic system is responsible for the destruction of a fibrin clot after its 
haemostatic function has been fulfilled. This system consists of plasminogen 
(proenzyme) which can be converted to plasmin (active enzyme) by several pathways. 
Two primary plasminogen activators in physiological conditions are tissue plasminogen 
activator (tPA) and urokinase-like plasminogen activator . 
Plasmin can also be generated 
by direct/indirect activation by FXIIa and kallikrein (Rojkjaer 1998). Unlike thrombin 
which has a very narrow substrate specificity, plasmin has a much broader spectrum of 
activity with a number of substrates. Plasmin biodegrades fibrinogen and fibrin into 
fibrin(ogen)-degradation products (FDPs). "Plasmin also degrades FV, FVIII, FIX and 
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FXI. Plasmin exists in both free and fibrin-adsorbed forms. Free plasmin is rapidly 
destroyed by antiplasmin. This confines the fibrinolytic activity to the site that it is 
required in physiologic conditions i. e. within the fibrin mass. The binding of plasmin to 
fibrin blocks the anitplasmin binding sites and protects plasmin from inactivation. 
The fibrinolytic system is regulated by several inhibitors (Table 1.3). The major 
inhibitors of plasmin are a2-antiplasmin (plasmin inhibitor) and a2-macroglobulin. The 
inhibitors of tPA are tissue plasminogen activator inhibitors 
t and 2 (tPAI-I and tPAI-2). 
1.1.4 Complement system 
Similar to the coagulation cascade, the complement system is activated through a 
cascade of proteolytic cleavage of its earlier components. Upon activation the 
complement proteins can give rise to mediators of chemotaxis, increased vascular 
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permeability, opsonic activity, phagocytic activation, and cytolysis (Table 1.4). The 
activation of complement system can occur via two pathways, classical and alternative as 
summarised in Figure 1.6. The classical pathway is initiated by complement-fixing 
immune complexes (IgG and IgM), while the alternative pathway is triggered by a variety 
of substances including IgA aggregates, endotoxin, and bacterial cell wall 
polysaccharides. 
The classical pathway proceeds by fixing Cl (Cl q, r, s) with the Fc portion of IgG 
or IgM. The activated Cl them cleaves C2 and C4 to form C3 convertase (C4b2a). The 
alternative pathway, however, cleaves C3 to C3a and C3b directly. C3b binds to factor B 
and D and is stabilised by properdin to form C3 convertase (C3bBbP). C3 convertase 
generated by either pathway cleaves C3. C3 convertase binds to C3b to form C5 
convertase which cleaves C5 into C5a and C5b. C5b is then binds to C6, C7, C8 and C9 
to form C5b-9, the membrane attack complex. (McAleer 1993, Meri 1998, Mollnes 1998) 
Figure 1.6 The activation of complement system. 
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Table 1.4 Proinflammatory complement components. 
Complement component Biological activity 
C3a (anaphylatoxin) Increases vascular permeability 
C5a (anaphylatoxin) Increases vascular permeability, chemotaxis and activation 
of granulocytes 
C3b Opsonises particulates e. g. bacteria, and binds to 
phagocytes 
C5b-9 (membrane attack complex) Cytolysis, trigger cytokine, prostaglandin release, and 
oxidant production by monocytes 
The complement system is regulated by three control systems: direct inhibition of 
serine proteases, decay and destruction of convertases, and control of the membrane 
attack complex. Table 1.5 describes the regulation of the complement system. 
Table 1.5 Control of the comQlement system. 
Inhibition of serine protease 
Cl inhibitor dissociates C1r and C1s from CI q-activated complex. 
Decay and destruction of convertases 
C2a and Bb are dissociated from C3a convertase and C5a convertase 
C4b-binding protein, factor 1, factor H, complement receptor type I (CR1) and decay 
accelerating factor (DAF) bind to C3a convertase and C5a convertase causing dissociation of the 
proteins with decay accelerating activity 
Control of membrane attack complex 
S-protein (vitronectin), SP40, and MAC-inhibiting protein (MIP) inhibit MAC formation. 
CD59 (protectin, homologous restriction factor HRF 20) inhibits cell lysis by preventing channel 
formation in the membrane. 
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1.2 PLATELET CONCENTRATES FOR TRANSFUSION 
1.2.1 Preparation of platelet concentrates 
Platelets for transfusion have been prepared since the 1960s (Aster 1965). The 
separation of platelets from whole blood is based on differential centrifugation as various 
cellular components of blood i. e. red blood cells, leucocytes and platelets have different 
specific gravity, and hence a different sedimentation velocity. Three main procedures for 
harvesting platelets for transfusion are currently in use. The first two use whole blood 
donations of 450 + 45 mL as the start material, while the third harvests platelets and 
return other blood elements to the donor. 
i. Platelet rich plasma method 
In this method, platelets are separated from whole blood by two-stage differential 
centrifugation. In the first stage, a "soft spin" (e. g. up to 1000 g, 2-4 minutes) is used to 
separate platelet rich plasma containing the majority of platelets and 30 to 50% of 
leucocytes as well as some red blood cells, from the majority of red blood cells. Platelet 
rich plasma is then transferred to a satellite bag and platelets are pelleted in the second 
stage using a "hard spin" (e. g. 2000-3000 g, 7-10 minutes). This is the routine method in 
North America. The high centrifugation g force used to pellet platelets against the bottom 
of the bag is highly traumatic to platelets. This leads to high levels of platelet activation 
and aggregation, as compared to platelets prepared by buffy coat method described below 
(Fijnheer 1990, Metcalfe 1997). 
ii. Buffy coat method 
This is the routine method in the UK. This method uses a special bag system, 
"bottom and top", and a "hard spin" (e. g. 2,000 to 3,000 g, 7 to 10 minutes) to separate 
buffy coat from plasma and red blood cells (Figure 1.7). The buffy coat obtained contains 
approximately 70 to 80% of the platelets and leucocytes, and 10% of the red 
blood cells 
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present in a unit of whole blood. Platelets can be prepared from either a single unit or a 
pool of 4 to 6 units of bully coats with plasma added. Platelets are harvested using a "soft 
spin" (e. g. 700 to 1000 g, 2-5 minutes). As the pelletting process is performed on a 
cushion of leucocytes and red blood cells, platelets prepared from bully coat method are 
less activated than platelet rich plasma method (Fijnheer 1990, Metcalfe 1997). 
W. Plateletpheresis 
Using automated apheresis machines, after platelets have been separated from 
whole blood, red cells and some plasma are either returned to the donor or collected as 
separate components. Although the underlying principle is still based on differential 
centrifugation, the final product from one donor contains sufficient number of platelets 
for at least one therapeutic dose i. e. 240x 109 platelets. Furthermore, with some new 
generation machines, double or even triple doses can be collected from a single donation 
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by selecting donors with a certain pre-donation platelet count. In addition, almost all of 
the modem apheresis machines provide leucocyte depleted products i. e. less than 5x 106 
leucocytes per unit of one therapeutic dose of platelets, either with or without the use of a 
leucocyte removal filter. 
Three major techniques for plateletpheresis are employed by various 
manufacturers: 
a. Buffy coat technique 
This technique is used in the Haemonetics MCS+ apheresis machine 
(Haemonetics, Baintree, MA, USA) (Haemonetics Manual) (Figure 1.8). Anticoagulated 
whole blood is pumped into a spinning "Latham" bowl and separated into red cells, buffy 
coat and plasma layers. Once the plasma separation is detected by the optical sensor, 
plasma is pumped into a plasma bag with some recirculating into the bowl to dilute the 
buffy coat layer for a better separation of platelets (dwell phase). The dwell phase is 
followed by the surge phase where plasma is pumped out of the bowl passing an optical 
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sensor and the light transmission is recorded as 100%. As platelets start to exit the bowl, 
the light transmission decreases and when it reaches the threshold setting i. e. 87%, the 
collection of platelets starts. The sensor continues to monitor the light transmission, and 
once the maximal number of platelets have exited the bowl the light transmission will 
start to increase which terminates platelet collection. Red cells which remain in the bowl 
are then returned to the donor with plasma before the next cycle begins. With the 
modification of software using the "LD" collection protocol, filtration of platelet 
concentrates can be carried out automatically during the last return cycle or during each 
return cycle (Holme 1999). 
b. Platelet rich plasma combined with fluidised particle-bed 
This technique is used in the COBE Spectra Leucoreduction System [LRS] 
(COBE BCT, Lakewood, KO, USA) to provide leucocyte depleted platelet concentrates 
without leucocyte filtration (Adams 1998) (Figure 1.9). The machine consists of a 
polyester conical shape chamber (LRS chamber) connected to a rotating blood collection 
" 
set. Firstly, platelet rich plasma is separated from whole blood in the blood collection set. 
Secondly, the platelet rich plasma is pumped into the rotating LRS chamber. As flow 
begins, the plasma flow velocity through the chamber is directed radially inward, 
whereas the platelet flow velocity is directed radially outward. Platelets start to sediment 
in the chamber and continue to accumulate to create a saturated platelet bed. At 
saturation, the interstitial plasma velocity between platelets is slightly greater than the 
plasma sedimentation velocity, and the flow past any single platelet is just large enough 
to lift the platelet slowly out of the gravitation field. The leucocytes that enter the 
chamber with platelets sediment much faster than platelets and remain trapped below 
(radially outward from) the platelet bed in the chamber. 
c. Platelet rich plasma combined with elutriation 
This technique is employed by the Amicus apheresis machine (Baxter Healthcare, 
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Illinois, USA) and provides leucocyte depleted platelets without the use of a leucocyte 
removal filter (Burgstaler 1997) (Figure 1.10). The system contains separation and 
collection containers connected like a belt by a multilumen tube. Anticoagulated whole 
blood is drawn into the separation chamber where platelet rich plasma is separated from 
red cells and most of the leucocytes by centrifugation. Inside the centrifuge is an interface 
detector which keeps the interface separation constant throughout the whole procedure. 
The platelet rich plasma is pumped into the collection chamber where platelets are 
concentrated; some of the platelet rich plasma is recycled back to the incoming whole 
blood to reduce the haematocrit prior to entering the separation chamber. As the reduced 
haematocrit blood enters the separation chamber, the platelet rich plasma exits quickly 
causing an elutriation effect, pushing large platelets on the interface out of the separation 
chamber at the same end w, here the whole blood enters. 
At the same time as platelet rich plasma is drawn out of the separation chamber, 
granulocytes, cells with relatively high specific gravity, drop to the bottom of the 
chamber and exit with red blood cells to be returned to the donor. Mononuclear cells are 
drawn off with platelet rich plasma but when they encounter more dilute red blood cells 
they drop back down again; hence they loop around the far end of the chamber. 
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Figure 1.7 Preparation of platelet concentrates by buffy coat method. 
a. Configuration of the "bottom and top" bag system. b. Whole blood is collected from 
the lower tubing into the primary bag containing CPD anticoagulant. c. After centrifugation, the 
plasma is transferred into the upper transfer bag, while the red cells are pressed simultaneously 
into the lower transfer bag. d. The bully coat remains in the primary bag. e. One unit of plasma 
and four units of huffy coats pooled into one of the buffy coat bags (BC4). f. The bag containing 
pooled bully coats is connected to an in-process leucocyte removal filter attached to a platelet 
storage bag. After centrifugation, the platelet rich plasma is passed through the filter into the 
storage bag. 
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Figure 1.9 Platelet collection by Cobe LRS. 
In the blood collection set (top) platelet rich plasma is separated from whole blood and 
pumped into the spinning LRS chamber (bottom). Leucocytes are trapped below the platelet bed 
in the chamber. 
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Figure 1.10 Platelet collection by Amicus. 
The separation and collection chambers are connected like a belt (top). In the separation 
chamber (bottom, cross section), platelet rich plasma (yellow) is separated from'red cells (red) and 
most of the leucocytes (round particles). The exit of platelet rich plasma causes an elutriation 
effect making leucocytes drop to the bottom of the chamber. 
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1.2.2 Storage of platelet concentrates 
Currently platelet concentrates for clinical use can be stored up to 5 days and still 
provide effective haemostatic function in vivo. However, they must be stored in optimal 
conditions influenced by the following: 
I. Storage bags 
To maintain their physiologic function platelets are required to be stored in a 
container made from biocompatible materials which allow oxygen/carbon dioxide 
exchange. For this purpose polyvinylchloride (PVC), a polymer, in combination with 
various plasticisers has been used. PVC, when unplasticised, is rigid. Plasticisers are 
liquids that dissolve in a polymer. The resultant mixture is a solution of a liquid in a 
solid. This lowers the attraction between the polymer chains and allows them to slide by 
each other. In effect, a plasticiser reduces the crytallinity of polymer, hence increasing the 
flexibility. 
Several plasticisers are currently in used in platelet storage bags. These are 
diethylhexylphthlate (DEHP, sometimes referred to as dioctylphthalate or DOP), trioctyl 
trimellitate (TOTM, sometimes referred to as triethylhexyl trimelliate or TEHTM), 
butyryl tri-n-hexyl citrate (BTHC), and di-n-decylphthalate (DnDP). 
Plasticisers are highly soluble in lipids. Various amounts of plasticisers, 
depending on their solubility characteristics, are leached into plasma and some are 
incorporated into the platelet membrane (Fratantoni 1992). Although significant amounts 
of plasticisers are transfused into patients receiving platelet concentrates, they are far 
below the toxic dose. More important are their effects on platelet function and membrane 
integrity. The partition of plasticisers into platelet membrane has been shown to enhance 
membrane stabilisation and reduce platelet responses to stimuli measured by shape 
change and aggregation (Ishikawa 1984, Shimizu 1989). However, it is unclear whether 
the reported findings were solely due to the effect of plasticisers or also the results of 
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other variables i. e. oxygen content and pH. Furthermore, it is not known whether such 
effects are beneficial or harmful. On the one hand, the stabilisation of the platelet 
membrane reduces changes occurring during storage. On the other hand, the decrease of 
platelet response to stimuli may affect in vivo haemostatic effectiveness. 
More recently, platelet storage bag made from modified polyolefin has become 
available. Unlike PVC, it does not require plasticiser. 
ii. Agitators 
Continual gentle agitation is essential during the storage of platelet concentrates 
to facilitate gas exchange within the bag and reduce the formation of platelet aggregates. 
However, agitation may also stimulate platelets through interaction with the bag wall. 
Three kinds of agitators have been designed: flatbed (tumbler, horizontal) 90 cycles per 
minute, circular (end-over-end) 2 rpm, and elliptical (side-over-side) 6 rpm agitators. The 
importance of the type of agitators during storage has been highlighted by a study 
comparing changes in platelet concentrates kept on flatbed vs elliptical agitators. 
Platelets stored in the latter rotator showed higher levels of P-selectin, greater loss of 
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GPIb and higher level of microvesicles (George 1992). This observation was attributed 
to the mixing features of the agitators used in the study. In the flatbed agitator the platelet 
bags were face up or face down, with no trapping of platelets in the folds or edges of the 
bag, achieving thorough mixing of the platelet suspension. In the elliptical agitator the 
bags were placed edge up and edge down, and an end of the bag had to be folded to hold 
it in a clip of the rotator. This design led to trapping of some platelets into the folded 
edges and corners of the bag, and hence incomplete mixing and aggregate formation. 
iii. Storage temperature 
Platelet concentrates were routinely stored at 2 to 4°C in the same manner as red 
cell concentrates until 1969 when it was shown that the viability of refrigerated platelets 
was less than half that of platelets kept at 22°C (Murphy 1969). The mechanism of the 
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shortened life-span of cold stored platelets is unknown but appears to be related to cold- 
induced discoid-spheric transformation, loss of platelet membrane GPIb and 
microvesiculation (Bode 1994). 
iii. Platelet storage media 
Traditionally, platelets are suspended and stored in plasma. Platelet storage media 
(PSM) or platelet additive solutions (PAS) were developed to increase plasma 
availability for plasma protein fractionation, in particular to manufacture more FVIII 
used for haemophiliacs. The use of platelet storage media may also have some other 
potential benefits such as reducing the possible adverse reactions associated with plasma 
proteins and improving platelet quality by providing better nutritional supply (Adams 
1986, Eriksson 1990, Holme 1987,1992, Bertolini 1992a, b, Shimizu 1992, Gullikson 
1993,1995, Murphy 1995). TIie composition of -platelet storage media is variable as 
shown in Table 1.6. 
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The presence of glucose creates manufacturing problems because of its 
caramelisation during sterilisation at neutral pH. Consequently, the recent practice has 
been to not include glucose and use acetate as an alternative fuel. Acetate also provides 
buffering effect as it requires hydrogen ion to convert to acetyl CoA (Figure 1.10). The 
need for glucose in the storage media is debated because it contributes only approximately 
15% of ATP regeneration. Nevertheless, it may be required for the activity of the hexose 
monophosphate shunt and for the provision of ATP for specific membrane functions such 
as Na+/K+ exchange (Paul 1983). 
To date studies have shown that approximately 30% of plasma is required with the 
use of glucose-free storage media to provide an optimal storage condition (Murphy 1999). 
The benefit of the carryover plasma might be due to that it provides glucose as well as 
some proteins such as albumin that may play a role in maintaining the structural integrity 
of platelets. I 
1.3 LEUCOCYTE DEPLETION OF PLATELET CONCENTRATES 
According to the Guidelines for the Blood Transfusion Services in the UK, 
leucocyte depleted blood products contain less than 5x 106 leucocytes per unit of adult 
therapeutic dose. The use of leucocyte-depleted platelet concentrates has been associated 
with a number of clinical advantages e. g. reduction in HLA alloimmunisation, 
transmission of cell-associated viruses such as cytomegalovirus, and alloimmunisation 
(Bordin 1994). Since November 1999, all blood components in the UK have been 
subjected to a leucocyte depletion step, as a precaution against the theoretical possibility 
of variant Creutzfeldt-Jacob disease (vCJD) transmission. This is because of evidence that 
the infectivity may be leucocyte associated (Turner 1999). 
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1.3.1 Techniques available 
Currently leucocyte depleted platelet concentrates can be prepared by four major 
techniques: 
1. Leucocyte filtration of platelets derived from whole blood units 
ii. Leucocyte filtration of platelets collected by apheresis i. e. Haemonetics 
MCS+ LD 
iii. Fluidised particle bed technology using Cobe Spectra LRS apheresis 
machine 
iv. Elutriation using Amicus apheresis machine 
1.3.2 Mechanisms of leucocyte removal by filters 
Modem leucocyte removal filters for platelet concentrates are made of two major 
types of synthetic materials, i. e. polyester and polyurethane. While polyester microfibres 
require surface charge modification to increase selective leucocyte removal and to 
decrease platelet binding to the filter (Kickler 1989, Cenni 1993), polyurethane, due to its 
microdomain structure, does not (Branwood 1994). Furthermore, the structure of filters 
made from polyester fibres is described as7a mesh of nonwoven fibres, whereas those 
made from polyurethane are described as multiple layers of sponge-like porous sheet. The 
summary of the characteristic of major leucocyte removal filters is shown in Table 1.7. 
Scanning electron micrographs of polyester and polyurethrane filters are shown in Figure 
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Table 1.7 Synthetic material and structure of three commonly used white cell 
removal filters for platelet concentrates. 
Filter Manufacturer Synthetic material Structure 
Autostop BC Pall Biomedical 
Sepacell PLXS Asahi Medical 
Imugard III Terumo 
negatively charged mesh of nonwoven fibres 
polyester 
positively charged mesh of nonwoven fibres 
polyester 
neutrally charged layers of sponge-like porous 
polyurethane sheet 
Figure 1.11 Scanning electron micrographs of polyester and polyurethane filters. 
Top panels-polyurethane, bottom-polyester. (x3000) 
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While the mechanisms by which leucocytes are retained by filters for red cell 
products have been studied (Steneker 1992, Dzik 1993), the mechanisms involved in 
filters for platelet concentrates are not precisely known and some of the mechanisms 
described in the former are not applicable to the latter. Nevertheless, it is believed that the 
mechanisms are multifactorial and include: 
i. Sieving or mechanical retention 
This mechanism is based on size exclusion as platelets are smaller than leucocytes. 
The efficiency of this process involved several factors. These include cell deformability, 
cell concentration, and composition of blood product, as well as filter fibre diameter, 
density, total surface area, surface tension, pore diameter and pore size distribution (Dzik 
1993). 
ii. Cell adhesion, 
Leucocytes can adhere to filter materials by several mechanisms, i. e. direct 
binding; indirect binding mediated by leucocyte adhesion molecules (such as 02 integrins) 
and/or pre-adsorbed plasma proteins (such as immunoglobulin, fibronectin); and 
interaction with platelets via P-selectin (Dzik 1993). 
1.3.3 Effect of leucocyte removal filters for platelets on blood physiology 
The contact of platelets and plasma proteins with filter materials can lead to a 
number of biological interactions: 
i. Interaction with platelets 
Several studies have shown that leucocyte filtration using various filters does not 
cause platelet activation (Bertolini 1990, Pedigo 1993, Metcalfe 1997). However, it is also 
possible that activated platelets expressing P-selectin are retained by the filters through the 
interaction with leucocytes. 
ii. Generation or removal of microvesicles 
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During leucocyte filtration, platelets are subjected to shear stress. Studies have 
shown that shear stress can induce platelet activation and microvesiculation (Sakariassen 
1998). On the other hand, it is possible that the pre-formed microvesicles can be removed 
by filter through the interaction between microvesicles expressing P-selectin and 
leucocytes. It is not known whether the final filtered products contain higher or lower 
numbers of microvesicles than pre-filtered counterparts. 
iii. Activation of the contact system of coagulation 
The interaction between FXII and the artificial surface of filters, in particular those 
with a net negative charge, leads to the activation of the contact system resulting in the 
generation of bradykinin, a potent vasodilatory peptide. This interaction is reportedly 
associated with hypotensive reactions in transfused patients also receiving angiotensin 
converting enzyme (ACE) inhibitors (Hume 1996, 'Sano 1996, Mair 1998). Normally, 
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bradykinin in plasma is degraded very rapidly (half-life 15 seconds) by kininase I and II. 
Kininase II (angiotensin converting enzyme) is inhibited by ACE inhibitors, thus the half- 
y 
life of bradykinin is prolonged. The levels of bradykinin generated in platelet concentrates 
filtered with negatively charged filters are variable (Shiba 1997). If the level is sufficiently 
high, 0.5-1 gg/kg body weight (Bonner 1990), it can cause hypotensive reactions. The 
interaction between negatively charged filters, bradykinin generation and ACE inhibitors is 
summarised in Figure 1.12. 
The activation of the contact system may also lead to thrombin generation which 
can activate platelets. 
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Figure 1.12 The interaction between negatively charged filter, bradykinin 
generation and ACE inhibitors. 
Dashed arrow shows the inhibitory effect of ACE inhibitors on kininase. 
FXII 
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iv. Interaction with complement 
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The artificial surface of leucocyte removal filters can either activate complement 
via the alternative pathway or remove anaphylatoxins, C3a, C4a and C5a, depending on 
the type of filters used. Negatively charged polyester filters remove anaphylatoxins, which 
are positively charged, most likely by electrostatic interactions, whereas positively charged 
polyester filters increase the levels of anaphylatoxins (Snyder 1996, Geiger 1997). 
1.4 PLATELET STORAGE LESION 
Despite the continual improvement in platelet storage conditions, deleterious 
changes in platelets during storage, the so called platelet storage lesion, resulting in 
impaired platelet function in vivo remains a challenging area to be resolved. Platelets are 
extremely sensitive to their microenvironment and the storage lesion starts from the 
41 
moment of blood collection from the donor to the administration to a patient. The platelet 
storage lesion encompasses multiple changes in platelet morphology, metabolism, 
activation and microvesiculation, leading to impaired functionality. Although much 
emphasis has been placed on the effect of pH on platelet storage lesion, several other 
factors during processing and storage of platelet concentrates can also influence the 
storage lesion. These include preparation method, composition of the storage bag, storage 
condition, and leucocyte content as described in section 1.5. 
1.4.1 Platelet metabolism during storage 
There are some differences between platelet metabolism in vivo and during in 
vitro. Although glucose is a significant substrate for oxidative phosphorylation of 
platelets in vivo, during the storage of platelet concentrates the major substrate appears to 
be plasma free fatty acid (Cesar 1987). Almost all glucose used is metabolised via 
glycolysis by converting through pyruvate to lactate and hydrogen ions. Hydrogen ions 
are buffered by bicarbonate in plasma and converted to water and carbon dioxide, which 
r 
can leave through the wall of the storage'container. There is only enough bicarbonate in 
plasma to buffer a rise in lactate concentration to approximately 20 mmol/L. Beyond that 
concentration, the pH will fall rapidly to below 6.3 where platelet viability will be lost 
(Murphy 1985,1999). Very little pyruvate is decarboxylated to acetyl coenzyme A 
(acetyl CoA) and carbon dioxide. Instead acetyl CoA for entry into the tricarboxylic acid 
is derived from free fatty acid. Acetate used in some platelet storage media described 
below can also be converted to acetyl CoA. Figure 1.13 summarises the platelet 
metabolism in the storage conditions used for platelet concentrates for transfusion. 
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Figure 1.13 Platelet metabolism during storage. 
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1.4.2 Changes in platelet morphology 
Y 
Platelet morphology remains the best practical indicator of the survival of stored 
platelets (Murphy 1994, Holme 1997). Even freshly prepared platelets appear to form 
some pseudopods (White 1992). Figures 1.14 nd 1.15 show scanning electron 
micrographs of a discoid shape platelet as compared to a platelet with pseudopod 
formation. During storage a decline in pH, caused by lactic acid produced by glycolysis, as 
well as platelet activation, triggers the disc-to-sphere shape change, pseudopod formation, 
fusion of granule membranes to the open canalicular syste}n, swelling of the open 
canalicular system, vacuolisation due to the release of granule contents, platelet 
aggregation, and microvesicle formation (White 1992, Klinger 1994,1996). 
1.4.3 Platelet activation 
Trace amounts of thrombin and plasmin generated during blood collection and 
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contact of platelet membrane with the artificial surface of a storage container are reported 
to activate platelets (Michelson 1990). Artificial surfaces can activate platelet directly 
through the activation of specific ligands on the platelet membrane or indirectly through 
the generation of activated complements via the alternative pathway. The activation of 
platelets leads to a decrease of GPIb, increase of GPIIb/IIIa, P-selectin and CD63 
expression on platelet membrane (Bode 1991, Rinder 1993). It is controversial whether the 
loss of GPIb is due to the proteolytic cleavage or resequestration into the canalicular 
system (Michelson 1990, Bode 1991, Divers 1995). The increase in GPIIb/Illa expression 
is caused by the release of this glycoprotein from the storage pool inside platelets i. e. a- 
granules (George 1988,1992). 
y 
T 
44 
Figure 1.15 A scanning electron micrograph of an activated platelet with 
pseudopod formation. (x20,000) 
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Figure 1.14 A scanning electron micrograph of a discoid platelet. (x20,000) 
Although the same complex events (shape change, adhesion, release reaction and 
aggregation) which occur during the platelet response to various platelet agonists also 
take place in platelets during storage, they are not identical. Firstly, the above changes of 
stored platelets occur over several days as the result of continuous mild stimulation, in 
which the end products of platelet metabolism i. e. carbon dioxide and lactic acid may 
contribute to the degree of change. By contrast the activation of fresh platelets under 
laboratory conditions occurs and finishes in minutes. Secondly, platelets in stored platelet 
concentrates, which are unable to aggregate upon stimulation with low concentrations of 
ADP, still aggregate after incubation in fresh plasma (Rao 1992). Finally, platelets in 
stored platelet concentrates which express high level of P-selectin on the membrane, 
have reasonable recovery and survival in vivo (Michelson 1996). In contrast activated 
fresh platelets, which have passed the stage of reversible aggregation, are committed to 
complete the release reaction leading to the demise of the cells. 
While a fair correlation between P-selectin expression and in vivo survival has 
been reported (Holme 1997), and some sfudies point to P-selectin expression as a signal 
for the clearance of activated platelets (Larsen 1989, Rinder 1991), some studies have 
provided evidence that increased P-selectin levels may not be an indicator of decreased in 
vivo circulation time (Michelson 1996, Berger 1998). Studies performed in baboons have 
shown that transfused activated platelets have similar recovery values to transfused 
resting platelets (Michelson 1996). It has been suggested that activated platelets shed 
their surface expressed P-selectin upon transfusion and remain in circulation as P-selectin 
-negative platelets. These degranulated platelets also continue to function in vivo as seen 
by their participation in bleeding time wounds, binding to Dacron in an arteriovenous 
shunt, and-the generation of microvesicles (Michelson 1996). 
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1.4.4 Senescence of platelets 
During storage, a fraction of platelets will reach the end of their normal life span 
and subsequently release the contents of their granule contents independently of 
activation-induced release reaction. Some released substances such as ADP activate the 
remaining platelets, whereas AMP reduces platelet reactivity (Fijnheer 1992). 
The formation of platelet-derived microvesicles, another important phenomenon 
during in stored platelet concentrates, is described in detail in section 1.5. 
1.5 PLATELET-DERIVED MICROVESICLES 
1.5.1 Definition 
There is no consensus on the precise definition of a platelet-derived microvesicle 
(Plt-MV). Nevertheless it is generally agreed that Pit-MV are particulate material derived 
from the membrane of intact platelets. Several definitions have been used to describe Plt- 
MV depending on the techniques employed. Using electron microscopy, Pit-MV are 
defined as membranous structures with highly polydispersed size and intracytoplasmic 
contents. They appear to be in the range of 1 µm or smaller, some contain cytoplasmic 
organelles and some are empty membranous sacs (Warren 1972). For assessment of their 
pro/anticoagulant properties, Plt-MV are defined as material isolated from platelet poor 
plasma by either ultracentrifugation or ultrafiltration (Wolf 1967). More recently flow 
cytometry has become a method of choice for the quantitative measurement of Pit-MV. 
In this technique, Plt-MV are defined by an arbitrary gate set., by using 0.5,1 or 2µ latex 
particles or fluorescent beads or by using fresh or washed or gel filtered platelets (Miller 
1987, Fox 1991, Pasquet 1996). 
Both "microvesicle" and "microparticle" have been widely used in literature as 
synonyms. However, some consider the word "particle" is unspecific and undefined, 
47 
whereas "vesicle", as used in cell biology and pathology, has a more specific 
morphological meaning implying materials derived from endocytosis/exocytosis processes 
and containing cytoplasmic contents of the parent cell. There is ample evidence that Pit- 
MV generated by various mechanisms have different morphological and biological 
properties. In this thesis platelet-derived "microvesicle" is defined as material derived from 
the platelet membrane, regardless of its cytoplasmic contents and mechanism of 
generation. 
Although this thesis mainly deals with MV derived from platelets (MV will use as 
an abbreviation for platelet derived microvesicles, unless otherwise stated), it should be 
noted that membrane microvesiculation is not unique to platelets. Red blood cell and 
leucocytes as well as some other eukaryotic cells can also undergo microvesiculation under 
various conditions although the mechanisms involved are not well defined. For example 
red cell-derived MV have been demonstrated during storage of red cell concentrates 
(Greenwalt 1991) and the increase in intracellular Ca2+ (Bucki 1998), monocyte-derived 
MV after stimulation by lipopolysaccharide.. (Satta 1994), lymphocyte-derived MV in 
human immunodeficiency virus (HIV) type 1 infection or after stimulation (Aupeix 1997. 
Armstrong 1998), endothelial cells after stimulation by thrombin (Bizios 1988), and MV 
derived from mouse sublingual glands during secretiorr(Bos-Vreugdenhil 1985). 
1.5.2 Mechanisms of platelet-derived microvesicle formation 
Several potential mechanisms of MV formation have been proposed with 
considerable evidence that the increase in cytoplasmic calcium is a key event in most 
scenarios. No single mechanism can explain the formation of MV in all cases and it is 
highly likely that the majority of mechanisms are interdependent as shown in Figure 1.16. 
Some proposed mechanisms are also described below. 
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i. Exocytosis 
Using electron microscopy, this proposed mechanism of MV formation is based on 
the concept that upon activation MV are pre-formed inside platelets and released into the 
surrounding media when platelet membrane ruptures (Warren 1972). It is possible, 
however, that this finding was an artefact from the fixation process used in electron 
microscopy. 
ii. Shear stress and mechanical injury 
Microvesicles can be generated by blebbing of cell membranes under high shear 
stress. This mechanism is supported by the evidence that blood collected by intraoperative 
and postoperative salvage systems during cardiopulmonary bypass contains high levels of 
MVs (Sloand 1995). 
iii. Destabilisation of membrane cytoskeleton 
Different methods of physico-chemical disruption of the membrane cytoskeleton 
have shown to induce microvesiculation as shown in Figure 1.17. These include prolonged 
exposure to cold (4°C) or heat (49°C), freeze'thawing, alkali or acid pH and changes in 
calcium content (Bode 1994, George 1986). Upon exposure to cold, the microtubular ring 
disintegrates and bundling of actin filaments occurs, resulting in spheric transformation, 
pseudopod formation, and microvesiculation of plaf! lets. The effect of pH on platelet 
activation and microvesiculation are shown in Figure 1.18. At a neutral pH most platelets 
are in discoid shape. At low and high pH platelets become activated indicating by discoid 
to sphere transformation and pseudopod formation leading to microvesiculation (Solberg 
1986). 
iv. Transbilayer movement of phospholipids 
Upon activation by platelet agonists, an increase in cytoplasmic calcium occurs via 
either the transport of calcium from the external medium across the membrane or via the 
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release from the internal storage pools. The rise in cytoplasmic calcium triggers two 
potential mechanisms resulting in MV formation. Firstly, calcium induces the 
rearrangement of cytoskeletal proteins with protrusion and fusion of the apposing 
segments of plasma and/or granule membrane. This results in shedding of MV and 
transient formation of nonbilayer structures at the point where the membranes fuse to form 
MV. Secondly, the rise in cytoplasmic calcium produces a bi-directional movement of 
membrane phospholipids, the so called "flip-flop", with the outward transport of 
aminophospholipids occurring faster than inward transport of phosphatidyl choline, 
resulting in PS exposure and eversion of membrane membranes (Comfurius 1990, Bevers 
1991). 
v. Activation of calpain 
Calpain is an endogenous calcium-dependei%t protease which is activated upon 
stimulation by physiological platelet agonists such as collagen and thrombin. Activated 
calpain generates MV by hydrolysis of actin-binding protein on the membrane. The role of 
calpain in MV formation is supported by the `finding that the degree of calpain activation 
correlates positively with the amount of MV formation; and calpeptin, a membrane- 
penetrating calpain inhibitor, at concentrations that are sufficient to inhibit calpain-induced 
hydrolysis of actin-binding protein, inhibits the shedding of MVs (Fox 1991, Pasquet J-M 
1996). 
vi. Complement activation 
The component which plays a major role in platelet activation and 
microvesiculation is the membrane attack complex, C5b-9. The assembly of C5b-9 on the 
platelet membrane leads to the influx of calcium from the extracellular medium across the 
plasma membrane and secretory-fusion of alpha-granules with the plasma membrane 
(Sims 1988). 
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vii. . 
Antigen-antibody complexes 
Antibodies which bind to the platelet membrane can act as a potent activator and 
generate MV through an undefined pathway. High levels of microvesicles are found in 
idiopathic thrombocytopenic purpura (ITP) (Jy 1992), and heparin-induced 
thrombocytopenia (Warkentin 1994). Moreover, purified IgG or sera from heparin-induced 
thrombocytopenic patients can stimulate normal platelets to generate MV (Warkentin 
1994). 
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Figure 1.18 The effect of pH on platelet activation and microvesiculation. 
Left panels-scanning electron micrographs, right-transmission. At neutral pH, 
most platelets are discoid (middle panels). At low pH, platelets are activated and form 
pseudopods as well as microvesicles (top panels). At high pH, a high degree of 
microvesiculation occurs (bottom panels). (x4500) 
pH 5.87 
pH 6.91 
lp g 
pH 7.3 
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viii. Peroxidation of platelet membrane lipid 
It has been shown that all platelet membrane lipids are steadily lost during storage 
(Okuma 1971, Hamid 1980, Koerner 1986), while phospholipid membranes containing 
PF3 activity are increased in the supernatant plasma (Bode 1986, Solberg 1987). It is 
believed that this observation is related to platelet microvesiculation but it is unknown 
whether the loss of platelet membrane lipids is the cause or the effect. There are limited 
studies on platelet membrane lipids in stored platelet concentrates for transfusion. This is 
possibly because of the requirement of a special equipment and technology i. e. laser light 
scattering detection - high performance liquid chromatography. Nevertheless, it has been 
proposed that lipid peroxidation (auto-oxidation), a mechanism of lipid destruction in a 
system exposed to atmospheric oxygen, may be responsible for the loss of platelet 
membrane lipid (Koerner 1992). Figure 1.19 describes the proposed mechanism for 
peroxidation of platelet membrane lipid using ganglioside as an example. Other platelet 
membrane lipids can undergo peroxidation in the same fashion. 
v 
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Figure 1.19 The proposed mechanism for peroxidation of platelet membrane 
lipid. 
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1. A lipid in the membrane is located next to an endogenous antioxidant (AH) which is 
in its reduced form. 
2. After oxygen has been continually diffused into the cell and all of the antioxidant 
has been converted to the oxidised form (Ao). 
3. If more oxygen gets into the avll, a peroxidation of the unprotected lipid occurs, 
converting the olefinic double bond into two aldehydes and clipping the two 
hydrophobic lipid anchors that hold the lipid in the membrane. 
4. The loss of polar head group, the moiety that is responsible for the specificity of 
lipid functional activity. 
ix. Apoptosis 
It has been suggested that microvesiculation is part 'of apoptosis or programmed 
cell death, an important physiological process in eukaryotic cells which allows the 
removal of damaged cells by phagocytosis in vivo (Steller 1995). Recently, it has been 
reported that platelets, despite being anucleated cells, undergo apoptosis in vitro (Vanags 
1997, Li 1999). Some common features of apoptosis are illustrated in Figure 1.19. 
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Central to the apoptotic process is the activation of enzymes (caspases), which 
subsequently activate endonucleases and proteolytic enzymes through a cascade 
mechanism. The endonucleases digest DNA and the proteolytic enzymes digest proteins 
of the membrane cytoskeleton. The apoptotic cell disintegrates in an orderly manner into 
microvesicles, which are then cleared by phagocytosis in vivo. Cytochrome C release 
from mitochondria appears to be an important trigger by activating caspase, setting the 
cascade in motion. Exposure of phosphatidyl serine on the cell membrane surface has 
been shown in cells undergoing apoptosis (Steller 1995, Vanags 1997). 
Figure 1.19 Some common features in apoptosis. 
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1.5.3 Microvesicle in platelet concentrates for transfusion 
The presence of MV in platelet concentrates has long been demonstrated (Wolf 
1967). However, limited studies on MV during the storage of platelet concentrates are 
available. Several processing methods currently used for the preparation of platelet 
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concentrates as well as sub-optimal storage conditions may influence the platelet storage 
lesion and the rate of MV formation as discussed below. 
i. Collection and processing 
Platelets are extremely sensitive to microenvironmental conditions. From the 
initial contact of blood with the collection tubing to the time of transfusion to the 
recipient, platelets are easily activated due to contact with artificial surfaces, mixing, 
centrifugation and cell-cell interaction. These can lead to MV formation. Different 
collection and processing techniques can influence platelet activation and 
microvesiculation to variable degrees. Platelets prepared from whole blood, where during 
the initial phase of collection platelets are exposed to a high concentration of 
anticoagulant, express a higher degree of activation and microvesiculation than those 
prepared from apheresis, where they are in contact with lower concentrations of 
anticoagulant (Sloand 1996). However, it should be noted that the different 
centrifugation g force used in both techniques could also account for the degree of 
platelet activation and microvesiculation 0 the final products. 
More recently, leucocyte depletion has been implemented as a standard practice. 
Its potential effects on blood was discussed in section 1.3. 
ii. Leucocyte content 
Reports on the effect of residual leucocytes on platelet storage lesion are 
contradictory. While some studies have shown that leucocytes in platelet concentrates 
accelerate the platelet storage lesion (Sloand 1990), others have not found any difference 
between leucocyte depleted and non-leucocyte depleted products (Dzik 1992). The role 
of residual leucocytes in platelet microvesiculation is unknown but it is possible that 
proteases released from leucocytes such as elastase, cathepsin and other chymotrypsin- 
like enzymes, may contribute to proteolytic fragmentation/ microvesiculation of platelets. 
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iii. Storage containers and storage conditions 
Several types of containers with different shape, size, thickness and plasticizer 
have been designed for platelet storage. However, the currently available containers are 
still not ideal in terms of blood-biomaterial compatibility characteristics and may 
contribute to platelet activation and MV formation. Complement activation via either the 
classical or alternative pathway occurs when blood is initially exposed to the collection 
tubing and container as well as during storage (Gyongyossy-Issa 1994). It is possible that 
the inner wall of most plastic containers provides a site for complement fixation that 
could interact with platelets. The observed benefit of a reduced container surface/volume 
ratio in terms of MV generation in certain experiments (Bode 1991) may be partially 
related to a reduction in platelet collision rate with active complement compounds on the 
container wall. 
The pH of platelet concentrates has been considered as one of the major quality 
parameters. When pH falls below 6.1, platelets become spheric and form a large number 
of pseudopods on their surfaces which can" lead to MV formation. High pH, above 7.3, 
induces platelet fragmentation, generating more MV than low pH (Solberg 1986). 
The type of agitators used for the storage of platelet concentrates has been found 
to affect the degree of MV generation. Storage on an elliptical rotator leads to a higher 
concentration of MV compared with a flat bed agitator (George 1988). 
1.5.4 Clinical Implications 
Platelet-derived microvesicles are present in low levels in normal circulation. 
Higher levels have been reported in several pathological conditions in association with 
some clinical manifestations such as unstable angina (Singh 1995), diabetes mellitus 
(Strano 1991), sickle cell disease (Wun 1998), HIV infection (Holme 1998), as well as 
some other haematological disorders as described below. Although MV generated during 
processing and storage of blood components are infused along with the native cells, their 
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clinical significance have not been clarified. The possible clinical implications of MV in 
transfusion-related clinical scenarios are discussed below. 
L Haemostatic and thrombotic effects 
Microvesicles contain high proportion of phosphatidyl serine on their surfaces 
and provide an optimal catalytic surface for tenase and prothrombinase complex 
formation, leading to significant thrombin generation in vivo. The procoagulant activity 
of MV could be accountable for the observation in ITP that the patient's tendency to 
bleed does not necessarily correlate with the degree of thrombocytopenia. Patients with 
higher concentrations of MV have fewer bleeding manifestations, e. g. fewer petechiae, 
less mucous membrane bleeding, than patients who have lower levels of MV (Jy 1992). 
High levels of MV associated with thrombotic risk were also found in paroxysmal 
nocturnal haemoglobinuria (Hugel 1999). Furthermore, a haemorrhagic tendency is also 
displayed in a rare disease, Scott syndrome, in which reduced shedding of MV upon 
platelet activation is observed (Weiss 1986). 
It seems plausible that the procoagulant activity of MV may contribute to the 
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therapeutic effects of cryoprecipitate or fresh frozen plasma on the correction of bleeding 
disorders in patients with uremia and platelet storage pool disease. Significant amounts 
of platelet contamination in plasma harvested To prepare fresh frozen plasma and 
cryoprecipitate leads to MV formation produced by freezing and thawing (George 1986). 
In cryoprecipitate, MV are concentrated more than 100 times that of the original plasma. 
Cryoprecipitate obtained from desmopressin (DDAVP)-treated donors, as routinely 
practiced in some countries, is reported to be much more effective than that from normal 
donors (Konecka 1990). The improvement in efficacy may be at least partly due to the 
high content of MV as DDAVP has been found to induce platelet microvesiculation 
(Horstman 1995). 
Studies of frozen platelets have demonstrated their haemostatically effectiveness 
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to be superior to conventional liquid stored platelets, although the former shows shorter 
survival (Khuri 1999). This observation could be attributed to the MV, generated during 
the freeze-thawing process, which express higher level of bound factor V than intact 
platelets (Khuri 1999, Barnard 2000). 
Infusible MV in freeze-dried form have been demonstrated to shorten bleeding 
time in thrombocytopenic patients although their circulatory half-life is markedly shorter 
than intact platelets (Chao 1996). Nevertheless, a multiple dose infusion of these MV 
may give a sustained haemostatic effect equivalent to stored PCs. 
It should be noted that MV membrane expressing phosphatidyl serine provides a 
catalytic surface for anticoagulant as well as procoagulant reactions (Tans 1991, 
Dahlblick 1992), although the evidence for the clinical importance of MV anticoagulant 
property has not been shown. 
ii. Immunomödulation 
It has been shown that the exposure of phosphatidyl serine on cell surfaces can 
trigger the reticuloendothelial recognition process leading to adherence of the cells to 
monocytes and macrophages and clearance from the circulation into liver and spleen 
(Zwaal 1996). This process is thought to be a significant mechanism of senescence for 
circulatory blood cells. It is possible that phosphatidyl serine on MV and activated 
platelets can also trigger monocyte/macrophage recognition and consequently accelerate 
the removal of MV as well as platelets from the circulation. 
Microvesicles as well as activated platelets expressing P-selectin can adhere to 
neutrophils (Miyamoto 1998). This interaction is thought to correlate with the leucopenia 
seen in haemodialysis patients (Gawaz 1994). It remains to be elucidated whether this 
interaction leads to neutrophil activation or could potentially cause leucopenia leading to 
immunosuppression in recipients receiving blood components containing a large number 
of MV. 
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It has also been demonstrated that MV can activate adjacent platelets, endothelial, 
and monocytes, enhancing their adhesive interaction (Barry 1999a, b). 
The exposed phosphatidyl serine on MV and activated platelet membranes can 
bind to certain plasma proteins such as prothrombin and ß2-glycoprotein I, both of which 
have a high affinity to phosphatidyl serine and are relatively abundant in plasma. It has 
been proposed that this interaction may lead to the expression of neoantigens and 
providing that it is present long enough at a sufficiently high concentration in the 
circulation, it could cause antiphospholipid antibody formation (Comfurius 1995). 
iii. Alloimmunisation 
Microvesicles share several membrane antigens with intact platelets and it is 
possible that patients can be alloimmunised to these membrane antigens. This is 
supported by the evidence that ssome patients receiving cryoprecipitate develop platelet 
antibodies (George 1986). It seems likely that this is due to MV concentrated in the 
cryoprecipitate product as described previously. 
iv. Transmission of infectioUS disease 
More recently, attention has focussed on the hypothetical role of MVs in the 
transmission of variant Creuzfeldt Jacob disease by blood transfusion. This is related to 
the finding that platelets are the most abundant source of normal prion protein (PrPc) in 
blood (MacGregor 1999, Prowse 1999) and upon activation by platelet agonists, PrP° in 
platelets is expressed on the platelet surface in parallel to the platelet activation markers, 
CD62P (a-granule membrane protein) and CD63 (lysosomal membrane protein) (Holada 
1999, Perini 1996). Furthermore, ruptured platelets containing CD62P also contain PrP°. 
At least on a theoretical basis, MV could be carriers for abnormal prion protein as it is 
known to be membrane associated (Cashman 1990, Bendheim 1992). 
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1.6 WORK DESCRIBED IN THIS Ph. D. THESIS 
The main objectives of this thesis are: i) to investigate whether leucocyte 
depletion generates or removes MV in platelet concentrates for transfusion, comparing 
between three in-process leucocyte removal filters for buffy coat derived platelets, and 
between various platelet preparation/leucodepletion methods; ii) to investigate whether 
various leucocyte filters and leucocyte depletion technologies activate the activation of 
coagulation/complement systems; iii) to investigate whether MV isolated from platelet 
concentrates can act as a catalytic surface for the coagulant and anticoagulant reactions; 
and iv) to apply soluble annexin V, an intracellular protein, to the assessment of platelet 
storage lesion. 
Chapter 2 describes the general methods used in this study. For clarification, the 
methods of the assessment of MV procoagulant/anticoagulant properties are described 
separately in Chapter 7. 
Chapter 3 investigates whether leucocyte depleted platelet concentrates prepared 
by the three techniques commonly used in the UK, i. e. filtration of huffy coat derived 
platelets, MCS+ LD and Cobe LRS apheresis, have the same functional reserve as 
measured by the changes in platelet size indices upon exposure to EDTA. 
Chapter 4 investigates whether leucocyte removal filters for bully coat derived 
platelets generate or remove MV, as well as whether different filters made from different 
synthetic materials, i. e. negatively charged polyester, positively charged polyester, and 
neutrally charged (non-charged) polyurethane, have the same effects. 
Chapter 5 investigates whether the three commonly used platelet 
preparation/leucodepletion methods have the same effects on the generation and removal 
of MV. 
Chapter 6 investigates whether various filters as well as various leucodepletion 
technologies have the same effects on the activation of coagulation and complement 
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systems 
Chapter 7 investigates whether MV isolated from platelet concentrates can act as 
a catalytic surface for the coagulant and anticoagulant reactions. 
Chapter 8 investigates whether soluble annexin V can be used to assess platelet 
storage lesion. 
Finally, general discussion and references are presented in Chapters 9 and 10, 
respectively. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 FULL BLOOD COUNTS 
For platelet enumeration, an automated haematology analyser based on the direct 
current (DC) principle, Sysmex SE-9000 (TOA Medical Electronics Co. Ltd, Kobe, 
Japan), was used. After the blood sample is aspirated at a predetermined volume and 
diluted, it is sent to each detection chamber containing a small opening called aperture. 
On each side of the aperture, there is an electrode through which DC flows. When the 
blood cells pass through the aperture in a single file, the DC resistance between the 
electrodes changes, causing changes in the electrical pulse proportional to the size of the 
blood cell. Data on electrical pulses are collected and used to draw a particle size 
distribution which reflects the size of the blood cells. 
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Platelets are measured in the same detection chamber as red cells using lower and 
upper discriminators (LD and UD) set automatically for each type of cell. The red blood 
cell count is obtained from the number of particles-with size between 25-75 fL (LD) and 
200-250 fl, (UD). The platelet count is obtained from the number of particles with size 
between 2-6 fL (LD) and 12-30 fL (UD). 
2.2 FLOW CYTOMETRY TECHNIQUES 
A Coulter Epics XL flow cytometer (Coulter Electronics, Miami, Florida, USA) 
was used. The instrument was calibrated for fluorescence and light scattering using the 
manufacturer's standard beads, Flow-Check fluorospheres (Coulter Electronics). FL I 
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(fluorescein isothiocyanide, FITC), FL2 (R-phycoerythrin, RPE), FL3 (phycoerythrin- 
Texas red), and FL4 (phycoerythrin-cyanide 5, PC5) were detected using 525,575,620, 
and 675 nm band pass filters, respectively. All data were obtained with gain settings in 
the logarithmic mode. 
The optimal volume of each fluorochrome-labelled monoclonal antibody was 
determined by a titration curve. To ensure that the antibodies were always present in 
excess, twice the optimal volume was used. All antibodies were used undiluted. Each 
new batch of antibodies was titrated against the previous one. 
Flow-Check fluorospheres (Coulter Electronics, Miami, Florida, USA) were used 
for daily quality control. Following the manufacturer's instruction, the target range for 
each parameter was determined by collecting 20 data points over at least 5 days, using 
the same instrument settings as in the test protocols, and the mean of peak intensity ±2 
standard deviations was calculated. The peak intensities of FS (forward scatter signal), 
SS (side scatter signal), FLI, FL2, FL3, and FL4 were monitored and if necessary the 
voltage and amplification were adjusted so that the values fell within the target ranges. 
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2.2.1 Absolute leucocyte count in leucocyte depleted blood components 
i. Principle 
The levels of leucocytes (WBC) in platelet concentrates are below the lower 
detection limit of automated cell counters, i. e. less than 0.5 x109/L, and therefore require 
a more sensitive method of measurement such as flow cytometry. The WBC are stained 
with propidium iodide (PI), which is a nucleic acid dye and when used with ribonuclease 
(RNAse), stains only DNA. Platelets and red cells do not contain deoxyribonucleic acid 
(DNA), and their ribonucleic acid (RNA) is digested by RNAse, so that they do not stain 
with PI. The reagent also contains detergent which permeabilises cell membranes to 
allow the entry of Pl. The absolute WBC counts are obtained by using a known number 
of fluorescent beads as an internal reference. 
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ii" Reagents 
All reagents were part of the LeucoCOUNT kit (Becton Dickinson, San Jose, 
California, USA). 
1. LeucoCOUNT reagent containing propidium iodide, RNAse and detergent 
2. TruCOUNT tube containing a known number (shown on the package) of 
4.2 pm lyophilised fluorescent beads 
iii. Method 
1. Pipette 100 gL of sample into a TruCount tube. 
2. Add 400 µL of LeucoCOUNT reagents 
3. Vortex gently for 10 seconds. 
4. Incubate the tube for five minutes at room temperature in the dark. 
5. Analyse samples within 1 hour. 
6. Acquire 10000 events of fluorescent beads. A flow cytometric plot of 
leucocytes and beads is shown on Figure 2.1. 
7. Calculate the absolute leucocyte count by using the following formula: 
Absolute WBC/µL = No. of beads per TruCOUNT tube x WBC events (B) 
Bead events (A) x Volume of sample stained (µL) 
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Figure 2.1 Absolute WBC count using flow cytometry. 
Region A-fluorescent bead, region B-WBC. 
Absolute WBC/µL = No. of beads per TruCOUNT tube x WBC events (B) 
Bead events (A) x Volume of sample stained (µL) 
Total Scatter 
FL I LOG 
-/ 
T 
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2.2.2 Expression of P-selectin (CD62P, GMP-140) on the platelet surface 
membrane 
i. Principle 
P-selectin is an a-granule membrane protein. Upon platelet activation the a- 
granule membrane fuses with the platelet membrane and P-selectin is expressed on the 
platelet surface, where it can be detected by a fluorescein-conjugated monoclonal 
antibody specific to P-selectin. 
ii. Reagents 
1. Fluorescein-conjugated mouse IgG1 monoclonal antibody specific to 
human P-selectin (Serotec, Oxford, UK) 
2. Fluorescein-conjugated mouse IgGI Isotype control antibody (Serotec, 
Oxford, UK) 
3. Phosphate-buffered saline (PBS) (Sigma-Aldrich Company Ltd, Dorset, 
UK) 
4.0.5% Formaldehyde (Sigma-Aldrich Company Ltd, Dorset, UK) in PBS 
5.12x75 mm Polystyrene tubes (Falcon 2052, Becton Dickinson Labware, 
Lincoln Park, New Jersey, USA) 
ii. Method 
I. In the first tube add 5 µL anti-CD62P, in the second tube add 5 µL of an 
isotype control antibody 
2. Add 50 µL PBS to each tube. 
3. Add 2 µL platelet concentrate sample to each tube. 
4. Incubate at room temperature in the dark for 20 minutes. 
5. Add I mL 0.5% formaldehyde in PBS. 
6. Analyse the sample on flow cytometer within one hour. For each sample a 
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region was set to include 1% of total events in the positive region using an 
isotype control (Schmitz 1998). 
2.2.3 Microvesicle count 
i. Principle 
Microvesicles express the same membrane antigens as their parent cells, i. e. 
platelet membrane glycoproteins IIb/IIIa (CD41/CD61) for platelet derived (Plt-MV), 
glycophorin A for red blood cell derived (RBC-MV), and CD45 for white blood cell 
derived microvesicles (WBC-MV). They can thus be detected by flow cytometry using 
flurochrome labelled monoclonal antibodies specific to CD41, glycophorin A, and CD45, 
respectively. MV are differentiated from the instrument background by their fluorescent 
signals and from the native intact cells by forward scatter signal (FS), which reflects the 
size of the particle. Using microvesicle containing plasma, the absolute count of MV was 
obtained by adding a known number of fluorescent beads as a reference (Miller 1987, 
Combes 1997). 
ii. Reagents 
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1. Mouse IgG 1 anti-human CD41-RPE, mouse IgG 1 anti-human 
glycophorin A-FITC (Dako Ltd, Cambridge, UK), and mouse IgGI anti- 
CD45-PC5 (Coulter Electronics, Miami, Florida, USA) 
2. TruCount tube (Becton Dickinson, San Jose, California, USA) containing 
a known number of lyophilised fluorescent beads 
3. PBS pH 7.4 (Sigma-Aldrich Company Ltd, Dorset, UK) filtered through a 
0.2 µ filter twice and degassed 
4.0.5% paraformaldehyde in PBS (Sigma-Aldrich Company Ltd, Dorset, 
UK) 
iii. Method 
1. For Pit-MV, centrifuge I mL of platelet concentrates in a 1.5 
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polypropylene eppendorf tube (BDH-Merck, Leicester, UK) at 16100 g 
for 1 minute. 
2. Transfer 300 pL of supernatant plasma into another tube. 
3. Using a TruCount tube, add 5 µL anti CD41-RPE, 5 µL of anti 
glycophorin A-FITC, 50 µL supernatant plasma and 100 pL PBS. 
4. Incubate at room temperature in the dark for 20 minutes. 
5. Add I mL of 0.5% paraformaldehyde in PBS. 
6. Analyse the sample immediately, before analysis vortex the tube at 1400 
rpm for 5 seconds. 
7. Acquire 2000 beads with minimal threshold (1) on side scatter (SS). 
8. Calculate the number of MV using the following formula: 
MV count (x103/mL) = total number of beads x number of MV counted 
number of beads counted x volume of sample (pL) 
iv. MV region setting 
The region setting for Plt-MV is arbitrary as their size and intracellular contents 
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are heterogeneous, and there is no clear demarcation between Plt-MV and intact platelets. 
However, once the regions for MV were set as described below, they were kept constant 
throughout the whole period of study. This, together with the daily quality control of the 
flow cytometer, enabled comparative analysis between results obtained from different 
runs. 
The region for Plt-MV was set by using gel filtered fresh platelets. Using a 
Sepharose 2B gel column (Pharmacia, Piscataway, New Jersey, USA), intact platelets 
having bigger size eluted in the early fractions, where as Plt-MV having smaller size 
eluted in the later fractions. The early fractions containing almost all intact platelets was 
used to set the Plt-MV region by including 1% of the population with the lowest FS 
signal (Figure 2.2). 
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For RBC-MV the region was set by using day 35 red cell concentrates and all 
events with FS signal lower than the homogeneous intact RBC population were classified 
as RBC-MV (Figure 2.3). 
For WBC-MV the region was set by using 0.2 mmol/L calcium (Ca) ionophore 
A23187 (Sigma-Aldrich Company Ltd, Dorset, UK) activated WBC separated by 
gradient media (Figure 2.4). 
V. Assay linearity 
Linearity of each assay was performed by serially diluting samples obtained from 
day 6 platelets or day 35 red cell concentrates in fresh AB plasma which had been double 
filtered through 0.2 µ filters. The linearity of Plt-MV and RBC-MV assays is shown in 
Figure 2.5. The lower detection limit of Plt-MV and RBC-MV was 50/µL (50x 103/mL). 
For WBC-MV, even with the use of enriched WBC (93x109/L) activated by high 
concentration of Ca ionophore, only 36 x103/mL were generated. Although repeated 
assays gave a coefficient of variance of 10%, further dilutions to establish linearity did 
not provide accurate results. 11 
During a pilot study, non-leucocyte depleted and leucocyte depleted platelet 
concentrates were used to validate MV assays. While Plt-MV and RBC-MV were 
detected at all times, WBC-MV were not. This was most likely because the concentration 
of intact WBC (approximately 100/µL and less than 20/µL in non-leucocyte depleted and 
leucocyte depleted platelets, respectively) was much lower than platelets and RBC, and 
thus the level of WBC-MV was lower than the detection limit. 
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Figure 2.2 Region setting for Pit-MV. 
Top-gel filtered platelets, bottom-day 6 platelets. Using gel filtered platelets, Pit-MV 
region was set by including I% of the population with the lowest FS signal. 
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Figure 2.3 Region setting for RBC-MV. 
Using day 35 red cell concentrates, a region of RBC-MV was set to include all events 
with FS signal lower than intact RBC. 
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Figure 2.4 Region setting for WBC-MV. 
Using gradient media enriched, Ca i_onöphore activated WBC, the region for WBC-MV 
was set to include all events with FS signal lower than intact WBC. 
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2.5 Linearity of microvesicle count. 
Top-Pit-MV, middle-RBC-MV. ideal line where r2=l. Linearity of each assay 
was performed by serially diluting samples obtained from day 6 platelets or day 35 red cell 
concentrates in fresh AB plasma which had been double filtered through 0.2 µ filters. 
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2.3 PREPARATION OF PLATELET POOR PLASMA (PPP) 
Platelet poor plasma was prepared by spinning 40 mL of platelet concentrate in a 
50 mL sterilised graduated polypropylene centrifuge tube (BDH-Merck Ltd, Leicester, 
UK) at 3000 rpm (2000 g) at 22 °C for 30 minute with the brake off, using a bench top 
centrifuge (IEC Centra-7, International equipment company, Miami, Florida, USA). 
Thirty-eight mL supernatant were transferred to another tube before being aliquotted (0.5 
mL) into 1.5 mL microtubes (Sarstedt, Numbrecht, Germany). Samples were kept frozen 
at -40°C for further testings. The PPP prepared by this method was used for various 
enzyme linked immunosorbent (ELISA) as well as chromogenic assays on kallikrein-like 
and thrombin-like activities. 
2.4 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
ELISA were used to measure superilatant levels of markers of platelet activation 
(P-selectin), activation of coagulation system (FXIIa, prothrombin fragment 1+2, 
thrombin-antithrombin complex, complement activation (C3a) and platelet storage lesion 
(annexin V). 
General principle 
All the ELISA used employ a direct sandwich method. Plastic microtitre plates 
are coated with an antibody specific to the protein (antigen) of interest by passive 
adsorption (capture antibody). Unbound antibody is removed by washing the plate. Test 
sample containing antigen of interest is added and incubated. The unbound antigen is 
removed by washing the plate. A second antibody (detection antibody) against the 
antigen of interest but not for the same epitope(s) as the capture antibody, conjugated to 
an enzyme, peroxidase or alkaline phosphatase, is added. The reaction is visualised by 
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the addition of a colourless substrate, which is then cleaved by the enzyme conjugate to 
produce a coloured product. The colour produced is measured by spectrophotometry and 
is proportional to the amount of antigen bound to the plate. 
Quality control 
A quality control plasma was included in all plates using the control plasma 
provided in ELISA kits. An in-house reference plasma was also included to monitor 
inter-assay variation. The reference plasma was prepared by pooling platelet poor plasma 
obtained from 5 units of day 3 platelet concentrates. The acceptable range for this plasma 
was defined as the mean ±2 standard deviations from assays performed on 10 separate 
occasions. Results from assays where either the control plasma fell outside the range 
defined by manufacturer or the reference plasma fell outside the acceptable range were 
rejected. All assays were performed in duplicatd. If the CV between duplicates was 
greater than 10%, the results were rejected. 
2.4.1 Soluble P-selectin (sP-selectin) 
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i. Principle 
The P-selectin expressed on platelet surface membrane upon platelet activation 
can be cleaved into the plasma, so called soluble P-selectin (sP-selectin). 
ii. Reagents 
All reagents were part of a kit from R&D System (R&D Systems Europe Ltd., 
Oxford, UK). 
1. Microtitre plate coated with a murine monoclonal antibody to human sP- 
selectin 
2. Sheep polyclonal antibody to recombinant human sP-selectin conjugated 
to horseradish peroxidase - diluted according to manufacturer's instruction 
3. sP-selectin standards consisting of 6 concentrations of sP-selectin ranging 
from 0-50 ng/mL, reconstituted according to the manufaturer's 
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recommendation 
4. sP-selectin control - reconstituted according to the manufacturer's 
recommendation 
5. Substrate - tetramethylbenzidine 
6. Sample diluent 
7. Conjugate diluent 
8. Wash buffer concentrate - diluted according to manufacturer's instruction 
9. Stop solution containing acid 
iii. Method 
1. Dilute control, test and reference plasma 1 in 20 with sample diluent. 
2. Add 100 µL of standards, diluted control, reference and test plasma to 
each well. 
3. Add 100 µL sP-selection conjugate to each well. 
4. Incubate at room temperature for 1 hour. 
5. Wash the plate 3 times by adding 300 gL of wash buffered solution per 
well. 
6. Add 100 µL of substrate. 
7. Add 100 pL stop solution. 
8. Measure the absorbance at 450 nM with reference wavelength set at 620 
nm. 
9. The concentrations of P-selectin were derived from a linear-linear four 
parameter logistic plot standard curve. The 
'control, test and reference 
results were multiplied by the dilution factor. 
2.4.2 FXIIa 
i. Principle 
Factor XII is activated and becomes aFXIIa, upon exposure to negative charged 
78 
surfaces. aFXlla binds to surfaces and is protected from plasma protease inhibitors. 
Further proteolytic cleavage of aFXIIa leads to the formation of 1FXIIa which does not 
have the surface binding property and is inhibited by inhibitors such as Cl inhibitor. The 
assay used measured both aFXIIa and (3FXIIa. 
ii. Reagents 
All reagents were part of a kit from Shield Diagnostics (Shield Diagnostics Ltd., 
Dundee, UK). 
1. Microtitre plate coated with a mouse monoclonal antibody to activated 
FXII 
2. Sheep polyclonal antibody to human activated FXII conjugated to alkaline 
phosphatase - diluted according to manufacturer's instruction 
3. Activated FXII standards consisting of 5 concentrations of purified 
activated FXII ranging from 0-20 ng/mL, reconstituted according to the 
manufaturer's recommendation 
4. Activated FXII controls -., reconstituted according to the manufacturer's 
recommendation 
5. Substrate - phenolphthalein monophosphate 
6. Wash buffer concentrate - diluted according to manufacturer's instruction 
7. Stop solution containing sodium hydroxide and EDTA 
iii. Method 
1. Add 100 µL of standards, control, and test plasma to each well. 
2. Incubate at room temperature for I hour. 
3. Wash the plate 5 times by adding 300 pL of wash buffered solution per 
well. 
4. Add 100 pL of conjugate. 
5. Incubate at room temperature for 1 hour. 
79 
6. Wash the plate 5 times by adding 300 µL of wash buffered solution per 
well. 
7. Add 100 µL substrate to each well. 
8. Incubate at room temperature for 15 minutes. 
9. Add 100 µL stop solution. 
10. Measure the absorbance at 550 nM. 
11. The concentrations of FXIIa were derived from a linear-linear four 
parameter logistic plot standard curve. 
2.4.3 Prothrombin fragment 1+2 (F1+2) 
i. Principle 
The conversion of prothrombin to thrombin generates F1+2 as shown below. 
Therefore the level of F1+2 can be used to quantify, the amount of thrombin generated. 
FXa, FVa, Ca 2+ FXa, FVa, Ca 2+ 
Prothrombin , Meizothtombin ----º Thrombin + Fragment 1+2 
Phospholipid Phospholipid 
ii. Reagents 
All reagents were part of a kit from Dade Behring (Dade Behring, Marburgh, 
Germany) 
1. Microtitre plate coated with rabbit antibodies to human F 1+2 
2. Rabbit anti-human prothrombin conjugated to peroxidase 
3. Conjugate buffer containing Tris, Tween, and 6ovine serum albumin 
4. F 1+2 standards, concentrations range 0.04 to 10 nmol/L - diluted 
according to manufacturer's instruction 
5. F 1+2 control plasma - diluted according to manufacturer's instruction 
6. Sample buffer containing Tris, Tween and sodium chloride 
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7. Wash solution containing phosphate and Tween - diluted according to 
manufacturer's instruction 
8. Substrate buffer containing hydrogen peroxide in citrate-buffer solution 
9. Substrate - o-phenylendiamine-dihydrochloride 
10. Stop solution - 0.5 N sulphuric acid 
iii. Methods 
1. Dilute standards, control, and test plasma 1 in 2 with sample buffer. 
2. Add 100 pL of diluted standards, control, and test plasma to each well. 
3. Incubate at 37 °C for 30 minutes. 
4. Wash the plate three times by adding 300 µL of wash solution per well. 
5. Add 100 pL of conjugate into each well. 
6. Incubate at 37 °C for 30 minutes. 
7. Same as step 4. 
8. Add 100 µL substrate and incubate at room temperature in the dark for 15 
minutes. 
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9. Add 100 µL stop solution. 
10. Measure the absorbance at 492 nm. 
11. Plot a log-log point to point standärd curve. Read the control and test 
results against the standard curve. 
2.4.4 Thrombin-antithrombin III complex (TAT) 
i. Principle 
Once thrombin is generated, it forms a complex rith a natural inhibitor in 
plasma, antithrombin III. 
ii. Reagents 
All reagents were part of a kit from Dade Behring (Dade Behring, Marburgh, 
Germany) 
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1. Microtitre plate coated with rabbit antibodies to human thrombin 
2. Rabbit anti-human ATIII conjugated to peroxidase 
3. Conjugate buffer containing Tris buffer and bovine serum albumin 
4. TAT standards, concentrations range 2 to 60 µg/l, - diluted according to 
manufacturer's instruction 
5. TAT control plasma - diluted according to manufacturer's instruction 
6. Sample buffer containing Tris, Tween and EDTA 
7. Wash solution containing phosphate and Tween - diluted according to 
manufacturer's instruction 
8. Substrate buffer containing hydrogen peroxide in citrate-buffer solution 
9. Substrate - o-phenylenediamine-dihydrochloride 
10. Stop solution - 0.5 N sulphuric acid . 
iii. Methods 
1. Dilute standards, control, and test plasma I in 2 with sample buffer. 
2. Add 100 . tL of standards, diluted control, and test plasma to each well. 
3. Incubate at 37 °C for 15 minutes. 
4. Wash the plate three times by adding 300 gL of wash solution per well. 
5. Add 100 µL of conjugate into each well. 
6. Incubate at 37 °C for 15 minutes. 
7. Same as step 4. 
8. Add 100 µL substrate and incubate at room temperature in the dark for 30 
minutes. 
9. Add 100 µL stop solution. 
10. Measure the absorbance at 492 nm. 
11. Plot a log-log linear regression standard curve. Read the control and test 
results against the standard curve. 
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2.4.5 Complement C3a 
i. Principle 
C3a is generated during the activation of complement system via the classical or 
the alternative pathway. C3a is short-lived and is cleaved into C3a-desArg by removal of 
an arginine residue. This assay measures C3a-desArg. 
ii. Reagents 
All reagents were part of a kit from Quidel (Quidel, San Diego, CA, USA). 
1. Microtitre plate coated with mouse monoclonal anti-human C3a 
2. Rabbit anti-C3a conjugated to peroxidase 
3. C3a standard - diluted according to manufacturer's instruction 
4. C3a control plasma - diluted according to manufacturer's instruction 
5. Sample buffer - diluted according to manufacturer's instruction 
6. Wash solution - diluted according to manufacturer's instruction 
7. Substrate - tetramethylbenzidine 
8. Stop solution -1N sulphuric+acid 
T 
iii. Methods 
1. Reconstitute and dilute standard and control according to manufacturer's 
instruction. - 
2. Dilute test plasma 1 in 100 with sample buffer. 
3. Add 100 pL of standards, diluted control, and test plasma to each well. 
4. Incubate at room temperature for 1 hour. 
5. Wash the plate three times by adding 300 µL of wash solution per well. 
6. Add 100 pL of conjugate into each well. 
7. Incubate at room temperature for 1 hour. 
8. Same as step 4. 
9. Add 100 µL substrate and incubate at room temperature for 15 minutes. 
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10. Add 100 µL stop solution. 
11. Measure the absorbance at 450 nm. 
12. Plot a linear-linear point to point standard curve. Read the control and test 
results against the standard curve. 
2.4.6 Annexin V 
i. Principle 
Annexin V is an intracellular protein which is released upon cellular damage. The 
detailed property of annexin V is discussed in Chapter 9. 
ii. Reagents 
All reagents were part of a kit from Asserachrom (Stago, Genevilliers, France) 
unless otherwise stated. 
1. Microtitre plate coated with rabbit polyclonal anti-human annexin V 
2. Polyclonal anti-annexin V peroxidase conjugate - diluted according to 
manufacturer's instruction 
3.100 ng/mL annexin V standard - reconstituted according to manufacturer's 
instruction 
4. Substrate - o-phenylenediamine dihydrochloride in distilled water 
containing urea peroxide 
5. Dilution buffer 
6. Wash solution 
7.3 M sulphuric acid 
iii. Method 
1. Dilute annexin V standard with dilution buffer to the concentrations of 20, 
10,5,2, and 0.5 ng/mL. 
2. Dilute reference and test plasma 1: 5 with dilution buffer. 
3. Add 200 gL of standards or diluted plasma to each well and incubate at 
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room temperature for 2 hours. 
4. Wash the plate 5 times by adding 300 µL of washing solution per well. 
5. Add 200 pL of anti-annexin V peroxidase conjugate per well. 
6. Incubate the plate at room temperature for 2 hours. 
7. Wash the plate 5 times by adding 300 µL of washing solution per well. 
8. Add 200 pL of substrate freshly made before use. 
9. Incubate at room temperature for exactly 5 minutes. 
10. Stop the reaction by adding 50 µL of 3M sulphuric acid. 
11. Leave the plate for 10 minutes for colour stabilisation. 
12. Measure the absorbance at 492 nm. 
13. The concentrations of test samples were derived from a log/log standard 
curve. 
11 
2.5 AMIDOLYTIC SUBSTRATE ASSAYS 
These were used to measure kallikrein-like and thrombin-like activities in 
supernatant plasma, as well as the ability of MV isolated from platelet concentrates to 
support the formation of prothrombinase complex. 
General Principle 
Amidolytic substrate assays are based on the use of synthetic peptide substrates 
which are covalently linked to a chromophore, p-nitroaniline (pNA). Proteases cleave the 
substrate with the liberation of pNA. The pNA released is measured using 
spectrophotometrically at 405 nm and the change in absorbance is proportional to the 
enzyme activity (kinetic determination). Alternatively the substrate is incubated for a set 
time and the absorbance is then measured (end-point determination). 
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2.5.1 Kallikrein-like activity 
i. Principle 
The activation of the contact system of coagulation system generates kallikrein, 
which can be measured by a synthetic substrate for kallikrein (S2302). However, this 
substrate is not only sensitive to plasma kallikrein but also to FXa, activated protein C, 
complement Cis and thrombin. Therefore the measured enzyme activity is called 
kallikrein-like activity (KLA). 
ii. Reagents 
1.50 mmol/L Tris buffer pH 8.0 (Sigma-Aldrich Company Ltd, Dorset, UK) 
2. Chromogenic substrate S2302 (Chromogenix AB, Mölndal, Sweden) 
reconstituted with distilled water to obtain a concentration of 2 mM. 
3. Flat bottom polystyrene microtitre plate (Alpha Laboratories Ltd, 
Hampshire, UK) 
iii. Methods 
1. Dilute plasma I in 20 with Tris buffer. 
2. Add 200 µL diluted plasma into each well. 
3. Add 50 µL chromogenic substrate and read the absorbance immediately at 
405nm to get a blank reading. 
4. Incubate at room temperature for 2 hours and read the absorbance again. 
5. KLA is calculated from the difference between the absorbance at 2 hours 
and blank. 
2.5.2 Thrombin-like activity 
i. Principle 
The activation of coagulation system leads to the generation of thrombin which 
can be measured by a synthetic substrate for thrombin (S2238). This substrate is also 
sensitive to FXa, FXIa, APC, and kallikrein. Therefore the measured enzyme activity 
is 
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called thrombin-like activity (TLA). 
ii. Reagents 
1.50 mmol/L Tris buffer pH 8.0 (Sigma-Aldrich Company Ltd, Dorset, 
UK). 
2. Chromogenic substrate S2238 (Chromogenix AB, Mölndal, Sweden) 
reconstituted with distilled water to obtain a concentration of 2 mM. 
3. A flat bottom polystyrene microtitre plate (Alpha Laboratories Ltd, 
Hampshire, UK). 
iü. Methods 
1. Dilute plasma 1 in 20 with Tris buffer. 
2. Add 200 µL diluted plasma into each well. 
3. Add 50 µL chromogenic substrate and read the absorbance immediately at 
405nm to get a blank reading. 
4. Incubate at room temperature for 2 hours and read the absorbance again. 
5. TLA is calculated from the -difference between the absorbance at 2 hours 
and blank. 
2.6 ASSAY PERFORMANCE 
To assess the performance of all assays used in this study, the coefficient of 
variation (CV) of intra- (within) and inter- (between) assays were calculated. The intra- 
assay CV was calculated from 10 measurements of a single sample on one occasion. The 
inter-assay CV was calculated from the measurement of a single sample on 10 different 
occasions over a period of at least 10 days. The intra- and inter-assay CVs for tests 
described in this chapter are shown in Table 2.1. 
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Table 2.1 Intra- and inter-assay coefficient of variations. 
Tests Level assayed Intra-assay CV (%) Inter-assay CV (%) 
P-selectin on platelet 
membrane 
13.5 % 8.9 NA 
Pit-MV 1970 x10 /mL 8.3% NA 
RBC-MV 230 x10 /mL 7.6% NA 
WBC-MV 3 36 x10 /mL 10% NA 
Soluble P-selectin 98 ng/mL 4.8 6.2 
FXIIa 1.20 ng/mL 4.6 10.0 
Prothrombin F1+2 0.6 nmol/L 5.6 12.5 
TAT 2.3 µg/L 4.5 9.2 
C3a 1753 ng/mL 7.3 12.8 
Soluble annexin V 9.2 ng/mL 6.8 8.4 
KLA* OD405nm 114 x10 7.2 9.8 
TLA* OD405nm 178 x 10" 7.6 11.3 
Prothrombinase 
activity 
0.07 U/mL 3.1 8.7 
NA-inter-assay CV cannot be measured as these parameters change over storage of samples. 
*Results were expressed as the difference between the OD405nm at zero time and 2 hours. 
2.7 COMPUTER HARDWARE AND SOFTWARE 
A Compaq Presario 1060 was used to prepared this thesis. Data was initially 
organised using Excel 95 (Microsoft Corp. ). Data analysis was performed using Excel 97 
and GraphPad Prism 2.0. Routine manual checks were carried out to ensure that 
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spreadsheet and statistical package software transformation of data was correct. The 
exact nature of the statistical analysis used will be stated in each chapter. 
11 
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CHAPTER 3 
PLATELET INDICES OF PLATELET CONCENTRATES 
3.1 INTRODUCTION 
Modem automated haematology analysers provide not only the platelet count but 
also platelet indices i. e. mean platelet volume (MPV), platelet distribution width (PDW), 
and platelet-large cell ratio (P-LCR). These indices are obtained from the principle 
shown in Figure 3.1 and described below. 
Figure 3.1 PDW, P-LCR and MPV from an automated haematology analyser 
based on the direct current principle. 
100% 
20Yo 
Particles with the size between the lower discriminator (LD) 2-6 fL and the upper 
discriminator (UD) 12-30 if. are counted as platelets. A fixed discriminator (FD) is set at 12 fl,. 
PDW is the distribution width at the 20% level when the peak is equivalent to 100%. P-LCR is 
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PDW 
the ratio of large platelets which fall in the range between the FD and the UD divided by the 
number of platelets falls in the range between LD - and UD and multiplied by 100. MPV is 
calculated from the following formula: 
MPV (fL) = PCT(%) x 1000 
PLT (x 103/µL) 
where PCT (plateletcrit or platelet volume ratio) is the weighted frequency of platelet at each 
MPV channel. 
MPV can be used as a quantitative indicator of the presence of younger, larger 
platelets, which are more haemostatically active. MPV has been shown to be a useful 
marker in several pathological conditions (van der Loo 1997). For instance, MPV is 
increased in patients after myocardial infarction and can be used as a predictor of a 
further ischemic event. High MPV is also seen in patients with diabetes mellitus 
(Tschoepe 1991). Other platelet indices, P-LCR and PDW have also been shown to be 
useful diagnostic indicators. It has been demonstrated that MPV, P-LCR and PDW 
increase at the onset of disseminated intravascular coagulation (DIC). Furthermore, 
PDW can be used to differentiate between reactive thrombocytosis and thrombocytosis 
seen in myeloproliferative diseases, the latter giving a higher PDW (Osselaer 1997). 
Reports on the application of platelet indices to blood components, in particular 
platelet concentrates, are limited. Early rep(5rts have suggested that different 
subpopulations of platelets measured by MPV may be recovered by different preparation 
methods (Brozovic 1992, Van der Planken 1999), and that MPV of stored platelets is 
lower than fresh (Vickers 1991, Racz 1992). 
The difference in MPV before and after the addition of EDTA to a citrate sample, 
so called delta (d) MPV, has been shown to be correlated with various markers of the 
platelet storage lesion and platelet function e. g. pH, ß-thromboglobulin, lactate 
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dehydrogenase, glycocalicin, hypotonic shock response (HSR), and platelet aggregation 
in response to ADP or ADP and collagen (Vickers 1991). PDW and P-LCR have also 
been shown to correlate with pH and HSR (Farrugia 1995). 
The mechanism of EDTA induced platelet shape change leading to the, increase 
in platelet size indices is unclear. Nevertheless, it has been hypothesised that the degree 
of shape change upon exposure to EDTA reflects the functional reserve of platelets 
(Seghatchian 1994). Platelets, which have already undergone activation, respond to 
EDTA to a lesser degree than those which are in resting state. 
The objectives of this study were: 
i. To investigate whether leucocyte depleted platelet concentrates prepared 
by three different methods contain the same profiles of platelet size 
indices. 
ii. To investigate whether leucocyte depleted platelet concentrates prepared 
by three different methods contain the same functional reserve as 
measured by the response to EDTA. 
3.2 MATERIALS AND METHODS 
3.2.1 Preparation of platelet concentrates 
i. Leucocyte filtered pooled huffy coat derived platelets 
Whole blood (450 + 45 mL) was collected into top and bottom packs containing 
63 mL of citrate-phosphate-dextrose anticoagulant (PL 146, Baxter Healthcare, Deerfield, 
Illinois, USA). Buffy coats were prepared using a `hard spin' (Beckman centrifuge 
J6MC, 3400 rpm, 11.5 min, 22°C) and kept overnight at 22°C. For each unit of platelet 
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concentrate, 4 units of ABO identical bully coats and 1 unit of plasma from I of the 4 
huffy coat donors were pooled together on the day following collection. An in-process 
leucocyte removal filter (Autostop BC, Pall Biomedical, Portsmouth, UK) was connected 
to the pool. Platelets were harvested using a `soft spin' (1850 rpm, 5 min, 22°C). 
I Apheresis platelets 
Platelets collected by Haemonetics MCS+ LD were leucocyte depleted by 
passing through a leucocyte removal filter (LRF6H, Pall Biomedical, Portsmouth, UK) 
during the last return cycle (detail described in Chapter 1). The detailed principle of 
Cobe LRS apheresis system was previously described in Chapter 1. 
Ten units of platelet concentrates prepared by each method were tested on day 1, 
the earliest time a product can be issued for clinical use. This also allowed direct 
comparison with bully coat derived platelets. Each unit was tested again at the end of the 
5-day storage shelf life. To maintain the sterility of the products, samples were taken in a 
close system by connecting to a Transfer Pack® (Baxter Healthcare, Deerfield, IL, 
USA), using a Sterile Connecting Device® (Terumo, Leuven, Belgium). 
V 
3.2.2 pH and leucocyte count 
7 
pH was measured on an AVL 9110 pH analyser (AVL Medical Instruments, 
Graz, Austria). Leucocyte counts were measured by flow cytometry as described in 
Chapter 2. 
3.2.3 Platelet count and platelet indices 
An automated haematology analyser, Sysmex SE-9000 (TOA Medical 
Electronics Co. Ltd, Kobe, Japan), was used. The detail of this instrument was described 
in Chapter 2. 
For each platelet unit, 2 mL of sample were placed in a4 mL plain polystyrene 
tube tightly capped, and 250 µL in a 1.8 mL dipotassium ethylenediamine tetraacetic 
93 
acid (EDTA) tube (L. I. P. Equipment & Services Ltd., West Yorkshire, UK). The final 
concentration of EDTA was 25.4 mmol/L. The latter was gently mixed by rolling the 
tube manually for 5 seconds. Both paired samples were kept static at room temperature 
for 1 hour and then analysed on the haematology analyser at the same time. The 
difference of the results between the paired samples was calculated using the formula 
below: (Seghatchian 1994) 
dMPV = MPVEDTA - MPVcitrate 
dPLT, dP-LCR and dPDW were calculated in the same fashion. 
3.2.4 Statistical analysis 
Paired t-test and ANOVA test were used to compare two and more than two sets 
of results, respectively. Pearson test was used to analyse the correlation between results. 
Results of the three types of platelets were compared between groups and within each 
group at day 1 and day 5. , 
3.3 RESULTS 
Y 
T 
3.3.1 pH and leucocyte count 
There was no significant difference in pH between groups on dayl, but on day 5 
both MCS (p<0.01) and Cobe (p<0.001) were lower than Autostop filtered BC-PC 
(Table 3.1). All units were within the acceptable range (6.4-7.4) (Guidelines for the 
Blood Transfusion Services in the United Kingdom 1998). Residual leucocyte counts 
were less than 5x106/unit in all products. 
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Table 4.1 pH of all three groups. 
Mean +SD 
Autostop MCS Cobe 
Day 1 7.10±0.03 7.14±0.08 7.11±0.12 
Day 5 7.27±0.03 7.14±0.11 7.16±0.06 
3.3.2 Platelet count 
In all cases the platelet counts were higher in EDTA samples than citrate 
(p<O. 001), as platelet aggregates which tend to form in citrate samples are dispersed by 
EDTA. Therefore, the results of platelet count in EDTA samples were used for statistical 
analysis on the basis that they represented more accurately the number of platelets in 
each product. MCS platelets showed high variability between units. The platelet counts 
of Cobe products were significantly higher than Autostop (p<0.001) and MCS (p<0.01) 
(Figure 3.2). However, the platelet yields (platelet count x volume of each unit) were not 
statistically different. No difference was seen in the platelet counts within the same type 
of products tested on day 1 and day 5. 
The difference between platelet counts of paired citrate and EDTA samples 
(dPLT), reflecting the amount of reversible aggregates, were significantly higher in Cobe 
than Autostop (p<0.001) (Figure 3.3). No difference in dPLT was found within the same 
product over storage. A significant correlation between platelet count and dPLT was 
observed in Autostop (r=0.6113, p=0302) and MCS (r=0.7987, p=0.0028) but not in 
Cobe (Figure 3.4). 
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Figure 3.2 Platelet count (PLT) in citrate (C) and EDTA (E) samples of 
Autostop filtered pooled buffy coat derived, MCS+ and Cobe apheresis platelets on day 1. 
Mean   and SD. E were higher than C in all cases. Cobe were higher than Autostop 
(p<0.01) and MCS (p<0.001). 
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Figure 3.3 dPLT in all four groups on day 1. 
Cobe were higher than Autostop filtered BC-PC (p<0.00I ). 
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Figure 3.4 Correlation between dPLT and platelet count (PLT) in Autostop 
and MCS on day 1. 
Top-Autostop, bottom-MCS. Autostop r-0.6113, p=0.0323, MCS r-0.7987, p=0.0028. 
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3.3.3 MPV, P-LCR and PDW 
There was no significant difference in the MPV of citrate samples between the 
three groups either immediately after production or on storage. However, they responded 
to EDTA to various degrees, resulting in differences in dMPV. Figure 3.5 shows the 
change in platelet size distribution upon the addition of EDTA. On day 1, both Autostop 
(p<0.01) and MCS (p<0.05) platelets gave higher dMPV than Cobe. On day 5, all three 
groups were different from each other (p<0.01,0.001, and 0.01 for Autostop vs MCS, 
Autostop vs Cobe, and MCS vs Cobe, respectively). (Figure 3.6) 
The MPV within the same group did not change on storage. The dMPV 
significantly increased on storage in all groups (p<0.0001, =0.0351, and =0.0005 for 
Autostop, MCS, and Cobe, day 1 vs day 5, respectively) (Figure 3.7). No correlation was 
found between MPV and dMPV. 
Similar patterns to'MPV and dMPV were seen with P-LCR, dP-LCR, PDW, and 
dPDW. No difference was found in P-LCR and PDW between day 1 and day 5 either 
within the same type of platelets or between the three types. On day 1, Cobe 
dP-LCR 
was lower than Autostop (p<0.001). On day 5 both MCS and Cobe were 
lower than 
Autostop (p<0.05 and 0.001, respectively) (Figure 3.8). All three types showed higher 
dP-LCR on day 5 than day 1 (p<0.001, =0.0147, =0.0008, 
for Autostop, MCS, and Cobe 
day 1 vs day 5, respectively) (Figure 3.9). 
On day 1 dPDW of Cobe was lower than Autostop (p<0.01). On day 5, both 
Cobe and MCS were lower than Autostop (p<0.01 and 0.001, respectively). 
(Figure 3.10) 
All three types of platelets showed higher dPDW on day 5 than day 1 (p=0.0002,0.0225, 
and 0.0009 for Autostop, MCS, and Cobe day I vs day 5, respectively). (Figure 3.11) 
Significant correlations between platelet count and MPV (r=0.7056, p=0.0226) or 
PDW (r=0.6991, p=0.0245), were found only in Autostop, but not in either type of 
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apheresis platelets (Figure 3.13). The correlation between platelet count and P-LCR was 
not significant (rß. 5583, p=0.0935). MPV and PDW showed high degree of correlation 
(rß. 9944, p<0.0001) as shown in Figure 3.14, whereas no correlation was found 
between either of these indices with P-LCR. 
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Figure 3.5 Change in platelet size distribution after adding EDTA. 
Left-citrate sample, right-EDTA sample. PLT-platelet count, MPV-mean platelet 
volume, P-LCR-platelet large cell ratio, PDW-platelet distribution width. 
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Figure 3.6 MPV and dMPV of three types of platelets. 
Left panels-MPV, right-dMPV, top-day 1, bottom-day 5. No differences in MPV was seen 
between products. dMPV day 1, Autostop and MCS were higher than Cobe (p<0.01,0.05, 
respectively), on day 5 all were significantly different from each (p<0.01,0.001, and 0.01 for 
Autostop vs MCS, Autostop vs Cobe, and MCS vs Cobe, respectively). 
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Figure 3.7 Changes in MPV and dMPV of each type of platelets on storage. 
Top-Autostop, middle-MCS, bottom-Cobe, left-MPV, right-dMPV. No significant 
difference was seen in MPV between day I and day 5, whereas dMPV was significantly higher 
on day 5 than day I (p<0.000 1, =0.0351, and =0.0005 for Autostop, MCS, and Cobe, day I vs 
day 5, respectively). 
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Figure 3.8 P-LCR and dP-LCR of three types of platelets. 
Left panels P-LCR, right dP-LCR, top-day 1, bottom-day 5. No difference was found in 
P-LCR on day I or day 5. On day I, Cobe dP-LCR was lower than Autostop (p<0.001). On day 5 
both MCS and Cobe were lower than Autostop (p<0.05 and 0.001, respectively). 
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Figure 3.9 Changes in P-LCR and dP-LCR of each type of platelets on storage. 
Left panels P-LCR, right dP-LCR, top-Autostop, middle-MCS, bottom-Cobe. No 
difference was found in P-LCR between day I and day 5. All three types showed higher dP-LCR 
on day 5 than day I (p<0.001, =0.0147, =0.0008, for Autostop, MCS, and Cobe day I vs day 5, 
respectively). 
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Figure 3.10 PDW and dPDW of three types of platelets. 
Left panels PDW, right dPDW, top-day 1, bottom-day 5. No difference was found in 
PDW on day I or day 5. On day 1, Cobe dPDW was lower than Autostop (p<0.01). On day 5 
both MCS and Cobe were lower than Autostop (p<0.05 and 0.001, respectively). 
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Figure 3.11 Changes in PDW and dPDW of each type of platelets on storage. 
Left panels-PDW, right-dPDW, top-Autostop, middle-MCS, bottom-Cobe. No difference 
was found in PDW between day I and day 5. All three types showed higher dPDW on day 5 than 
day 1 (p=0.0002,0.0225, and 0.0009 for Autostop, MCS, and Cobe day I vs day 5, respectively). 
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Figure 3.12 Correlation between platelet count and MPV or PDW in Autostop 
on day 1. 
Top-PLT VS mpv, bottom-PLT vs PDW. Significant correlations were seen in only 
Autostop (r-0.7056, p=0.0226, and r-0.6991, p=0.0245, for PLT vs MPV and PDW, 
respectively. 
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Figure 3.13 Correlation between MPV and PDW 
i=0.9944, p<0.0001, all day 1 data pooled. 
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3.4 DISCUSSION 
All platelet concentrates prepared., by the three methods, pooled buffy coat 
derived, Autostop filtered, MCS+LD and COBE LRS apheresis, met the UK 
specification for leucocyte depleted platelet concentrates, i. e. platelet yield 240 x 109/unit, 
residual leucocyte content less than 5x 106/unit, and pH at the end of 5-day storage 
between 6.4 to 7.4 (Guidelines for the Blood Transfusion Services in the United 
Kingdom 1998). Minimal changes in pH i. e. slightly increase were observed on storage 
as the third generation storage bags currently in use allowed good gas exchange. 
Citrate anticogulants are routinely used in the preparation of platelet concentrates 
for transfusion. Using this anticoagulant, the concentration of Caz+ is reduced from 1-2 
mmol/L to 46-74 µmol/L (Bode 1989). It has been suggested that the level of Caz+ 
present in citrated anticoagulated platelet concentrates is sufficient to activate some Ca 
2+ 
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dependent proteases in platelets and plasma resulting in platelet activation, and thrombin 
generation (Bode 1989). These may lead to the formation of loose platelet aggregates 
which can be dispersed by the addition of EDTA, a strong chelating agent, leading to 
approximately 10 % higher platelet count on average. A previous report has shown that 
platelet counts in EDTA added samples are 6-22% higher than citrate (McShine 1990). 
The higher dPLT in Cobe product was probably secondary to the fact that this product 
contained higher platelet count, as the ratio of dPLT to total platelet count were 
approximately 1: 10, the same as the other two products. The clinical significance of 
these dispersible platelet aggregates presence in platelet concentrates is unknown. It is 
possible that they may adhere to the bags when kept without agitation during transport or 
transfusion, leading to some loss of platelets. 
Platelet size indices (MPV, PDW, and P-LCR) did not show any difference either 
between the three types of platelets or within the same type on storage. This was because 
no gross difference in pH occurred as these parameters had been shown to be correlated 
with pH. A recent report using the third generation storage bag has also demonstrated 
that the MPV remains unchanged during storage, but no data on pH is presented (Van 
der Planken 1999). 
The correlation between platelet count and MPV or PDW seen in only Autostop 
filtered, buffy coat derived platelets may be explained by the preparation method. 
During 
the first spin in the buffy coat method, the platelets with relatively larger size are 
sedimented near the red blood cell/leucocyte layer. For the production of platelet 
concentrates, to recover maximum platelets this population had to be extracted' 
into the 
final product, whereas in both apheresis preparations this was achieved by increasing the 
volume processed. 
Upon the addition of EDTA, the three types of products 
behaved differently. 
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Cobe showed the least changes in platelet size indices, whereas Autostop and MCS were 
equivalent. The difference between Cobe and Autostop was greater than between Cobe 
and MCS, or MCS and Autostop. This might be related to the basic principles employed 
by the three methods. Both MCS and Autostop shared a common principle, in which a 
buffy coat was prepared as an intermediate product and the final product was passed 
through a leucocyte removal filter. By contrast, platelets prepared by Cobe LRS 
apheresis method required a platelet rich plasma as an intermediate product before being 
leucodepleted in a conical chamber by a fluidised particle bed principle. 
In the early days of development of platelet concentrates for transfusion, when 
EDTA was used as an anticoagulant, it was found that the viability of platelets was 
markedly reduced as compared to those collected into acid citrate dextrose (ACD) (Aster 
1965). Previous study using electron microscopy showed that EDTA induced platelet 
swelling (Brozovic 1991). Furthermore, a-granule release with P-selectin expression was 
demonstrated in platelets prepared from EDTA anticoagulant (Golanski 1996, Holme 
1997). The mechanism of EDTA induced changes in platelets is unclear. Nevertheless, it 
has been suggested that EDTA induces conformation changes of platelet membrane 
structural protein as well as triggering the tyrosine kinase signal transduction pathway 
via non-specific receptors (Golanski 1996). 
Although leucocyte depleted platelet concentrates prepared by all three methods 
have the same platelet size indices profile when using citrate samples, they responded to 
the addition of EDTA in different fashions. This indicated that platelets recovered by the 
three preparation methods contained different functional reserve. It remains to be 
elucidated whether they have the same haemostatic effectiveness in vivo. Nevertheless, it 
could be hypothesised that platelets with a higher level of functional reserve were 
110 
desirable, as they would respond more effectively to stimuli when required. 
CHAPTER 4 
MICROVESICLES IN POOLED BUFFY COAT-DERIVED 
PLATELET CONCENTRATES 
4.1 INTRODUCTION 
During the preparation of platelet concentrates (PCs) from pooled buffy coats, 
platelets are kept in contact with a high number of leucocytes overnight at 20-22°C. The 
proteolytic enzymes released by leucocytes such as elastase may cause proteolysis of the 
platelet membrane (Brower 1985, Sloand 1990). This may lead to platelet 
microvesiculation. It is not known whether the process of leucocyte filtration removes 
the pre-formed microvesicles (MV) and/or whether the leucocyte filtration process might 
lead to shear-induced platelet or red cell microvesiculation. In addition, different types of 
filters made from different materials, namely positively charged polyester, negatively 
charged polyester and neutrally charged polyurethane, may not have the same effects on 
platelet microvesiculation, although they appear to be equivalent in terms of leucocyte 
removal. The types of plastic, plasticisers and the-volume/surface area of storage bags 
provided by various manufacturers are also different from each other. These may lead to 
differences in MV formation during storage. 
It should be noted that for comparison between various filters, it is important to 
eliminate inter-donor variability by using a pooled study design. To date comparisons 
between filters have used either platelet concentrates from different donors or have 
pooled and re-split several units of pre-manufactured platelets. In this study, to reflect the 
procedure commonly employed in routine production of platelet concentrates in Europe, 
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pooled bully coats from the same donors in combination with in-process filters were 
used. This approach allows comparison of three commercially available in-process 
filter/storage bag combinations and unfiltered controls while minimising inter-donor 
variability. 
The aims of this study were: 
i. To investigate whether leucocyte filtration activates platelets. 
ii. To investigate whether leucocyte filtration removes or generates platelet- 
derived and red cell-derived microvesicles (Pit-MV, RBC-MV) and 
whether various filters made from different materials have the same 
effects. 
iii. To investigate whether leucocyte depleted platelets prepared by various 
filters undergo the same degree of microvesiculation upon storage. 
4.2 MATERIAL AND METHODS 
4.2.1 Filters and platelet storage bags 
Three in-process leucocyte removal filter/PC storage bag combinations currently 
provided by manufacturers were used: 
i) Autostop BC/CLX (Pall Biomedical, Portsmouth, UK) 
ii) Sepacell PLX5/PL2410 (Asahi Medical Co. /Baxter Healthcare, Lessine, 
Belgium) 
iii) Imugard III-PL 4P/Teruflex (Terumo Europe NV, Leuven, Belgium). 
In addition, Cobe platelet sample bags (Cobe Laboratories Ltd., Denver, USA) 
were used to stored a sample from each unit. 
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The compositions and structures of filters were described previously in Chapter 
1, Table 1.7. The volume, plastic and plasticisers used in the storage bags are shown in 
Table 4.1 below. 
Table 4.1. Synthetic material used in three filters, their structures, plastic, 
plasticiser and volume of various storage bags 
Filter/Bag Bag 
Plastic 
Bag 
Plasticiser 
Bag 
Volume (L) 
Autostop BC/CLX polyvinyl chloride trioctyl trimellitate 1.5 
Sepacell PLX5/PL24 10 polyolefin 
_ 
1.3 
Imugard III/Teruflex polyvinyl chloride di n-decylphtallate 1.0 
Control/CLX polyvinyl chloride trioctyl trimellitate 1.5 
Cobe sample bag polyvinyl chloride butyryl tri-n-hexyl citrate 55 mL 
/ 
4.2.2 Preparation of platelet concentrates 
Whole blood (450 + 45 mL) was collected into bottom and top packs containing 
63 mL of citrate-phosphate-dextrose anticoagulant (PL146, Baxter Healthcare). Buffy 
coats were prepared using a `hard spin' (Beckman centrifuge J6MC, 3400 rpm, 11.5 min, 
22°C) and kept overnight at 22°C. For each set of experiments, 4 identical pools of buffy 
coats were prepared on the day following collection from 16 ABO identical bully coats 
and 4 units of plasma from the same donors (Figure 4.1). Each pool was connected to 
one of the three in-process filters/storage bags described alcove. The control unfiltered 
pool was connected directly to a CLX storage bag (Pall Biomedical), the bag in routine 
use in the National Blood Service-London and South East Zone. Platelet concentrates 
were prepared using a `soft spin' (1850 rpm. 5 min, 22°C). Using a sterile technique, a 
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sample from each unit was taken for testing after preparation by docking on a Transfer 
Pack® (Baxter Healthcare). Twenty-five mL of each unit were also taken into a Cobe 
sample bag (Cobe Laboratories Ltd., Denver, USA) for storage. Both Cobe sample bags 
and the original bags provided by the manufacturers were kept on a flat bed platelet 
agitator (Helmer, Baxter Healthcare, Illinois, USA) at 22°C. Samples were taken again 
on day 5. In total 10 sets of pools were analysed. 
4.2.3 pH, platelet and leucocyte counts 
pH was measured on an AVL 9110 pH analyser (AVL Medical Instruments, 
Graz, Austria). Platelet counts were measured on an automated cell counter (Sysmex 
SE9000, Kobe, Japan). Leucocyte counts were measured by flow cytometry as described 
in Chapter 2. 
4.2.4 Platelet activation 
The expression of'P-selectin on platelet surface membrane was measured by flow 
cytometry, and P-selectin in the supernatant plasma (soluble P-selectin) was measured by 
ELISA as described in Chapter 2. ' , 10 
4.2.5 Platelet and red cell-derived microvesicles 
These were measured by flow cytometry as described in Chapter 2. 
4.2.6 Statistical analysis 
Friedman ANOVA test was used for a multiple group comparison i. e. the 
unfiltered and the three types of filtered platelet concentrates. Spearman test was used to 
analyse the correlation between results. 
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Figure 4.1 Preparation of pooled buffy coats 
Each set of experiments consists of 16 units of buffy coats (BC) of the same ABO group 
and 4 plasma units from the same donors. 
< .> step 1. Pool 4 units of plasma and equally subdivide 
into the 4 original bags. For each set 
of BC, pool 4 units together and equally subdivide into the 4 original bags. 
step 2. Pool I unit of plasma and 4 units of BC (one from each set). 
step 3. Connect each of the 4 pools of BC to one of the filter/storage bag combinations. 
Plasma 
BC set I 
BC set 2 
BC set 3 
BC set 4 
Filter 
Bag 
F 
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PL2410 Teruflex CLX CLX 
4.3 RESULTS 
4.3.1 Volume, platelet and leucocyte contents and pH (Table 4.2) 
No significant difference was found in the volume of pooled buffy coats and 
platelet concentrates between the four types of products. The platelet yields in control, 
Autostop and Imugard III filtered platelets were equivalent. PLX5 filtered platelets 
showed 10% lower platelet yields than three other groups (not statistically significant). 
All filtered units contained less than 1x 106 leucocytes. pH was within acceptable range 
(6.4-7.4) both on day 1 and day 5. 
Table 4.2 Volume of pooled buffy coats (BCs) and platelet concentrates (PCs), 
platelet (Pit) yield, leucocyte (WBC) content and pH, shown as median (range). n =10 
Control Autostop PLXS Imugard III 
BCs (mL) 515 (434-558) 512 (469-577) 518 (469-566) 519 (501-563) 
PCs (mL) 346 (291-364) 336 (308-371) 
y 
Pit (x109/unit) 310 (289-343) 314 (239-388) 
WBC (x106/unit) 45 (30-74) 
349 (302-381) 335 (312-368) 
284 (228-372) 311 (249-365) 
* 
pH 
* 
day 1 7.13 (7.07-7.16) 7.10 (7.05-7.151 7.12 (7,11-7.18) 7.12 (7.07-7.18) 
day 5 7.25 (7.24-7.28) 7.26 (7.23-7.31) 7.33 (7.28-7.37) 7.23 (7.20-7.27) 
*Lower than the detection limit of I WBC/µL, equivalent to approximately less than 4x10'/unit. 
4.3.2 P-selectin on platelet membrane and in plasma supernatant 
On day 1, the levels of P-selectin on the platelet membrane and in the supernatant 
plasma in all four types of platelets were equivalent. Both were increased by 3-4 fold on 
day 5 in all four types of platelets (all p<0.05), with Imugard III expressing significantly 
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lower P-selectin on platelet membrane than control platelets (p<0.05) (Figure 5.2). The 
differences between groups were greater with soluble P-selectin, with Imugard III giving 
significantly lower values than control (p<0.001) and Autostop (p<0.001) (Figure 5.3). A 
significant correlation was observed between P-selectin on platelet membrane and in the 
supernatant plasma (r=0.8035, p<0.0001). (data from all four groups day I and day 5 
pooled, Figure 5.4). 
No significant difference in soluble P-selectin was found between the four types 
of platelets in the Cobe sample bag. 
No correlation was found between platelet count and platelet activation measured 
by both assays. 
4.3.3 Microvesicles 
There was considerable variability between pools in levels of Plt-MVs and RBC- 
MV. On day 1, Plt-MV numbers were not significantly different between groups, 
implying that leucocyte filtration did not generate or remove Plt-MV (Figure 4.5). By 
day 5 Imugard III showed significantly lower values than control (p<0.05) and Autostop 
PCs (p<0.05). Pit-MV increased during Storage in all 4 groups, although no correlation 
was found between Pit-MV numbers on day 1 and day 5. 
No statistically significant difference was seen in the levels of Plt-MV in 
different types of PCs stored in the Cobe sample bag. 
The levels of RBC-MV in PLX5 and Imugard III were lower than control and 
Autostop (all p<0.01) on day 1, suggesting removal by the two former filters (Figure 
4.6). Day 5 values in control units were increased from day 1, 
but in all three filtered PCs 
were unchanged. All filtered platelets showed lower values than control 
but only PLX5 
and Imugard III reached statistical significance (p<0.01). PLX5 was also lower than 
Autostop (p<0.05) 
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Similar results of RBC-MV were observed in all platelets stored in the Cobe 
sample bag. 
No correlation was found between platelet count and Plt-MV on both day I and 
day 5. Furthermore, no correlation was found between P-selectin on platelet membrane 
or soluble P-selectin and Plt-MV on day 1. However, on day 5a low degree but 
significant correlation was observed between P-selectin on platelet membrane or soluble 
P-selectin and Pit-MV (r=0.4215, p=0.0081, and r=0.5423, p=0.0.0002, respectively). 
(Figure 4.7) 
No correlation was found between Pit-MV and RBC-MV in filtered platelets, 
whereas unfiltered control showed significant correlation (r=0.5714, p=0.0042). (Figure 
4.8) 
-0 
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Figure 4.2 P-selectin on platelet membrane on day I and day 5. 
_ 
Median. On day 5, Imugard III was significantly lower than control (p<0.05). 
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Figure 4.3 Soluble P-selectin on day 1 and day 5 in original and Cobe sample 
bags. 
_ 
Median. Day 5 in original bags Imugard 111 was significantly lower than control 
(p<0.001) and Autostop (p<0.001). 
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Figure 4.4 Correlation between P-selectin on platelet membrane and soluble P- 
selectin. 
r= 0.8035, p<0.0001, pooled data from all 4 groups day I and day 5. 
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Figure 4.5 PU-MV on day 1 and day 5 in original and Cobe sample bags. 
Median. By day 5 in original bags, Imugard III were significantly lower than control 
(p<0.05) and Autostop (p<0.05). 
Day I 
JA 
3000 
C 
x 2000 
1000 " 
TTV 
Control Autostop PLX5 Im ugardlll 
Day, 5 
6000- 
"" 4000- A 
JA 
3000 "" 
. ".. .. o AAA 
X 2000- A 
. . " 
1000 " ,. 
Control Autostop PLX5 Im ugardlll 
Day 5 
Cobe sample bag 
7000 ,  50001 
5000 
J 4000 E 
   
3000 : ", rA 
xv 
2000    ýýý "V - 
1000  " 
ýý ' 
0 
Control Autostop PLX5 Imugard III 
123 
Figure 4.6 RBC-MV on day 1 and day 5 in original and Cobe sample bags. 
Median. Day 1, PLX5 and Imugard III were significantly lower than control (p<0.01) 
and Autostop (p<0.01). Day 5 in both original and Cobe sample bags, PLX5 and Imugard III 
were significantly lower than control values (p<0.00I PLX5 vs control, p<0.01 Imugard III vs 
control). PLX5 was also lower than Autostop (p<0.05). 
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Figure 4.7 Correlation between P-selectin on platelet membrane or soluble P- 
selectin and Pit-MV on day 5. 
Top-P-selectin on platelet membrane vs Plt-MV (r-0.4215, p=0.0081), bottom soluble P- 
selectin vs Pit-MV (r=0.5423, p=0.0.0002). 
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Figure 4.8 Correlation between Plt-MV and RBC-MV in control unfiltered 
platelets. 
r-0.5714, p=0.0042, pooled data from day I and day 5. 
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4.4 DISCUSSION 
All three filters used in this study provided leucodepleted platelets which met the 
specifications, i. e. platelet yield 240 x109/unit, residual leucocyte content less than 
5x106/unit, and pH at the end of storage between 6.4 to 7.4 (Guidelines for the Blood 
Transfusion Services in the United Kingdom 1998). 
Although it has been previously reported that leucocyte filtration leads to 10-20% 
loss of platelets in filtered platelets as compared to unfiltered control (Bertolini 1990), 
this degree of platelet removal was seen in this study only with the positively charged 
filter, PLX5. The loss of platelets found in this filter could be due to the charge 
interaction between the filter and platelets as platelets are known to contain a net 
negative charge on their surface. The lower platelet loss in this study compared to others 
may be explained by the study design used by others, in which there was an additional 
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step involving transfer of platelet rich plasma into a platelet bag prior to filtration. This 
study, which used the current production method of direct filtration of platelet rich 
plasma, can allow maximal recovery of platelets without significant loss. 
The assessment of platelet activation and quantitation of Pit-MV has been 
included in the current recommendations for the evaluation of novel platelet concentrates 
by the American Food and Drug Administration (FDA) (Vostal 1999). Levels of P- 
selectin on platelet membrane and soluble P-selectin in plasma supernatant of PCs have 
been shown to be correlated with each other (Divers 1995, Kostelijk 1996). The results 
from this study confirm this observation. Soluble P-selectin is more easily standardised 
and practical and can be performed in a large scale. The results in this study showed that 
filtration did not have a net effect on the levels of P-selectin. Similar findings have been 
reported by others (Bertolini 1990, Pedigo 1993, Boomgaard 1995, Metcalfe 1997). This 
implies that either filtratip dict not activate platelets and/or activated platelets expressing 
P-selectin were removed by the filter. Nevertheless, one study has reported that filtration 
causes platelet activation (Devine 1999). It should be noted that the filtration and platelet 
.0 
preparation process used in this report were greatly different ftom others. In other reports 
filtration was carried out after platelets had been pelletted. By contrast, in this report 
after the first centrifugation of whole blood, platelet rich plasma was passed through a 
filter. The second centrifugation to pellet platelets was then carried out on the filtered 
platelet rich plasma using a high centrifugation g force. It is possible that subjection of 
platelets to a high speed centrifugation step shortly after the exposure of platelets to the 
artificial surface of the filter increases platelet activation. 
In respect to microvesiculation, none of the three filters had a net effect on the 
levels of Pit-MV on day 1. This could be because either filtration did not generate or 
remove (pre-formed) Pit-MV or filtration both generated and removed Plt-MV resulting 
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in a balanced net effect. On storage, Imugard III filtered platelets showed the lowest 
increment in Plt-MV. 
Although several factors can influence the levels of platelet activation and 
microvesiculation, the differences seen in platelets stored in various bags originally 
supplied with the filters on day 5 were most likely to be related to the types of the bags 
used. This was because platelets passed over different filters but stored in the same type 
of bag, i. e. Cobe sample bag, did not show any difference. It has been shown that the 
inner wall of most plastic bags provides a site for complement fixation that could interact 
with platelets during storage (Gyongyossy-Issa 1994). In this respect, different types of 
bags may have different characteristic properties. Furthermore, bags with a larger 
volume/surface area may enhance the collision between platelets and the bags, resulting 
in higher degrees of mechanical injury to platelets. Therefore, the lower levels of platelet 
activation and microvesiculation observed in Imugard III filtered platelets on storage 
could be partly due to the smaller volume/surface area of the Teruflex bag used with this 
filter, as compared to other bags. This was substantiated by the fact that the differences 
in platelet activation and microvesiculation between platelets kept in Teruflex (1.0 L) 
and PL241 0 bags (1.3 L) were less than those kept in CLX bag (1.5 L). It has previously 
been shown that the reduction in surface area of the storage bag reduces the levels of 
platelet activation and microvesiculation (Bode 1991). 
In designing bags for platelet storage, apart from biocompatibility, oxygen (02) 
and carbon dioxide (C02) exchange property is also important. The gas exchange 
property of the bags depends on both the type of plastic/plasticisers and the total surface 
area. It should be noted that the bags currently available are not specifically designed for 
the 5-day storage of leucocyte depleted platelet concentrates and the focus has been 
placed on maximising 02 and C02 exchange in the presence of higher levels of 
128 
leucocytes. Leucocyte depleted products generate less C02 during storage due to reduced 
acid metabolites generated by lower numbers of leucocytes. In addition, leucocyte 
depleted products also require less 02 as the 02 consumption by leucocytes is reduced. 
When 02 from the atmosphere continues to diffuse into the bag and exceeds the demand, 
P02 and pH increase (Dzik 1992). The increase in pH on storage was also observed in 
this study. A good balance between the elimination Of C02 and the supplementation of 
02 is required for optimised storage conditions. While high C02 leads to less effective 
buffering by bicarbonate, resulting in a fall in pH and platelet activation, excess 02 may 
lead to peroxidation of membrane lipids, resulting in microvesiculation (Koerner 1992). 
Both PLX5 and Imugard III reduced pre-formed RBC-MV on day 1. On day 5 
RBC-MV in all three filtered were unchanged whereas the levels in unfiltered control 
increased. These could be explained by that the leucocytes in unfiltered platelets caused 
further microvesiculation, of the intact RBC present in the products. The effect of 
leucocytes on the integrity of red cell membrane has been previously demonstrated in red 
cell concentrates (Heaton 1994). By contrast, for platelet microvesiculation, the effects 
. 01 
of other factors such as the type of plactfc/plasticiser and surface area/volume of storage 
bags, the interaction of plasma proteins with the filters, might be more pronounced. An 
earlier report has shown that the presence of leucocyte in platelet concentrates did not 
grossly influence the platelet storage lesion as compared to non-leucocyte depleted 
control stored in the same type of storage bag (Dzik 1992). 
In conclusion leucocyte filtration did not generate or remove Plt-MV. Upon 5-day 
storage platelets which had passed through different filters showed different levels of Plt- 
MV. However, this appeared to be related to the differences in the storage bags used in 
various filters, as when platelets from various filters were kept in the same type of bag 
the results became similar. 
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CHAPTER 5 
EFFECTS OF PLATELET PREPARATION AND 
LEUCOCYTE DEPLETION METHODS 
ON MICROVESICULATION 
5.1 INTRODUCTION 
Approximately 40% of platelet concentrates transfused are provided from 
apheresis. In apheresis method, after platelets have been separated from whole blood, 
other blood elements i. e. red cells, some leucocytes and plasma, are returned to the 
donor. This strategy provides orie or more adult therapeutic doses of platelet concentrates 
from one donor, hence it reduces the number of donor exposures in multi-transfused 
patients. In addition, platelet concentrates prepared by apheresis method are the only 
option to provide a specific phenotype of ýILA or Human Platelet Antigen (HPA) match. 
In the UK, leucocyte depletion of apheresis platelets are achieved by two 
techniques i. e. a fluidised particle bed used in Cobe LRS apheresis machine, and 
leucocyte filtration of the harvested platelets during the last return cycle used in 
Haemonetics MCS+ LD apheresis machine. The collection sets used in various typesof 
apheresis machine are different from each other, and also different from those used in 
pooled buffy coat method. These collection sets are made from various materials and 
have different configuration as described previously in Chapter 1. It is not known 
whether all these combined variables will have similar effects on platelet activation and 
microvesicle formation. Furthermore, leucocyte depleted platelets prepared by apheresis 
130 
methods may differ from those prepared by the pooled buffy coat method. 
The aim of this study was to investigate whether leucocyte depleted platelet 
concentrates prepared by three different methods, i. e. Cobe LRS apheresis, MCS+ LD 
apheresis using LRF6H leucocyte removal filter, and pooled buffy coat method using 
Autostop filter, contained the same levebof MV. 
5.2 MATERIAL AND METHODS 
A paired study design is not possible when apheresis platelets are examined. 
Equally, it is not possible to compare the same donor bled on two different machines, as 
donors are frequently only suitable for one type of machine. 
Ten units of leucocyte depleted platelet concentrates prepared by each 
technology, Cobe LRS, Haemofietics MCS+ LD, and Autostop filtered pooled buffy coat 
method, were analysed. The methods of platelet preparation, the measurement of pH, 
leucocyte count, platelet count, platelet activation assessed by soluble P-selectin, and 
microvesicles were described previously in Chapters 1,2 and 3. For apheresis platelets, 
samples were tested on the day of production (day 0), day 1, and day 5. For MCS, a pre- 
filtered sample from each unit was also tested. For Autostop filtered platelets, samples 
were tested on day 1 and day 5, since in this preparation method platelet concentrates 
were made from pooled bully coats on day 1 (described in detail in Chapter 3). The 
following comparisons were made: 
i. MCS pre- and post-filtration 
ii. Cobe and post-filtered MCS on day 0 
iii. Cobe, post-filtered MCS and Autostop on day 1 and day 5 
iv.. The same type of platelets tested at different times 
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Mann-Whitney test, Wilcoxon matched pairs test, and ANOVA test were used to 
compare between unpaired, paired, and more than two sets of results, respectively. 
Spearman test was used for the correlation between results. 
5.3 RESULTS 
5.3.1 pH, leucocyte and platelet counts 
There was no difference in pH between Cobe and MCS platelets on day 0, and no 
difference between Cobe, MCS, and Autostop on day 1. However, on day 5 both Cobe 
(p<0.001) and MCS (p<0.01) were lower than Autostop (Table 5.1). All units were 
within the acceptable range (6.4-7.4) (Guidelines for the Blood Transfusion Services in 
the United Kingdom 1998). Residual leucocyte counts were less than 5xlO6/unit in all 
products. The platelet c6unt in Cobe was higher than MCS (p<0.01) and Autostop 
(p<O. 00 1). (Figure 5.1). 
5.3.2 Platelet activation as assessed by soluble P-selectin 
Pre-filtered MCS platelets contained higher levels of soluble P-selectin than post- 
filtered (p=0.0315) implying that the filter used (LRF6H) absorbed some soluble P- 
selectin (Figure 5.2). Post-filtered MCS PC were equivalent to Cobe PC : on day 0. On 
day 1, the levels were not significantly different from day 0 and all leucocyte depleted 
products were equivalent. On day 5, all groups showed increases levels of soluble P- 
selectin as compared to day I (all p<0.01). Cobe (p<0.05) and Autostop (p<0.01) were 
significantly higher than MCS (Figure 5.3). No correlation % 
was found between platelet 
count and soluble P-selectin. 
5.3.3 Microvesicles 
The levels of Pit-MV in MCS pre-filtered samples were lower than post filtered 
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(p--0.0020), whereas RBC-MV were equivalent (Figure 5.4). The Plt-MV of post filtered 
MCS were equivalent to Cobe on day 0. On day 1, no significant difference was found in 
both products as compared to day 0. Furthermore, post-filtered MCS, Cobe, and 
Autostop showed similar levels. On day 5, Plt-MV were significantly increased in all 
products as compared to day I (p<0.01 in all groups). Furthermore, MCS showed lower 
levels than Cobe (p<0.01) and Autostop (p<0.01). (Figure 5.5). 
The levels of RBC-MV were significantly lower in post-filtered MCS than in 
Cobe (p=0.0021) on day 0. During storage, RBC-MV remained unchanged. Cobe 
(p<0.05) and Autostop (p<0.001) were higher than MCS on both day 1 and day 5 (Figure 
5.6). 
No correlation was found between platelet count and Pit-MV on day 1 or day 5. 
In addition, no correlation was found between the levels of Plt-MV on day 1 and day S. 
There was a highl}'significant correlation between Plt-MV and soluble P-selectin 
on day 5 (r=0.7155, p<0.0001, all groups pooled) (Figure 5.7) but not on day 0 or day 1. 
No correlation was found between Plt-MV and RBC-MV. 
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Table 5.1 pH of Cobe, MCS, and Autostop on day 0, day 1, and day 5. 
Median (range). On day 5 both Cobe (p<0.001) and MCS (p<0.01) were lower than 
Autostop. 
Days Cobe MCS Autostop 
0 7.06 (7.02-7.10) 7.10 (7.00-7.22) NA 
1 7.06 (6.93-7.30) 7.16 (7.00-7.25) 7.10 (7.05-7.15) 
5 7.16 (7.03-7.24) 7.19 (6.95-7.26) 7.26 (7.24-7.31) 
NA-not applicable 
Figure 5.1 Platelet counts of Cobe, MCS, and Autostop. 
Median. Cobe was higher than MCS (p<0.01) and Autostop (p<0.001). 
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Figure 5.2 P-selectin in the supernatant plasma of pre- and post-filtered MCS 
platelets. 
Median. Post-filtered was significantly lower than pre-filtered (p=0.0315). 
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Figure 5.3 Soluble P-selectin of Cobe, post-filtered MCS and Autostop 
on day 0, day 1, and day 5. 
Median. Top-day 0, middle-day 1, bottom-day5. Cobe and Autostop were 
significantly higher than MCS on day 5 (p<0.0 I). 
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Figure 5.4 Pit-MV and RBC-MV of pre- and post-filtered MCS platelets. 
Median, top-Plt-MV, bottom-RBC-MV. Pit-MV in pre was significantly lower than 
post (p=0.0020). 
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Figure 5.5 Pit-MV of Cobe, post-filtered MCS and Autostop on day 0, day 1 
and day 5. 
Median, top-day 0, middle-day 1, bottom-day 5. On day 5 Cobe (p<0.01) and 
Autostop (p<0.01) were significantly higher than MCS. 
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Figure 5.6 RBC-MV of Cobe, post-filtered MCS and Autostop on day 0, day 1, 
and day 5. 
Median, top-day 0, middle-day 1, bottom-day 5. On day 0 Cobe was significantly 
higher than MCS (p--0.002 1). On day I and day 5, both Cobe (p<0.05) and Autostop (P<0.00 1) 
were higher than MCS. 
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Figure 5.7 Correlation between Pit-MV and soluble P-selectin on day 5. 
r-0.7155, p<0.0001. Cobe, MCS and Autostop pooled. 
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5.4 DISCUSSION 
The leucocyte removal filter (LRF6H) used in the preparation of platelet 
concentrates by MCS removed both soluble P-selectin and Plt-MV. An earlier report on 
MCS platelets using the same filter did not find any difference in P-selectin expression on 
platelet membrane between before and after filtration (Holme 1997). This might be 
because different filtration processes were used. In this study, filtration was carried out 
during the last return cycle, at the end of platelet collection, whereas in the earlier report a 
slow continuous filtration was carried out from the beginning through the end of platelet 
collection. It might be possible that in the latter process soluble P-selectin was absorbed 
and then later eluted into the filtrate, hence the levels of pre- and post-filtered products 
were unchanged. 
While no difference in the levels of soluble P-selectin and Plt-MV was seen 
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between Cobe and MCS on day 0 or between Cobe, MCS and Autostop on day 1, on day 
5 both Cobe and Autostop were higher than MCS. The higher levels of P-selectin and Plt- 
MV in Cobe could not be explained by the higher platelet count as there was no 
correlation between platelet count and the two parameters. However, several other 
variables could be responsible for the higher levels of soluble P-selectin and Pit-MV seen 
in Cobe on day 5. These include the differences in centrifugation g force used to separate 
platelets from red cells, the design of the collection units, the artificial surface of the 
harness and storage bags, as well as the leucocyte depletion process. All these variables 
may lead to the recovery of different subpopulations of platelets, undergoing various 
degrees of activation/microvesiculation. This hypothesis was supported by the results in 
Chapter 3 showing the difference in their response to EDTA between the three types of 
platelets. 
A previous report 6n the comparison of platelet activation and microvesiculation 
in platelet concentrates prepared by apheresis technique and from units of whole blood 
using the platelet rich plasma method has liown that the latter express higher levels of 
platelet activation and microvesiculation (Sloand 1996). The authors attributed this 
finding to the type of anticoagulant and the way in which it was mixed with whole blood 
before the process of platelet separation. In apheresis technique, whole blood was mixed 
with acid citrate dextrose (ACD) in a uniform way, whereas in platelet rich plasma 
method, blood flowed into a measured volume of citrate phosphate dextrose adenine 
(CPDA). Consequently, in the latter method blood obtained early in the donation was 
transiently subjected to high concentrations of citrate. In this study, although whole blood 
units used for the preparation of platelets by pooled buffy coat method were collected in 
the same way as those used in the platelet rich plasma method, the effect of anticoagulant 
on platelet 'activation and microvesiculation had not been demonstrated. Nevertheless, it 
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should be noted that platelets prepared by platelet rich plasma method causes higher 
degree of platelet activation than buffy coat method due to the second centrifugation step 
in which platelets were sedimented on the bottom of plastic bag (Fijnheer 1990). This 
could be accountable for the higher degree of platelet activation seen in platelet rich 
plasma method as compared to apheresis. 
The result on Plt-MV reported by Sloand et al was expressed as percentage of 
total CD61 (GPIIbllla) positive events, therefore, it cannot be compared with the 
quantitative result shown in this study. Furthermore, the Plt-MV region setting was not 
fully described. 
The LRF6H filter used in MCS apheresis reduced Plt-MV but not RBC-MV, 
whereas the Autostop filter used for leucodepletion of platelet concentrates derived from 
pooled buffy coats did not affect MV levels as compared to non-filtered control (Chapter 
4). This could be related tothe aifference in the internal structure of the filters although 
both filters are made from negatively charged polyester fibres. Nevertheless, among the 
three platelet preparation/leucocyte depletion methods, MCS gave the lowest level of 
RBC-MV. This could be explained by the difference in the process of platelet collection. 
As the specific gravity of RBC-MV is relatively higher than platelets, after the 
centrifugation to separate platelet from red cells, RBC-MV are settled between the 
interface of plasma containing platelets and red cell layer. In the MCS apheresis machine, 
platelet collection in each cycle was terminated at the level far from this interface, and 
hence leaving most of RBC-MV behind. In the Cobe LRS apheresis machine, the platelets 
were collected until the interface with red cells was reached. In Autostop filtered platelets, 
the collection of platelets was stopped when a mass of red cells started to enter the filter, 
hence more RBC-MV were collected as compared to MCS and Cobe. 
The, correlation between Plt-MV and platelet activation assessed by soluble P- 
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selectin seen at the end of shelf-life but not at the beginning implied that platelet 
activation was one of the mechanisms of microvesicle formation during storage. 
However, at the beginning of shelf-life the influence of other variables such as shear 
stress caused by centrifugation and the interaction with the artificial surface of collection 
set, on platelet microvesiculation are more pronounced than platelet activation. 
In summary Cobe LRS, MCS+ LD apheresis technologies, and Autostop filtered 
platelets did not show gross differences in terms of platelet activation and 
microvesiculation on day 1, but upon 5-day storage Cobe LRS showed higher levels of 
platelet activation and microvesiculation than the other two methods. 
y 
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CHAPTER 6 
EFFECT OF LEUCODEPLETION ON THE ACTIVATION 
OF COAGULATION AND COMPLEMENT SYSTEMS 
6.1 INTRODUCTION 
While citrate anticoagulant used in the preparation of platelet concentrates 
sufficiently chelates calcium ions to prevent clotting, activation of coagulation and 
complement systems still proceeds as demonstrated by the generation of thrombin, 
plasmin, and activated complement components such as C3a, C5a, C5b-9 (Hesselvik 
1989, Bode 1989,1992, Miletic 1993, Gyongyoss-Issa 1994, Krailadsiri 1996). The type 
and ratio of anticoagulant used, various leucocyte removal filters and different artificial 
surfaces of apheresis harness, may affect the coagulation and complement systems to 
different degrees. These may also contribute to platelet activation and microvesiculation. 
The objectives of this study were: 
i. To investigate whether the three commonly used leucocyte removal filters 
for pooled buffy coat derived platelets concentrates i. e. negatively charged polyester 
(Autostop), positively charged polyester (PLX5), and neutrally charged polyurethane 
(Imugard III), activate the coagulation and complement systems. 
ii. To investigate whether different leucocyte depletion technologies 
currently in use in routine production i. e. filtration of pooled buffy coat derived platelets 
using Autostop filter, filtration of apheresis platelets (MCS+ LD) using LRF6H filter, 
and leucocyte depletion by a fluidised particle bed (Cobe LRS), have the same effects on 
the coagulation and complement systems. 
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iii. To investigate whether the activation of coagulation/complement systems 
correlates with platelet activation/microvesiculation. 
6.2 MATERIAL AND METHODS 
Ten sets of pooled buffy coat derived platelet concentrates (BC-PCs) were 
prepared. Each set consisted of 4 units of PCs made from the same pool of buffy coats. 
One unit served as a non-filtered control, and each of the rest three was filtered with a 
negatively charged polyester (Autostop) or a positively charged polyester (PLX5) or a 
neutrally charged polyurethane (Imugard 111). Ten units of Cobe LRS and MCS+LD 
apheresis PCs were also analysed. The detail on platelet preparations was described in 
Chapters 4 and 5. A sample ftom each unit was taken on day I and day 5. 
The activation of contact system was measured by FXlla using ELISA, and by a 
microtitreplate chromogenic assay using a synthetic substrate sensitive to kallikrein 
(S2302), so called kallikrein-like activity (KLA). The generation of thrombin was 
measured by prothrombin fragment 1+2 (FI+2), thrombin-antithrombin complex (TAT) 
using ELISA, and by chromogenic assay using a synthetic substrate sensitive to thrombin 
(S2238), so called thrombin-like activity (TLA). The activation of complement system 
was measured by C3a using ELISA. All assays were performed on the supernatant 
plasma on day I and day 5 following the methods described in Chapter 2. 
Results between the control and three filtered BC-PCs, and between Autostop 
filtered BC-PCs and the two apheresis PCs were compared using the Friedman and 
Kruskal-Wallis ANOVA tests, respectively. Results between day I and day 5 of the same 
products were compared using the Wilcoxon matched pairs test. The Spearman test was 
used to analyse the correlation between two sets of results. 
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6.3 RESULTS 
6.3.1 Comparison between unfiltered control and three filtered BC-PCs 
i. KLA and T1A 
On day I KLA and TLA were comparable in control, PLX5 and Imugard 111, but 
over 2-fold higher in Autostop filtered PCs compared to the other three groups (all p< 
0.0001). On day 5 KLA in control, PLX5 and Imugard III filtered PCs were unchanged 
from dayl. Autostop values had slightly decreased (not significant) from day I but were 
still significantly higher than other groups (all p<0.0001). TLA remained constant in all 
products during storage (Figure 6.1). Significant correlation was found between KLA 
and TLA both on day I and day 5 (day I r=0.7489, p<0.00 1, day 5, r--0.6793, p<0.000 1, 
all four groups pooled) (Figure 6.2). 
ii. C3a 
On day I Autostop showed the lowest C3a (p<0.01,0.001,0.01 for Autostop vs 
control, PLX5, and Imugard 111, regpectivgly), whereas PLX5 showed the highest (all 
p<0.001). These indicated that the negatively charged filter absorbed C3a, whereas the 
positively charged filter generated it. Imugard 111, a neutrally charged filter, was not 
different from control. 
On day 5, the levels of C3a in all groups increased by approximately 3 fold from 
day 1, with Imugard III being the lowest. Significant differences were seen only between 
Imugard III and Autostop (p<0.001), and between Imugard III and PLX5 (p<0.01). 
(Figure 6.3) 
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6.3.2 Comparison between Cobe LRS, MCS+ LD apheresis PCs, and 
Autostop filtered BC-PCs 
i. - KLA and TLA 
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On day 1, Cobe showed the lowest level of KLA (p<0.05 and 0.001 for Cobe vs 
MCS and vs Autostop, respectively) and TLA (p<0.05 and 0.01 for Cobe vs MCS and vs 
Autostop, respectively). No significant difference was found between MCS and 
Autostop. On day 5, the levels of both KLA and TLA in Cobe and Autostop remained 
similar to the levels on day 1, whereas MCS significantly increased (day I vs day 5, 
KLA p--0.0037, TLA p<0.000 1). The pattern of KLA on day 5 between the three groups 
remained similar to that on day I i. e. Cobe was the lowest (Cobe vs MCS p<0.01, Cobe 
vs Autostop p<0.00 1, no difference between MCS and Autostop). However, the pattern 
of TLA was different from day 1, with MCS showing the highest level (MCS vs Cobe 
p<0.00 1, MCS vs Autostop p<0.05). Cobe and Autostop did not show any significant 
difference. (Figure 6.4) 
The degree of correlation between KLA and TLA was higher on day I 
,p 
day 5 (r=0.5903, p=0.0003) (Figure 6.5). This could be (r=0.6854, p<0.0001) tha 
because during storage thrombin bound to the surface of platelet membrane as well as 
the storage bag. 
4 
H. C3a 
On day 1, both Cobe (p<0.001) and MCS (p<0.01) showed higher C3a than 
Autostop BC-PCs. On day 5, no significant difference was observed between the three 
groups (Figure 6.6). 
6.3.3 FX11a, F1+2 and TAT 
The levels of FX11a, FI+2 and TAT in control and all types of leucodepleted PCs 
were at the basal levels, within the plasma normal ranges (FXIla <2.9 ng/mL, F1 +2 < 1.1 
nM, TAT <4 pg/L). No significant difference was found between control and leucocyte 
depleted products or between day I and day 5 of the same group. 
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6.3.4 Correlation between KLA, TLA, C3a and platelet 
activation/microvesiculation 
Only weak correlations were seen between TLA and Plt-MV on day 5 (all BC- 
PCs pooled r=0.3833, p=0.0146, both apheresis PCs pooled r--0.4874, p=0.0393). No 
correlation was seen between KLA, C3a and Pit-MV, or between KLA, TLA , C3a and 
platelet activation measured by soluble P-selectin. 
T 
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Figure 6.1 KLA and TLA in control and three types of filtered BC-PCs on day 
1 and day 5. 
_ 
Median. Left panels-KLA, right-TLA, top-day I, bottom-day 5. The levels of KLA 
and TLA in Autostop were significantly higher than other three groups (all p<0.0001) on both 
day I and day 5. 
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Figure 6.2 Correlation between KLA and TLA of BC-PCs on day 1. 
r=0.7489, p<0.00 1, all four groups pooled. 
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Figure 6.3 C3a in control and three filtered BC-PCs on day 1 and day 5. 
Median. Top panels-day], bottom day5. On day I Autostop was the lowest 
(p<0.01,0.001,0.01 for Autostop vs control, PLX5, and Imugard 111, respectively), whereas 
PLX5 the highest (all p<0.001). On day 5, Imugard III was significant lower than Autostop 
(p<0.00 1) and PLX5 (p<0.0 1). 
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Figure 6.4 The levels of KLA and TLA in Cobe, MCS, and Autostop filtered 
PCs on day I and day 5. 
_ 
Median. Left panels-KLA, right-TLA, top-day], bottom-day 5. On day 1, Cobe 
showed the lowest levels of both KLA (p<0.05 and 0.001 for Cobe vs MCS and vs Autostop, 
respectively) and TLA (p<0.05 and 0.01 for Cobe vs MCS and vs Autostop, respectively). On 
day 5, Cobe showed the lowest KLA (Cobe vs MCS p<0.0 1, Cobe vs Autostop p<0.00 1), MCS 
showed the highest TLA (MCS vs Cobep<0.001, MCS vs Autostopp<0.05). 
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Figure 6.5 Correlation between KLA and TLA on dayl. 
r--0.6854, p<0.000 1. Cobe, MCS and Autostop pooled, 
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Figure 6.6 C3a in Cobe, MCS, and Autostop filtered PCs on day 1 and day 5. 
Median. Top-day 1, bottom-day 5. On day 1, both Cobe (p<0.001) and MCS 
(p<0.01) were higher than Autostop BC-PCs. On day 5, no significant difference was observed. 
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6.4 DISCUSSION 
Leucocyte depleted platelet concentrates prepared by various filters and/or 
various methods were different from each other in terms of the activation of coagulation 
and complement systems. Autostop filtered BC-PCs showed higher levels of KLA than 
control or the other two filtered BC-PCs, possibly due to the activation of the contact 
system by the negatively charged surface of this filter. MCS apheresis PCs which used 
another negatively charged polyester filter also showed higher KLA than Cobe apheresis 
PCs. It has been reported that the activation of the contact system by a negatively 
charged leucocyte removal filter for PC leads to the generation of bradykinin, and is 
associated with hypotensive reactions in transfused patients also receiving angiotensin 
converting enzyme inhibitors (Fried 1996, Hume 1996, Sano 1996, Mair 1998). These 
reactions were previously Oescribed to be associated with the use of bed-side filters only, 
and not pre-storage in-process filters due to the short half-life of bradykinin. However, in 
the recent Serious Hazards Of Transftision Report, three patients receiving pre-storage 
filtered PCs developed hypotensive reilctions (Williamson 1999). It is not known 
whether these were associated with high levels of bradykinin. 
The level of FXIIa antigen did not increase in parallel to the increase in KLA, 
indicating that FXIla antigen alone is not a good marker of the activation of contact 
system in platelet concentrates. This could be due to its high affinity binding to surfaces 
i. e. plastic bags, various plasma protease inhibitors such as Cl inhibitor, cx2- 
macroglobulin, antithrombin 111, as well as protease inhibitors released from platelets 
such as platelet plasminogen activator inhibitor- I 
Previous reports measured the activation of contact system caused by negatively 
charged filters by detecting bradykinin (Shiba 1997, Hild 1998) or high molecular weight 
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kininogen index (HKI) (Scott 1998). Both assays have some limitations. Bradykinin 
contains an extremely short half-life (15 seconds) and required protease inhibitors to be 
added to the samples immediately after filtration (Shiba 1997). This prevents the 
handling of samples in a closed system where the same sample can be kept for further 
study on storage. HKI, measuring the ratio of high molecular weight kininogen before 
and after the generation of bradykinin, is not sensitive enough to detect the contact 
activation caused by negatively charged filters as only 0.2% of total kininogen is 
converted to bradykinin (Scott 1998). 
In parallel to KLA, TLA was increased in Autostop BC and MCS PCs. However, 
no elevation in the levels of TAT or FI+2 was observed possibly because these ELISA 
assays were not sensitive enough to detect the low levels of serine proteases generated. 
Synthetic substrates are more sensitive than a corresponding natural substrate and can 
detect both free serine profeases and proteases which binds to various inhibitors such as 
Cl-esterase, a2-macroglobulin, whereas ELISA assay did not. Similar finding where 
amidolytic activity in the supernatant plasma of PCs was observed using S2238, without 
elevated TAT, was previously reported (Wallvik 1992). 
While KLA and TLA in all BC-PCs and Cobe PCs on day 5 remained similar to 
the results obtained on day 1, the levels in MCS increased. This is possibly due to the 
difference in the type and ratio of anticoagulants used i. e. citrate-phosphate-dextrose 
(CPD) 1: 7 for BC-PCs, acid-citrate-dextrose formula A (ACD-A) using a protocol which 
the ratio ramping from 1: 7 to 1: 11 during a collection for Cobe, and ACD-A 1: 9 for 
MCS, hence a higher calcium ion concentration in the MCS. % 
The measurement of KLA and TLA provides a useful indicator of the activation 
of contact system and the generation of thrombin. 
With respect to the activation of complement system, all BC-PCs showed 
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increased levels of C3a on day I as compared to the normal plasma levels (26-146 
ng/ML). A previous study has demonstrated that the activation occurs from the moment 
that whole blood contacts the collection tubing and the initial collection bag 
(Gyongyossy-Issa 1994). Various filters used for BC-PCS interact with the complement 
system differently i. e. negative charged filter removed C3a, positively charged filter 
generated C3a, and neutrally charged filter was the same as control. The removal of C3a, 
a Positively charged protein, by the negatively charged filter is most likely due to an 
ionic interaction. Previous reports have shown that other positively charged proteins such 
as C4a, platelet factor 4, P-thromboglobulin, interleukin-8 are also adsorbed by 
negatively charged filters (Shimizu 1994,1998, Snyder 1996, Geiger 1997). The levels 
of Oa were further increased during storage with all products except Imugard III, 
reaching the same level. The lowest level of C3a in Imugard filtered PCs was seen on storage. 
This could be due to that the bag used with this filter might be more biocompatible than the bags 
used with the other two filters and control, and hence generated less C3a, or more C3a might be 
absorbed on the surface of this bag. Both leucocyte depleted apheresis PCs showed 
higher degrees of complement activation than Autostop filtered BC-PCs on day 1. This 
may be explained by the fact that in apheresis techniques blood is in contact with more 
surfaces of the collection sets as compared to BC-PCs. Nevertheless, on storage the 
levels of C3a in both apheresis PCs and Autostop BC-PCs increased to the same level. 
The mechanism of complement activation in platelet concentrates is not clearly 
defined. However, it has been proposed that complement activation occurs primarily via 
the classical pathway through the direct activation of Cl by artificial surfaces, and that 
the alternative pathway has little role, as activated factor B does not increase 
(Gyongyossy-Issa. 1994). 
It has been proposed that the activation of coagulation and complement systems 
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leading to the generation of thrombin and the membrane attack complex C5b-9 can cause 
Platelet activation and microvesiculation as demonstrated by in vitro experiments (Sims 
1988, Bode 1989). However, no study has been carried out to show their correlation. In 
this study, a trend between KLA/TLA and platelet activation/microvesiculation on day 5 
was observed i. e. among the 4 groups of BC-PCs Autostop filtered showed the highest 
KLA/TLA and the highest P-selectin and Plt-MV. However, only weak correlations were 
found. This is possibly due to that the generation of serine proteases is not the sole factor 
responsible for platelet activation and microvesiculation. The mechanisms involved in 
platelet activation and microvesiculation during the preparation and the storage of 
platelet concentrates are complex and multifactorial. Apart from the generated serine 
proteases and activated complement, these also include shear stress caused by 
centrifugation, filtration, and agitation; the interaction between platelet membranes and 
the leached material from the bag, platelet ageing, and apoptosis. 
In summary only the negatively charged filter activated the coagulation system as 
measured by chromogenic substrate assay. However, this filter removed some activated 
complement component C3a as compared to unfiltered control, whereas the positively 
charged filter generated C3a. The neutrally charged filter did not have significant effects 
on both the coagulation and complement systems. Both Cobe and Haemonetics apheresis 
appeared to activate the complement system more than buffy coat method. No 
correlation was found between the serine proteases or activated complement component 
and platelet microvesiculation. The clinical significance of the serine proteases 
detectable by only chromogenic substrate assay but not by conventional ELISA, as well 
as and activated complement components in platelet concentrates is unknown. 
Nevertheless, activated complement components such as C3a have pro-inflammatory 
effects and may cause transfusion reactions. 
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CHAPTER 7 
THE PROCOAGULANT AND ANTICOAGULANT 
PROPERTIES OF MICROVESICLES IN 
PLATELET CONCENTRATES 
7.1 INTRODUCTION 
Anionic phospholipids on the surfaces of MV and activated platelets play 
essential roles in two sequential reactions of the coagulation cascade, the formation of 
tenase and prothrombinase complexes, which lead to thrombin formation, the key step in 
the coagulation process (Mann 1990). The formation of tenase involves an active 
Proteolytic enzyme, FIXa, which in the presence of a co-factor FVlIla, Ca 2+ , and anionic 
phospholipid membrane, converts the zymogen FX into an active serine protease, FXa. 
Once FXa is formed, it assembles with a co-factor FVa, and Ca 2+ , on the anionic 
phospholipid membrane, and converts prothrombin to thrombin. 
The presence of a catalytic surface increases the local concentration of the 
subcomponents required for the reactions, as well as putting them in juxtaposition. These 
decrease the Michaelis constant (K, ý, ) of FX and prothrombin, the substrates of tenase 
and prothrombinase respectively, from far above to far below their respective plasma 
concentrations. Furthermore, the surface binding may also induce conformation changes 
in the proteins and help align the substrate cleavage sites with the active site of the 
enzyme. These enable both reactions to proceed at close to the maximum rate (V ýx), 
which is primarily determined by the co-factors FVllla and FVa (Rosing 1980, van 
Dieijen 1980). The combined decrease in the Kn of the two sequential reactions in the 
presence of anionic phospholipid surfaces can increase the rate of thrombin formation by 
several orders of magnitude. 
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The blood coagulation system is kept in balance by the coagulant and 
anticoagulant reactions. The binding of thrombin to thrombomodulin on the surface of 
endothelial cells converts thrombin's procoagulant property to anticoagulant, resulting in 
the conversion of protein C to activated protein C. Activated protein C then inactivates 
FVllla and FVa, the two co-factors for tenase and prothrombinase complex formation, 
by limiting proteolysis, inhibiting further generation of thrombin. While protein S is 
essential for activated protein C to exert its anticoagulant activity in plasma (Esmon 
1997), in purified systems the cleavage of FVa and FVllIa by activated protein C is 
accelerated less than four-fold (Bakker 1992). 
While the ability of MV to act as a procoagulant catalytic surface has been widely 
studied (Bach 1986, Rosing 1988, Mann 1990, Kalafatis 1994, Andree 1995), reports on 
their ability to act as an anticoagulant surface are limited. It has been demonstrated that 
protein S binds to MV but not to the remnant activated platelets, potentiating the binding 
Of activated protein C/protein C to MV. Furthermore, the same protein S binding 
Property was observed in MV generated by different agonists i. e. thrombin, calcium 
ionophore, and complement C5b-9 (Dahlback 1992). Using a purified system, it has been 
shown that MV also provide a catalytic surface for the inactivation of FVa by activated 
protein C and protein S in parallel to the formation of prothrombinase complex. In 
contrast to the first report, both the procoagulant and anticoagulant activities appeared to 
be dependent on the type of agonists used to generate MV (Tans 1991). 
In regard to MV present in platelet concentrates, limited information on their 
procoagulant property was available prior to the present study. Using platelet factor 3 
(PF3) assay, it has been shown that PF3 activity in the supernatant plasma of platelet 
concentrates increases during storage (Bode 1986). Furthermore, ultracentrifugation of 
this plasma removed the PF3 activity (Wolf 1967). The PF3 activity, hence, was thought 
to be associated with the sedimentable material derived from platelets. Nevertheless, 
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direct detection of MV had not been performed in these reports. The anticoagulant 
property of MV present in platelet concentrates has never been studied. It is not known 
whether MV in platelet concentrates generated during processing and storage have the 
same procoagulant/anticoagulant properties as MV generated by various platelet 
agonists. 
The objective of this study was to investigate whether MV present in platelet 
concentrates for transfusion contained procoagulant and/or anticoagulant properties, 
using purified systems for their assessment. 
7.2 MATERIALS AND METHODS 
7.2.1 Isolation of microvesicles 
Ten units of leucocyte depleted platelet concentrates were prepared by Cobe LRS 
apheresis machine. Samples were taken from each unit on day I and day 5. MV were 
isolated using the following procedure. 
Platelet-free, MV containing plasma was prepared by centrifuging I mL of 
platelet concentrates in a 1.5 polypropylene Eppendorf tube (BDH-Merek, Leicester, 
UK) at 16100 g (Eppendorf centrifuge 5417C, BDH-Merck, Leicester, UK) for I minute. 
0.5 mL of the supernatant (MV containing plasma) was saved and MV were measured 
quantitatively by flow cytometry as described in Chapter 2. Using ultrafiltration, MV 
were then isolated from the MV-containing plasma by pre-diluting I in 6 in 0.05 M 
Tris/0. IM NaCI/0.2% BSA (pH 8) to avoid blockage of the filter. The same buffer was 
also used in all the assays below. 0.4 mL of the diluted MV-containing plasma was filled 
into a 0.1 p (0.5 rnL holding volume capacity) low protein binding centrifugal filter unit 
(Millipore S. A., Molsheim, France) (Figure 7.1) and centrifuged at 20300 g for 5 
minutes. The filter unit was washed 3 times with Tris/NaCl/BSA and centrifuged at 
20300 g for 5 minutes. MV were not detected in the plasma filtrate or wash 
filtrate, 
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indicating that negligible amount of MV passed through the filter. 
All the assays below were perforined in the filter unit containing MV or where 
stated a blank empty filter. 
Figure 7.1 Filter unit used for the isolation of MV. 
A centrifugal filter unit consists of a container (B) with a holding volume of 0.5 mL and 
0.1 p filter in the bottom (grey), inside an Eppendorf tube (A). MV were isolated as described in 
the text above. 
0 
A 
7.2.2 Prothrombinase assay 
B 
The procoagulant activity of MV was assessed by their ability to act as a catalytic 
surface for the prothrombinase complex fon-nation. The subcomponents of 
prothrombinase complex, consisting of FXa, FVa, prothrombin and Ca 2+ , were added to 
the test system at a concentration which provided an optimal reaction rate i. e. occurred in 
a reasonable time as well as being linear in time, while MV provided phospholipids on 
their membrane and acted as the rate-limiting factor of thrombin generation. The amount 
of thrombin generated was measured using a chromogenic substrate for thrombin 
(S2238). 
The working concentrations of bovine FXa (Chromogenix AB, MbIndal, 
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Sweden), and human prothrombin (Enzyme Research Laboratories Ltd, Swansea, UK) 
were 0.4 and 0.7 U/mL, respectively, in Tris/NaCI/BSA. The working concentration of 
bovine FVa (Enzyme Research Laboratories Ltd, Swansea, UK) was 1.4 U/mL in 
TrisNaCI/BSA/12.5 mM CaC12. The substrate S2238 (Chromogenix AB, Mblndal, 
Sweden) was reconstituted in distilled water to obtain the concentration of 0.50 mM. The 
final concentrations in the reaction were 0.05 UlmL FXa, 0.2 U/mL FVa, 0.1 UlmL 
prothrombin, 2 mM CaC12, and 0.25 mM S2238. 
100 pL Tris/NaCl/BSA pre-warmed at 37'C were added to the filter unit 
containing MV, followed by 25 j& of each subcomponent, FXa, FVa and prothrombin. 
The filter unit was gently vortexed before being incubated at 37'C for 10 minutes. The 
reaction was stopped by the addition of 25 pL Na2EDTA into the filter unit, followed by 
gently vortexing. 100 gL of the reaction mixture were transferred to a flat bottom 
microtitre plate well. 100 gL of substrate S2238 pre-warmed at 37'C were added into 
each well. The absorbance at 405 nin was recorded every I minute for 10 minutes at 22 
T. The initial reaction rate was calculated from the change of absorbance per minute in 
the first 5 minutes and read against the standard curve plotted from the dilutions of 
human thrombin (National Institute of Biological Standard and Control, Potters Bar, UK) 
reconstituted and diluted to I U/ml and serially diluted 0.5,0.25,0.125,0.0625 U/mL. 
Results were expressed as thrombin activity generated. 
Serial dilutions of purified phospholipids obtained from human brain 
(Thrombosis Reference Centre, Manchester, UK) were used to demonstrate the 
phopholipid dose dependent of the assay. The molar ratio of phospholipid subclasses 
were 30% phosphatidylcholine, 10% sphingomyelin, 2% phosphatidylinositol, 38% 
phosphatidylethanolamine, and 20% phosphatidylserine (Stevenson 1986). 
Serial dilutions of MV were also used to assess whether the thrombin generated 
in the assay condition used was MV concentration dependent. 
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7.2.3 Protein Case assay 
The working concentrations of human protein C (Chromogenix AB, M61ndal, 
Sweden), human protein S (Enzyme Research Laboratories Ltd, Swansea, UK), 
recombinant human thrombomodulin (Alpha Laboratories Ltd, Hampshire, UK), human 
thrombin (National Institute of Biological Standard and Control, Potters Bar, UK), and 
CaC12, were 280 nM, 700 nM, 210 nM, 35 nM, and 2 mM, respectively, in 
Tris/NaCI/BSA. Substrate for activated protein C (S2366) and thrombin inhibitor (12581) 
were reconstituted in distilled water to obtain the working concentrations of 0.50 mM, 
and 0.14 mM, respectively. The final concentrations of each reagent in the reaction were 
40 nM protein C, 100 nM protein S, 30 nM thrombomodulin, 5 nM thrombin, 0.3 mM 
CaC12.0.25 mM S2366, and 0.02 mM 12581. 
25 gL Tris/NaCI/BSA pre-warmed at 37'C were added to the filter unit 
containing MV, followed by 25 ýLL of each subcomponent, protein C, protein S, 
thrombomodulin, thrombin, and CaC12. The filter unit was gently vortexed before being 
incubated at 37'C for 10 minutes. 25 pL 12581 was added to inhibit the amidolytic 
activity of thrombin which is 75% of activated protein C. The filter unit was vortexed 
gently and incubated for further 3 minutes. 100 gL of the mixture were transferred to a 
flat bottom microtitre plate well. 100 ýiL of substrate S2366 pre-warmed at 37'C were 
added into each well. The absorbance at 405 nm was recorded every I minute for 10 
minutes. The initial reaction rate was calculated from the change of absorbance per 
minute in the first 5 minutes and read against the standard curve plotted from the 
dilutions of human activated protein C (Chromogenix AB, M61ndal, Sweden) serially 
diluted to 100,50,25,12.5,6.25 nM. Results were expressed as activated protein C 
activity generated. 
As thrombin has 75% of activated protein C amidolytic activity using substrate 
S2366, a blank filter unit containing MV and all subcoponents except protein C was also 
164 
tested to assess the amidolytic activity of residual thrombin. Furthermore, investigate 
whether MV were required for the generation of activated protein C, the assay was also 
performed in a filter without the presence of MV. 
7.2.4 Activated protein C inactivation of FVa 
The working and final concentrations of FXa, FVa, prothrombin, CaC12, and 
substrate S2238 were similar to the prothrombinase assay. The working and final 
concentration of activated protein C was 1.12 nM and 0.16 nM, respectively. 75 PL 
Tris/NaCI/BSA pre-warmed at 37"C were added to the filter unit containing MV, 
followed by 25 gL FVa containing CaC12 and 25 gL of activated C or TrisNaCI/BSA. 
The filter unit was gently vortexed before being incubated at 37'C for 3 minutes. 25 ý11, 
of FXa, and prothrombin were added. The filter unit was gently vortexed before being 
incubated at 3 7'C for further 10 minutes. 100 pL of the mixture were transferred to a flat 
bottom microtitre plate well. The thrombin generated was measured using the same 
procedure as the prothrombinase assay. Results on FVa inhibition were expressed as the 
percent reduction in thrombin generated in the presence of activated protein C against 
that in the absence of activated protein C. 
All assays were performed in duplicate. If the CV between duplicates was greater 
than 10%, the results were rejected and the assays were repeated. 
7.2.5 Statistical analysis 
Wilcoxon matched pairs test was used to compared results between day I and day 
5. Spearman test was used for the correlation between two set of results. 
7.3 RESULTS 
7.3.1 Prothrombinase activity 
Using purified phospholipids, the phopholipid dose dependent generation of 
thrombin is shown in Figure 7.2. 
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A dose-dependent response similar to that seen with purified phospholipids was 
observed with MV serial dilutions, confirming the optimal conditions of the assay 
(Figure 7.3). 
MV isolated from day I platelets showed a significant correlation with the 
amount of thrombin generated (r--0.8909, p=0.0003, Figure 7.4). When MV were 
isolated from the same units of platelets after 5 day storage, all samples showed 
significantly increased levels of thrombin generated (p=0.0059, day I vs day 5) as well 
as MV (p--0.002, day I vs day 5) (Figure 7.5). However, no correlation in individual 
samples was seen between MV and the thrombin generated. 
7.3.2 Protein Case activity 
As the rate-limiting factor for the generation of activated protein C is the binding 
of protein C to thrombomodulin, not phospholipids, it was not possible to design an 
assay which showed the phospholipid dose dependent effect. In the conditions used in 
this study, MV isolated from day I and day 5 platelet concentrates generated the same 
levels of activated protein C, approximately 25-30 nM. (Figure 7.6). No MV 
concentration dependent effect was seen on day I or day 5. Furthen-nore, a similar 
amount of activated protein C was generated in a blank filter unit without MV. 
7.3.3 Activated protein C inactivation of FVa 
MV isolated from day I platelets expressed the ability to act as a catalytic surface 
for FVa inactivation by activated protein C, reducing by 15-30% the level of thrombin 
generated, as compared to the thrombin generated in the absence of activated protein C. 
On day 5, the percent reduction in the amount of thrombin generated in the presence of 
activated protein C was decreased to less than 10%. Furthermore, in some samples the 
amidolytic activities were slightly higher in the presence of activated protein C due to the 
cross reactivity of activated protein C with S2238 (Figure 7.7). No correlation was seen 
between MV and the percent reduction in thrombin generated. 
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Figure 7.2 The phospholipid dose dependent generation of thrombin. 
Serial concentrations of purified phospholipids were used in the prothrombinase reaction. 
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Figure 7.3 The MV concentration dependent generation of thrombin. 
Serial dilutions of MV were used in the prothrombinase reaction. 
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Figure 7.4 Correlation between MV concentration and the amount of thrombin 
generated on day 1. 
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Figure 7.5 MV and thrombin generated on day I and day 5. 
Median, Left-Plt-MV, right -thrombin generated. Both MV (p=0.002) and the level 
of thrombin generated (p=0.0059) increased on day 5 as compared to day 1. 
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Figure 7.6 Activated protein C generation on day 1 and day 5. 
Similar levels of activated protein C were generated on day I and day 5 
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Figure 7.7 Activated protein C inactivation of FVa on day I and day 5. 
No inactivation of FVa was seen on day 5. 
c 30 Z 
E 
20 
10 
.80. 
9- 
in- 
169 
day I day 5 
day 1 day 5 
7.4 DISCUSSION 
The phospholipids on the membrane of activated platelets as well as MV play 
essential roles in the coagulantlanticoagulant reactions. In this respect, anionic 
phospholipids, in particular phosphatidyl serine, contain the highest procoagulant 
property and act as a rate-limiting factor in the generation of tenase and prothrombinase 
complex (Mann 1988). Nevertheless, phosphatidylserine also participate in the 
inactivation of FVa by activated protein C, although the presence of 
phosphatidylethanolamine is also essential for the anticoagulant property of MV 
(Smirnov 1999). 
Studies have shown that MV generated by various platelet agonists can act as a 
catalytic surface for both procoagulant and anticoagulant reactions (Tans 1991, DahlbAck 
1992). In this study, MV generated during processing and storage of platelet concentrates 
also showed the ability to act as a catalytic surface for both reactions. However, only MV 
isolated from day I platelets correlated with the prothrombinase activity. This could 
possibly be because the phospholipid composition of MV present on day I and day 5 was 
different and that the phosphatidylserine content might be correlated with MV level on 
day I but not on day 5 due to the rearrangement of phospholipids. Furthermore, it could 
be that MV isolated from day 5 platelets were more heterogeneous in terms of 
phospholipid distribution. It is not known whether MV present in day I and day 5 
platelets are generated by the same mechanism. It has been demonstrated that MV 
generated by different mechanisms, i. e. activation vs non-activation have different 
characteristic properties. While MV generated by platelet activation express P-selectin 
on their membranes, MV generated by cellular fragmentation do not (Nomura 1993). In 
addition, MV formed upon platelet activation contained platelet form of FXIII, whereas 
MV formed upon mechanical-induced fragmentation contained both platelet and plasma 
forms (Holme 1993). Furthermore, it has been demonstrated that even MV generated 
170 
by the same platelet agonist i. e. thrombin are heterogeneous, some express P-selectin, 
CD63, and phosphatidylserine on their membranes, other did not (Heijnen 1999). MV 
present in platelet concentrates were likely to be generated by multiple mechanisms, and 
hence they may be heterogeneous in terms of their characteristic properties including the 
phospholipid distribution on their membranes. 
With regard to the inactivation of FVa by activated protein C, MV isolated from 
day I platelets showed the ability to act as a catalytic surface for this reaction. However, 
on day 5, this procoagulant property decreased substantially. This could be due to the 
inhibitory effects of high phospholipid concentrations and/or high phosphatidylserine 
molar ratio on the inactivation of FVa by activated protein C (Bakker 1992). The 
PrOCOagulant activity measured by the reduction in the amount of thrombin generated in 
the prothrombinase reaction in the presence and absence of activated protein C did not 
correlate with MV levels. This may be because the phosphatidylethanolamine content, an 
essential phospholipid for this reaction (Smirnov 1999) was heterogeneous, and did not 
correlate with the level of MV. 
The role of phospholipid membranes in the generation of activated protein C is 
unclear. Two models of phospholipid participation in activated protein C generation 
have been proposed: i) protein C interacts directly with phospholipids, leading to an 
increased affinity of protein C for thrombin-thrombomodulin; and ii) protein C does not 
directly interact with phospholipids but binds to thrombomodulin that is 
conformationally changed by interaction with phospholipids (Freyssinet 1986, Galvin 
1987, Horie 1994). Furthermore, it has been demonstrated that phosphatidylcholine, a 
neutral lipid, vesicles inserted with thrombomodulin can act as a surface for the binding 
of protein C and subsequent activated protein C generation but the binding of protein C 
to thrombomodulin, not phospholipids, is the rate limiting factor; and that 
phosphatidylserine is not an essential phospholipid for this reaction (Galvin 1987, Horie 
171 
1994). In addition, it has been reported that lipid vesicles containing 
phosphatidylcholine/phosphatidylethanolatnine catalyse protein C activation by 
thrombin-thrombomodulin with the highest rate as compared to other lipid vesicles 
(Horie 1994). More recently, the role of anionic phospholipids in the generation of 
activated protein C in vivo has been challenged. It has been proposed that plasma protein 
C binds to endothelial cell protein C receptor, which then presents protein C to thrombin- 
thrombomodulin complex for activation, and that these interactions do not require 
negatively charged membranes (Stems-Kurosawa 1996, Esmon 1997). 
In the study, it was found that MV isolated from platelet concentrates did not 
enhance the protein Case reaction as compared to the same assay system performed in 
the absence of MV. This support the hypothesis that the binding of protein C to 
thrombomodulin, not phospholipid contents, is the key step and the true rate limiting 
factor in the generation of activated protein C, and that the generation of activated 
protein C does not require phospholipid membrane. 
In summary, using purified systems this study has demonstrated that MV present 
in platelet concentrates can act as a catalytic surface for both procoagulant and 
anticoagulant reactions. While the procoagulant and anticoagulant activities of MV 
isolated from day I platelets appeared to be parallel, the procoagulant activity of MV 
isolated from the same products after 5-day storage became more pronounced. 
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CHAPTER 8 
THE APPLICATION OF ANNEXIN V AS A NEW MARKER 
OF PLATELET STORAGE LESION 
8.1 INTRODUCTION 
Annexin V is a cytosolic glycoprotein found in various cells including blood 
cells (Reutelingsperger 1988, Kaetzel 1989, Flaherty 1990, Romisch 1992). Although the 
physiologic function of annexin V is unknown, several studies have demonstrated its 
anticoagulant property in vitro. Annexin V is a potent inhibitor of both FX and 
Prothrombin binding to activated platelets (Reutelingsperger 1985, van Heerde 1994a, 
London 1996, Scandura 1996). In addition, it has been shown that in venous blood flow 
conditions, annexin V inhibits platelet adhesion possibly by the reduction of thrombin 
formation and fibrin deposition (van Heerde 1994b). It has also been shown that annexin 
V inhibits protein kinase C (Schlaepfer 1992) and phospholipase A2 activities (Haigler 
1987). Furthermore, it has been proposed that annexin V may play a role in membrane 
cytoskeleton function as it is copurified with cytoskeletal proteins (Tzima 1997). 
Low levels of annexin V are found in normal citrated plasma (1.1+1.7 ng/mL). 
Markedly increased levels are found in antiphospholipid syndrome, in particular 
systemic lupus erythematosus (SLE), in which high levels of anti-annexin V antibody are 
also found (Kaburaki 1997). Moderately increased levels are found in myocardial 
infarction (Romisch 1992). The level of annexin V in platelet concentrates has never 
been studied. 
Annexin V is present in different types of blood cells at various concentrations 
i. e. 2.5x 1 0-16 , 2.8x 1 0-14, and 5.9x 1 0-16 g/cell 
for red blood cells, leucocytes, and platelets, 
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respectively (Romisch 1992). As the numbers of red blood cells and leucocytes in buffy 
coat derived and apheresis platelet concentrates are much lower than numbers of platelets 
Le. red cells <IxIO9/L, leucocytes <Ixl0s/L, and platelets _IX1012 /L, an increased level 
of annexin V can be attributed to platelets as the main source. In platelets annexin V is 
not located in the granules as activation of platelets by strong agonists does not induce 
the secretion of annexin V (Murphy 1992). It has been proposed that at the intracellular 
concentration of Ca2+ (0.8 gM) seen in platelets stimulated by a physiological agonist, 
such as thrombin 0.1 unit/mL, annexin V is associated with platelet membrane 
cytoskeleton via annexin V binding protein and is released into the plasma upon 
membrane damage and/or proteolysis of the membrane (Trotter 1995). During storage of 
citrate anticoagulated platelet concentrates for transfusion, a similar level of intracellular 
Ca2+ is also observed (Sasakawa 1986), hence changes in the level of annexin V might be 
useful as a marker of platelet injury/microvesiculation. 
The objectives of this study were: 
i. To investigate the level of annexin V in non-leucocyte depleted and 
leucocyte depleted pooled buffy coat derived platelet concentrates 
prepared by three leucocyte removal filters. 
ii. To compare the level of annexin V in leucocyte depleted platelet 
concentrates prepared by Cobe and MCS+ LD apheresis platelets, and 
Autostop filtered pooled buffy coat derived platelets, the three methods 
used in routine production. 
iii. To investigate whether annexin V could be used as a surrogate marker of 
platelet injury/microvesiculation. 
8.2 MATERIALS AND METHODS 
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Ten sets of pooled buffy coat derived platelet concentrates were prepared. Each 
set consisted of 4 units of platelet concentrates made from the same pool of buffy coats. 
One unit served as a non-filtered control, and one of the other three was filtered with a 
negatively charged polyester filter (Autostop) or a positively charged polyester filter 
(PLX5) or a neutrally charged polyurethane filter (Imugard 111). The detailed method was 
described in Chapter 4. In addition, 10 units of Cobe LRS and MCS+LD (filtered with 
the LRF6H filter) apheresis platelets were also analysed. 
Annexin V was measured in the supernatant plasma of platelet concentrates on 
day I and day 5, using ELISA as described in Chapter 2. 
The concentrations of annexin V in leucocyte depleted pooled buffy coat derived 
Platelets prepared by the three different filters as well as unfiltered control were 
compared using Friedman ANOVA test. The results between leucocyte depleted platelet 
concentrates prepared by three different technologies i. e. Cobe, MCS, Autostop filtered 
platelets, were also compared using Kruskal-Wallis ANOVA test. Spearman test was 
used for the correlation between annexin V and platelet count, microvesicles or soluble 
P-selectin. 
8.3 RESULTS 
8.3.1 Comparison between control and three filtered pooled buffy coat 
derived platelets 
On day 1, the levels in control and the three filtered platelets were comparable. 
By day 5, the levels had increased approximately 2 fold from day I values in control, 
Autostop and PLX5. However, Imugard III filtered platelets gave significantly lower 
values than control (p< 0.001) and Autostop platelets (p< 0.01). 
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8.3.2 Comparison between Cobe, MCS, and Autostop filtered platelets 
On day 1, annexin V in Autostop filtered pooled buffy coat derived platelets was 
higher than Cobe (p<0.01) and MCS (p<0.001) apheresis platelets. By day 5, both Cobe 
(P<0.05) and Autostop (p<0.001) were higher than MCS (Figure 8-2). 
8.3.3 Correlation between platelet count, microvesides, soluble P-selectin 
and annexin V 
No correlation was found between platelet count and annexin V in platelets 
prepared by buffy coat or apheresis method. However, there was a significant correlation 
between the values of Plt-MV and annexin V in platelets prepared by buffy coat method 
(r--0.7328, p<0.0001, control and three filtered platelets day I and day 5 pooled) (Figure 
8.3). A significant correlation between Plt-MV and annexin V was also seen in apheresis 
Platelets (r--0.6233, p<0.0001, Cobe and MCS day I and day 5 pooled). (Figures 8.4) No 
correlation between RBC-MV and annexin V was found. 
Soluble P-selectin was correlated with annexin V in both platelets prepared by 
buffy coat (r=0.7782, p<0.0001, all data from day I and day 5 pooled) and apheresis 
method (r--0.623 3, p<0.000 1, Cobe and MCS day I and day 5 pooled). (Figures 8.5,8.6) 
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Figure 8.1 Annexin V in control and three filtered huffy coat derived platelets 
on day I and day 5. 
_ 
Median. Top-day 1, bottom-day 5. No difference was seen on day 1. On day 5 
Imugard III was lowerthan control (p<0.001)and Autostop platelets (p<0.01). 
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Figure 8.2 Annexin V in Cobe, MCS and Autostop filtered platelets on day 1 
and day 5. 
_ 
Median, top-day 1, bottom-day 5. Day 1, Autostop was higher than Cobe (p<0.01) 
and MCS(p<0.001). Day 5, MCS was lower than Cobe(p<0.05) and Autostop(p<0.001). 
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Figure 8.3 Correlation between Pit-MV and annexin V in control and filtered 
platelets prepared by buffy coat method. 
r=O. 7328, p<0.000 1, al I data day I and day 5 pooled. 
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Figure 8.4 Correlation between Plt-MV and annexin V in apheresis platelets. 
r=0.6233, p<0.000 1, Cobe and MCS day I and day 5 pooled. 
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Figure 8.5 Correlation between soluble P-selectin and annexin V in control and 
riltered platelets. 
r=0.7792, p<0.000 1, al I data day I and day 5 pooled. 
15 A 
.E 2( C» 
10 
0 
Figure 8.6 Correlation between soluble P-selectin and annexin V in apheresis 
platelets. 
r=0.8053, p<0.000 1, Cobe and MCS day I and day 5 pooled. 
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8.3 DISCUSSION 
Upon activation, platelets undergo changes in internal reorganisation, secretion of 
granule contents and aggregation. Activation by platelet agonists, such as thrombin, 
stimulates signal transduction pathways, which result in an increase in cytosolic Ca 2+ . 
However, the molecular events, which lead to the increase in Ca 2+, remain unknown. In 
platelet concentrates, during storage platelet activation caused by several factors, such as 
the interaction with serine proteases, also leads to the increase in cytoplasmic Ca 2+ 
(Sasakawa 1986,13ode 1989). 
In resting platelets, annexin V is thought to be located in the cytoplasm. In the 
presence of 0.8 ýM of cytoplasmic Ca2"', the level seen in platelets stimulated by 
physiological agonists as well as in stored platelet concentrates, annexin V binds to the 
membrane cytoskeleton via a 50kDa annexin V binding protein (Trotter 1995). 
Concomitantly, the increased cytoplasmic Ca2+ can also lead to the activation of calpain, 
a calcium dependent enzyme, resulting in the proteolysis of membrane cytoskeleton, the 
release of annexin V from the membrane, and/or microvesiculation. 
The levels of annexin V in the supernatant plasma of platelet concentrates on day 
I were approximately 2-5 times and further increased to 5-10 times higher than normal 
plasma levels during the 5-day storage. Both control and the three filtered pooled buffy 
coat derived platelets did not show any difference in annexin V on the day of production 
(day 1) implying that either filtration did not cause membrane damage which could result 
in the increased level of annexin V, or filtration both generated and removed annexin V 
resulting in no net effect. 
The higher level of annexin V seen in Autostop filtered pooled buffy coat derived 
platelets as compared to both Cobe and MCS apheresis PC on day I was possibly 
because during the preparation of platelets by buffy coat method, buffy coats containing 
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high concentrations of red blood cells, leucocytes and platelets were kept overnight at 
22T. The enzymes released from leucocytes such as elastase and cathepsin could cause 
proteolysis of red cell and platelet membranes, leading to the release of annexin V. 
However, the lower level of leucocytes present in the control unfiltered platelets (less 
than 100 leucocytes/l. LL) did not influence annexin V levels on storage as no difference 
was seen between control and Autostop filtered platelets, both were kept in the same type 
of storage bag. This implied that the level of leucocytes present in unfiltered platelets 
prepared by pooled buffy coat method did not influence platelet storage lesion. 
Furthermore, it indicated that platelets were the main source of the increase in annexin V. 
This was further substantiated by the finding that the higher level of RBC-MV in control 
as compared to Autostop filtered platelets on storage did not lead to the higher level of 
annexin V. In addition, considering the numbers of leucocytes and red cells present in 
Platelet concentrates, even with the complete cell lysis and total release of annexin V 
from these cells, it would only amount to less than 3 ng/mL of annexin V. 
A similar trend to annexin V was also observed with Plt-MV and P-selectin in 
control and Autostop filtered platelets on storage. Furthermore, Imugard filtered 
platelets, which showed the lowest level of annexin V on storage, also showed the lowest 
levels of Plt-MV and P-selectin, as compared to other groups of pooled buffy coat 
derived platelets. Cobe and Autostop platelets gave higher values of annexin V, Pit-MV 
and P-selectin than MCS. 
Although the release of annexin V is not directly platelet activation dependent i. e. 
no secretory-ftision occurs, the correlation with soluble P-selectin, an activation 
dependent marker, implies that activation has an indirect role by causing the proteolysis 
of membrane and/or microvesiculation. Furthermore, the correlation of annexin V with 
Plt-MV levels between the two parameters indicated that they shared some common 
mechanisms of generation 
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Several anticoagulant properties of annexin V have been demonstrated in vitro, 
but its physiologic role remains unknown. In the presence of 5 mM of CaCJ2 annexin V 
has a high affinity binding to phosphatidyl serine on the membrane of activated platelets, 
inhibiting the binding of FX and prothrombin. The mechanism of the inhibition has not 
been clarified but it is not by a simple competition (Scandura 1996). Antibodies to 
annexin V have been found in a number of patients with antiphospholipid syndrome (de 
Groot 1993, Matsuda 1994, Kaburaki 1997). It has been hypothesised that anti-annexin 
V antibodies inhibits its anticoagulant property (Kaburaki 1997, Rand 1998). This might 
Partly play a role in the thrombotic tendency seen in these patients. 
The clinical significance of the annexin V present in platelet concentrates is 
unknown. It is likely that after transfusion it will bind to anionic phospholipid membrane 
Of activated platelets or MV due to the high concentration of Ca 2+ , i. e. millimolar levels, 
in the circulation. Although under an optimal storage condition the amount of annexin V 
released was less than 10% of total annexin V content in platelets, suboptimal storage 
conditions may lead to higher levels of platelet activation/microvesiculation, and hence 
higher levels of annexin V. Transfusion of such platelets may reduce the haemostatic 
effectiveness of the products. 
As the changes in annexin V levels in platelet concentrates are directly and 
indirectly related to platelet activation/microvesiculation/fragmentation, it may be useful 
as a marker to detect the overall platelet storage lesion. 
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CHAPTER 9 
GENERAL DISCUSSION 
Since November 1999 all blood components in the UK have been subjected to 
leucocyte depletion, as a precaution against the theoretical possibility of variant 
Creutzfeldt-Jacob disease (vCJD) transmission. Leucocyte depleted platelet concentrates 
are currently prepared by three major methods, i. e. leucocyte filtration of pooled buffy 
coat derived platelets, leucocyte filtration of Haemonetics MCS+ LD apheresis platelets, 
and Cobe LRS apheresis platelets. Leucocyte depletion in the last method is achieved 
without the use of leucocyte removal filter, but employs the fluidised particle bed 
principle. 
Using an automated blood cell counter and a simple procedure, in which citrate 
anticoagulated platelets were exposed to EDTA, and platelet size distribution indices of 
citrate and citrate plus EDTA samples were compared, it has been demonstrated platelets 
prepared by various methods mentioned above responded differently to EDTA. This 
implied that platelets recovered from different preparation methods contained different 
levels of functional reserve. In this respect, platelets prepared by buffy coat method 
appeared to be the most reactive, whereas Cobe apheresis platelets were the least. 
Isolation of platelets for transfusion, from whole blood by any methods resulted 
in some degree of platelet activation and microvesiculation, which were further increased 
during storage. This study has quantitated platelet-derive microvesicles in platelet 
concentrates for transfusion for the first time. Although prior to this study, there have 
been reports on platelet-derived microvesicles in platelet concentrates, the measurements 
were carried out qualitatively (Wolf 1967, Solberg 1987, Bode 1991,1994). 
The effects of leucocyte filtration on platelet activation and microvesiculation 
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have never been explored. Leucocyte removal filters made from three different synthetic 
materials, namely negatively charged polyester (Autostop), positively charged polyester 
(PLX5), and neutrally charged polyurethane (Imugard 111), were investigated. An 
originally designed method for the preparation of four groups of platelet concentrates 
derived from the same pool of buffy coats was used to enable the comparison of three in- 
process leucocyte removal filter/storage bag combinations currently available in the 
market, as well as unfiltered control. None of the three leucocyte removal filters used 
gave a net effect in terms of platelet activation or platelet-derived microvesicles 
generation/removal. During storage, the levels of platelet activation and 
microvesiculation increased in all types of platelets. The increase in platelet activation 
and microvesiculation were remarkably influenced by the volume and surface area of the 
storage bags used. Storage bag with the lowest volume and surface area showed the 
lowest levels of platelet activation/microvesiculation. This was substantiated by the 
finding that the difference among the three filtered and unfiltered platelets were 
eliminated when all four types of platelets were stored in the same type of bag. 
Furthermore, the levels of residual leucocyte seen in the unfiltered platelets or filtration 
did not influence the degree of platelet activation/microvesiculation during storage if 
both unfiltered and filtered products were kept in the same condition. 
Platelets prepared by different methods did not show any difference in terms of 
platelet activation/microvesiculation at the beginning of shelf-life. However, at the end 
of the 5-day storage, platelets prepared by Haemonetics MCS+ LD apheresis technique 
showed the lowest level of platelet activation and platelet-derived microvesicles. 
The effect of platelet activation, assessed by the expression of P-selectin on 
platelet membrane, on the survival of transfused platelets is equivocal. Earlier reports 
suggested a shortened survival of activated platelets expressing P-selectin (Rinder 1991, 
Triulzi 1992, Holme 1997). The mechanism involved is thought to be the binding of 
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activated platelets to leucocytes and their subsequent clearance from the circulation 
either by the mononuclear-phagocyte system or by entrapment of the platelet-leucocyte 
aggregates in the microcirculation. Nevertheless, recent reports have shown that P- 
selectin deficient mice clear activated platelets at the same rate as normal mice (Berger 
1998) and that P-selectin positive platelets have normal survival in baboons (Michelson 
1996). It has also been shown that after transfusion, P-selectin on the platelet membrane 
is rapidly cleaved into the plasma to become the soluble forin (Berger 1998). These 
suggest that P-selectin expression per se may not directly account for in vivo survival of 
transfused platelets. Nevertheless, the expression of P-selectin on platelet membrane may 
have some biological implication as it has been shown to be associated with the 
inflammatory process by recruiting monocytes and neutrophils to the site of tissue injury 
(Larsen 1989, Hamburger 1990). More recently, it has been reported that platelet-derived 
microvesicles expressing P-selectin mediate leucocyte-leucocyte interactions on 
endotheliurn (Forlow 2000). 
The physiologic role of plasma soluble P-selectin is not clear. It is believed that it 
may reduce complement-mediated ischemia-reperfusion injury (Woodcock 1998). The 
P-selectin molecule contains nine short consensus repeats, which are common to proteins 
that bind the Ob and iC3b components of the classical pathway of complement 
(Johnston 1989). By competing with complement activating surfaces, soluble P-selectin 
may act to reduce complement-mediated injury. It remains to be elucidated if 
transfusions of platelets expressing surface P-selectin and/or containing plasma soluble 
P-selectin would have any effects on inflammatory process. Furthermore, it has been 
proposed that soluble P-selectin could act as an antiadhesive molecule in vivo, by 
competing with the membrane-bound P-selectin for the same receptor (Stohlaweiz 1998). 
This may have clinical consequences in terms of antithrombotic effect because treatment 
with a blocking monoclonal antibody to P-selectin has been shown to accelerate 
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thrombolysis in a primate model of arterial thrombosis (Toombs 1995). 
The physiologic significance of platelet derived microvesicles is not clear. 
Nevertheless, the increased levels of circulating platelet-derived microvesicles have been 
observed in patients with primary thrombotic disorders such as transient ischemic attacks 
and myocardial infarction (Lee 1993, Jy 1995), as well as patients with secondary 
activated coagulation i. e. disseminated intravascular coagulation (DIC) (Holme 1994). 
Furthermore, high levels of platelet-derived microvesicles have also been reported in 
thrombotic episodes associated with several other pathological conditions. These include 
sickle cell disease (Wun 1998), paroxysmal nocturnal haemoglobinuria (Wiedmer 1993, 
Hugel 1999), heparin induced thrombocytopenia (Warkentin 1994), and idiopathic 
thombocytopenic purpura (jy 1992). The prothrombotic property of platelet-derived 
microvesicles is attributed to the high proportion of phosphatidylerine on their membrane 
which enhances the tenase and prothrombinase reactions (Bevers 1991). Although 
studies have shown that platelet-derived microvesicles generated by various platelet 
agonists contain anticoagulant as well as procoagulant properties (Tan 1991, DahlbAck 
1992), the clinical significance of their anticoagulant property is yet to be demonstrated. 
Nevertheless, in this study it has been demonstrated for the first time that similarly to 
microvesicles generated by platelet agonists, microvesicles isolated from relative fresh 
platelet concentrates i. e. day I also contain both procoagulant and anticoagulant 
properties, but upon 5-day storage the procoagulant activity appears to be more 
pronounced. 
So far only one study has measured quantitatively the level of platelet-derived 
microvesicles in samples obtained from patients with various pathological cQnditions 
(Combes 1997). However, without interlaboratory standardisation, it is not relevant to 
compare the levels of microvesicles seen in platelet concentrates with those reported in 
clinical conditions due to differences in several variables employed by both settings 
187 
which could influence ex vivo platelet activation/microvesiculation. These include: i) the 
containers used for sample collection, while clinical samples are collected in a plastic 
test tube, whole blood for platelet concentrate preparation is collected in a much larger 
Plastic bag, both have different biocompatiblity; ii) the type and ratio of anticoagulant; 
iii) the shear force generated by centrifugation to isolate platelets; and iv) the method 
used to set the arbitary region for microvesicles. 
More recently, attention has been placed on the finding that platelets are the 
major source of normal prion protein (PrP) (MacGregor 1999, Prowse 1999) and upon 
activation by platelet agonists, PrP' in platelets is expressed on the platelet surface in 
parallel to the platelet activation markers, P-selectin and CD63 (Holada 1999, Perini 
1996). Furthermore, ruptured platelets containing P-selectin also contain PrP'. As 
abnormal prion protein is known to be membrane associated (Cashman 1990, Bendheim 
1 
1992), it remains to be elucidated whether platelet-derived microvesicles could act as a 
Carrier of abnormal prion protein. 
Artificial surfaces are known to activate coagulation and complement systems. 
The effects of leucocyte depletion on the activation of the coagulation system varied 
according to the assays used, i. e. while prothrombin fragment 1+2 and thrombin- 
antithrombin complex measured by ELISA did not show any difference between 
leucocyte depleted platelets prepared by different leucocyte removal fifters or by various 
leucocyte depletion technologies, kallikrein-like and thrombin-like activities measured 
by chromogenic assays were different. The latter assays are more sensitive and provide 
the overall information on the activation of coagulation system. The activation of contact 
system by negatively charged filters can cause hypotensive reactions in transfused 
patients also receiving angiotensin converting enzyme inhibitors (Fried 1996, Hume 
1996, Sano 1996, Mair 1998). The clinical significance of activated complements in 
platelet concentrates has not been reported. Nevertheless, as some activated complement 
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components such as C3a have pro-inflammatory effects, they may cause transftision 
reactions. 
In summary, all types of leucocyte removal filters and leucocyte depletion 
methods met the specification for leucocyte depletion. None of the leucocyte filters 
generated or removed platelet-derived microvesicles. Leucocyte depleted platelets 
prepared by different methods contained similar levels of platelet-derive microvesicles. 
The negatively charged polyester filter generated low grade serine proteases: but removed 
activated complement component C3a. The positively charged polyester filter generated 
C3a. The neutrally charged filter did not affect the levels of serine proteases or activated 
complement components. 
On one hand, it is plausible to conclude that an ideal product should contain 
platelets in their native state with the least degree of activation/release reaction and 
microvesiculation as well as without plasma activation so that platelets can provide 
optimal haemostatic functions at the site of injury in vivo while minimising transfusion 
reactions, On the other hand, high levels of activated platelets and microvesicles might 
be desirable for patients who require prompt haemostatic effectiveness. 
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